Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-12-350936.txt : 20120813 0001193125-12-350936.hdr.sgml : 20120813 20120813061601 ACCESSION NUMBER: 0001193125-12-350936 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120813 DATE AS OF CHANGE: 20120813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALSERES PHARMACEUTICALS INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-06533 FILM NUMBER: 121025970 BUSINESS ADDRESS: STREET 1: 239 SOUTH STREET CITY: HOPKINTON STATE: MA ZIP: 01748 BUSINESS PHONE: 508-497-2360 MAIL ADDRESS: STREET 1: 239 SOUTH STREET CITY: HOPKINTON STATE: MA ZIP: 01748 FORMER COMPANY: FORMER CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE DATE OF NAME CHANGE: 19950706 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 10-Q 1 d355656d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 0-6533

ALSERES PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)


Delaware		87-0277826
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

239 South Street, Hopkinton, Massachusetts		01748
(Address of Principal Executive Offices)		(Zip Code)

(508) 497-2360

(Registrant’s Telephone Number, Including Area Code)

None

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of July 31, 2012, there were 30,635,720 shares of the registrant’s Common Stock issued and outstanding.

ALSERES PHARMACEUTICALS, INC.

FORM 10-Q

TABLE OF CONTENTS


	Page
Part I FINANCIAL INFORMATION
Item 1 Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011		3
Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2012 and 2011, and for the period from inception (October 16, 1992) to June 30, 2012		4
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011, and for the period from inception (October 16, 1992) to June 30, 2012		5
Notes to Condensed Consolidated Financial Statements		7
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3 Quantitative and Qualitative Disclosures About Market Risk		18
Item 4 Controls and Procedures		18

Part II OTHER INFORMATION		18
Item 1 Legal Proceedings		18
Item 6 Exhibits		20

SIGNATURES		21
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101 DEFINITION LINKBASE DOCUMENT

In this report, “we”, “us”, and “our” refer to Alseres Pharmaceuticals, Inc. The following are trademarks of ours that are mentioned in this Quarterly Report on Form 10-Q: Alseres™ and Altropane ^®. All other trade names, trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners and are not the property of Alseres Pharmaceuticals, Inc. or any of our subsidiaries.

Part I — FINANCIAL INFORMATION

Item 1 — Financial Statements

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Balance Sheets


	(Unaudited)
	June 30, 2012			December 31, 2011
ASSETS
Current assets:
Cash and cash equivalents	$	63,552		$	135,843
Short-term investments		20,389			27,446
Prepaid expenses and other current assets		44,008			4,965


Total current assets		127,949			168,254

Property and Equipment, net		1,582			2,475


Total assets	$	129,531		$	170,729


LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	2,297,042		$	2,210,229
Convertible notes payable		21,827,588			21,827,588
Notes payable		6,185,000			5,900,000
Accrued interest payable on notes payable		694,946			486,691


Total current liabilities		31,004,576			30,424,508


Total liabilities		31,004,576			30,424,508


Commitments and contingencies

Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at June 30, 2012 and December 31, 2011, (liquidation preference of $300,000 at June 30, 2012)		358,915			348,444


Stockholders’ deficit:

Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively		—			—
Common stock, $.01 par value; 80,000,000 shares authorized at June 30, 2012 and December 31, 2011; 30,635,720 issued and outstanding at June 30, 2012 and December 31, 2011		306,357			306,357
Additional paid-in capital		166,160,384			166,170,855
Accumulated other comprehensive loss		(38,424	)		(31,367	)
Deficit accumulated during development stage		(197,662,277	)		(197,048,068	)


Total stockholders’ deficit		(31,233,960	)		(30,602,223	)


Total liabilities and stockholders’ deficit	$	129,531		$	170,729

The accompanying notes are an integral part of the condensed consolidated financial statements.

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,						For the period from October 16, 1992 (inception) to
	2012			2011			2012			2011			June 30, 2012
Revenue	$	250,000		$	—		$	500,000		$	—		$	1,400,000


Operating expenses:
General and administrative		418,676			571,282			865,039			1,168,879			69,679,927
Research and development		20,545			58,358			41,239			83,954			116,082,837
Purchased in-process research and development		—			—			—			—			12,146,544


Operating expenses before accrual reversal		439,221			629,640			906,278			1,252,833			197,909,308
Accrual reversal		—			(561,196	)		—			(561,196	)		(561,195	)


Total operating expenses		439,221			68,444			906,278			691,637			197,348,113

Loss from operations		(189,221	)		(68,444	)		(406,278	)		(691,637	)		(195,948,113	)

Interest expense		(105,716	)		(465,258	)		(209,113	)		(919,009	)		(14,698,223	)
Investment income		29			166			277			499			7,705,281
Other income (expense), net		—			—			905			—			(1,473,159	)
Gain on early extinguishment of debt		—			—			—			—			6,277,100
Forgiveness of debt		—			—			—			—			476,837


Net loss		(294,908	)		(533,536	)		(614,209	)		(1,610,147	)		(197,660,277	)

Preferred stock beneficial conversion feature		—			—			—			—			(8,062,712	)
Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders		—			—			—			—			(1,229,589	)


Net loss attributable to common stockholders		(294,908	)		(533,536	)		(614,209	)		(1,610,147	)		(206,952,578	)

Other comprehensive income
Net change in unrealized loss on marketable securities		(12,938	)		—			(7,057	)		—			(7,057	)


Comprehensive loss	$	(307,846	)	$	(533,536	)	$	(621,266	)	$	(1,610,147	)	$	(206,959,635	)


Basic and diluted net loss attributable to common stockholders per share	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.06	)


Weighted average common shares outstanding		30,635,720			28,302,129			30,635,720			27,548,076

The accompanying notes are an integral part of the condensed consolidated financial statements.

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows

(Unaudited)


							From Inception (October 16, 1992) to June 30,
	Six Months Ended June 30,						From Inception (October 16, 1992) to June 30,
	2012			2011			2012
Cash flows from operating activities:
Net loss	$	(614,209	)	$	(1,610,147	)	$	(197,660,277	)
Adjustments to reconcile net loss to net cash used for operating activities:
Purchased in-process research and development		—			—			12,146,544
Write-off of acquired technology		—			—			3,500,000
Loss on disposition of assets		—			—			3,391
Interest expense settled through issuance of notes payable		—			—			350,500
Expenses satisfied with the issuance of stock		—			—			28,680
Forgiveness of debt		—			—			(476,837	)
Gain on early extinguishment of debt		—			—			(6,277,100	)
Non-cash gain on restricted stock valuation		—			—			(58,814	)
Non-cash interest expense		—			—			3,966,394
Non-cash charges related to options, warrants and common stock		—			834			11,115,437
Amortization of financing costs		—			6,842			25,188
Amortization and depreciation		893			27,274			2,891,559
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets		(39,043	)		(24,112	)		461,320
Increase (decrease) in accounts payable and accrued expenses		86,813			(769,025	)		2,001,215
Increase in accrued interest payable		208,255			911,222			8,023,052
Decrease in accrued lease		—			(96,425	)		—


Net cash used for operating activities		(357,291	)		(1,553,537	)		(159,959,748	)


Cash flows from investing activities:
Cash acquired through Merger		—			—			1,758,037
Purchases of property and equipment		—			—			(1,654,487	)
Proceeds from the sale of property and equipment		—			—			3,430
Decrease (increase) in security deposits and other assets		—			88,600			—
Decrease in indemnity fund		—			85			—
Purchases of marketable securities		—			—			(132,004,923	)
Sales and maturities of marketable securities		—			—			132,004,923


Net cash provided by investing activities		—			88,685			106,980


Cash flows from financing activities:
Proceeds from issuance of common stock		—			—			66,731,339
Buyback of common stock		—			—			(26,356	)
Proceeds from issuance of preferred stock		—			—			39,922,170
Preferred stock conversion inducement		—			—			(600,564	)
Proceeds from issuance of promissory notes		285,000			1,440,000			58,770,000
Proceeds from issuance of convertible debentures		—			—			9,000,000
Principal payments of notes payable/repurchase of debt		—			—			(7,750,667	)
Dividend payments on Series E Cumulative Convertible Preferred Stock		—			—			(516,747	)
Payments of financing costs		—			—			(5,612,855	)


Net cash provided by financing activities		285,000			1,440,000			159,916,320


							From Inception (October 16, 1992) to June 30,
	Six Months Ended June 30,						From Inception (October 16, 1992) to June 30,
	2012			2011			2012
Net (decrease) increase in cash and cash equivalents		(72,291	)		(24,852	)		63,552
Cash and cash equivalents, beginning of period		135,843			98,514			—


Cash and cash equivalents, end of period	$	63,552		$	73,662		$	63,552


Supplemental cash flow disclosures:
Cash paid for interest	$	—		$	—		$	628,406

Supplemental disclosure of non-cash financing activity:
Conversion of notes payable to common stock	$	—		$	—		$	7,172,412
Capital contribution related to forgiveness of accrued interest	$	—		$	—		$	6,328,306
Accrued interest reclassified in connection with conversion of Series F convertible redeemable preferred stock to common stock	$	—		$	—		$	640,874

The accompanying notes are an integral part of the condensed consolidated financial statements.

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (Unaudited)

June 30, 2012

1. Nature of Operations and Basis of Presentation

Nature of Operations

Alseres Pharmaceuticals, Inc. and its subsidiaries (the “Company”) is a biotechnology company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system. The Company was founded in 1992 and merged with a publicly held company in 1995 (the “Merger”) whereby the Company changed its name to Boston Life Sciences, Inc. Effective June 7, 2007, the Company changed its name to Alseres Pharmaceuticals, Inc. During the period from inception through June 30, 2012, the Company has devoted substantially all of its efforts to business planning, raising financing, furthering the research and development of its technologies, and corporate partnering efforts. Accordingly, the Company is considered to be a “development stage enterprise” as defined in Accounting Standards Codification 915 (ASC 915) Development Stage Entities and will continue to be so until the commencement of commercial operations. Our development stage started on October 16, 1992 and has continued through June 30, 2012, and is expected to continue for the foreseeable future.

As of June 30, 2012, we had experienced total net losses since inception of approximately $206,953,000, stockholders’ deficit of approximately $31,234,000 and a net working capital deficit of approximately $30,877,000. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as we execute our current business plan. The cash and cash equivalents available at June 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. We believe that the approximately $185,000 in cash and cash equivalents available as of August 1, 2012 combined with minimal additional operating capital committed by our lead investor and our ability to control certain costs, including those related to clinical trial programs, preclinical activities, and certain general and administrative expenses will enable us to meet our anticipated cash expenditures into September 2012.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

The interim unaudited condensed consolidated financial statements contained herein include, in management’s opinion, all adjustments necessary for a fair statement of the financial position, results of operations, and cash flows for the periods presented. The results of operations for the interim period shown on this report are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the Company’s consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The uncertainty inherent in the need to raise additional capital and the Company’s recurring losses from operations raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Reclassification

Certain reclassifications have been made to the prior year’s condensed consolidated statements of comprehensive loss to conform to the current year presentation.

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid marketable securities purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.

Short-term Investments

The Company considers all marketable securities with maturities greater than three months and less than one year at the time of acquisition or purchase to be short-term investments. The Company evaluates such designation as of each balance sheet date to determine if the classification is appropriate. As of June 30, 2012 our short-term investments were classified as available-for-sale and were carried on the balance sheet at fair value. The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.

Comprehensive Loss

Components of comprehensive loss are reported in the Company’s condensed consolidated statements of comprehensive loss in the period in which they are recognized. The components of comprehensive loss include net loss and net change in the unrealized gains or losses in our marketable securities during the period.

Fair Value Measurements

The carrying amounts of the Company’s cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values as of June 30, 2012 and December 31, 2011 due to their short-term nature. Short-term investments were considered available-for-sale as of June 30, 2012 and are carried at fair value in the condensed consolidated balance sheets. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012 and the Company currently does not have the resources to repay the convertible debt.

Revenue Recognition and Deferred Revenue

The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.

Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.

On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.

Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2011-05, “Presentation of Comprehensive Income.” ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. The Company adopted these standards as of January 1, 2012. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and six months ended June 30, 2012.

3. Accounts Payable and Accrued Expenses

The Company’s accounts payable and accrued expenses consisted of the following:


	June 30, 2012		December 31, 2011
Research and development expenses	$	1,351,940	$	1,316,095
Professional fees		761,061		715,672
General and administrative expenses		107,848		99,746
Compensation related expenses		76,193		78,716


	$	2,297,042	$	2,210,229

4. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders has been calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.

Stock options to purchase approximately 3.0 million shares of common stock were outstanding at June 30, 2012, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. Stock options and warrants to purchase approximately 3.6 million shares of common stock were outstanding at June 30, 2011, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. In computing diluted earnings per share, common stock equivalents in the form of convertible redeemable preferred stock were not included in the calculation of net loss per share as their inclusion would be anti-dilutive. The exercise of stock options outstanding at June 30, 2012 could potentially dilute earnings per share in the future.

5. Accounting for Stock-Based Compensation

We have one stock option plan under which we can issue both nonqualified and incentive stock options to employees, officers, consultants and scientific advisors of the Company. At June 30, 2012, the 2005 Stock Incentive Plan (the “2005 Plan”) provided for the issuance of options, restricted stock, restricted stock units, stock appreciation rights or other stock-based awards to purchase 3,450,000 shares of our common stock. The 2005 Plan contains a provision that allows for an annual increase in the number of shares available for issuance under the 2005 Plan on the first day of each of the Company’s fiscal years during the period beginning in fiscal year 2006 and ending on the second day of fiscal year 2014. The annual increase in the number of shares shall be equal to the lowest of 400,000 shares; 4% of the Company’s outstanding shares on the first day of the fiscal year; and an amount determined by the Board of Directors. There was no adjustment made in January 2012.

We also have outstanding stock options in three other stock option plans, the 1998 Omnibus Plan, the Amended and Restated Omnibus Stock Option Plan and the Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan. These plans have expired and no future issuance of awards is permissible.

Our Board of Directors determines the term, vesting provisions, price, and number of shares for each award that is granted. The term of each option cannot exceed ten years.

No stock-based compensation expense was recorded during the three and six months ended June 30, 2012. No stock-based compensation was recorded during the three months ended June 30, 2011. Stock-based compensation of $834 was recorded during the six months ended June 30, 2011.

We use the Black-Scholes option-pricing model to calculate the fair value of each option grant on the date of grant. No stock options were granted during the three months ended June 30, 2012 and 2011.

A summary of our outstanding stock options for the six months ended June 30, 2012 and 2011 is presented below.


	2012					2011
	Shares			Weighted Average Exercise Price		Shares			Weighted Average Exercise Price
Outstanding at beginning of year		3,636,480		$	1.55		3,650,443		$	1.59
Granted		—			—		—			—
Exercised		—			—		—			—
Forfeited and expired		(625,000	)		1.75		(5,000	)		15.63


Outstanding at end of period		3,011,480		$	1.51		3,645,443		$	1.57


Options exercisable at end of period		3,011,480		$	1.51		3,645,443		$	1.57

The following table summarizes information about stock options outstanding and exercisable at June 30, 2012:


Range of Exercise Prices	Number Outstanding		Weighted Average Remaining Contractual Life	Weighted Average Exercise Price

$1.15 — $1.36		2,288,000	1.9 years	$	1.15
$2.00 — $3.00		539,980	3.2 years		2.33
$3.10 — $4.65		155,000	5.3 years		3.17
$4.99 — $6.96		28,500	1.5 years		5.47


		3,011,480	2.3 years	$	1.51

There was no intrinsic value of outstanding options and exercisable options as of June 30, 2012. As of June 30, 2012, 809,172 shares were available for grant under the 2005 Plan.

6. Notes Payable and Debt


Convertible Notes Payable to Significant Stockholders		June 30, 2012		December 31, 2011

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010		$	4,655,173	$	4,655,173
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010	BCF		10,000,000		10,000,000
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010	BCF		2,172,415		2,172,415
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010			5,000,000		5,000,000


Aggregate carrying value		$	21,827,588	$	21,827,588

No interest expense was incurred related to the convertible notes payable for the three and six months ended June 30, 2012. Interest expense totaling $362,499 and $724,998 was incurred related to the convertible notes payable for the three and six months ended June 30, 2011. In December 2011, Robert Gipson and Thomas Gipson elected to convert a total of $7,172,412 of their convertible notes payable into common stock of the Company. This transaction was part of a debt reduction agreement entered into through the Fifth Amendment to Convertible Note Purchase Agreement (“Amendment”) which also provided that all interest accrued or to be accrued related to these promissory notes would be waived.

The remaining unsecured convertible promissory notes may be converted, at the option of the Purchasers, into (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii). Any outstanding notes that are not converted into the Company’s common stock or into the right to receive future payments became due and payable on December 31, 2010. As of June 30, 2012, the holders of this debt have not made any formal demand for payment.

However, each Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under. There has been no demand for amounts due and the classification remains current.

The Company is subject to certain debt covenants pursuant to the March 2008 Amended Purchase Agreement and the June 2008 Purchase Agreement (the “Purchase Agreements”). If the Company (i) fails to pay the principal or interest due under the Purchase Agreements, (ii) files a petition for action for relief under any bankruptcy or similar law or (iii) an involuntary petition is filed against the Company, all amounts borrowed under the Purchase Agreements may become immediately due and payable by the Company. In addition, without the consent of the Purchasers, the Company may not (i) create, incur or otherwise, permit to be outstanding any indebtedness for money borrowed, (ii) declare or pay any cash dividend, or make a distribution on, repurchase, or redeem, any class of the Company’s stock, subject to certain exceptions or sell, lease, transfer or otherwise dispose of any of the Company’s material assets or property or (iii) dissolve or liquidate.

Beneficial Conversion Feature (BCF)

Two of the remaining unsecured promissory notes were issued with a conversion price of $2.50 which was below the market price of the Company’s common stock on the dates the agreements were entered into and resulted in the recording of a beneficial conversion feature (“BCF”). The Company recorded a BCF of $1,400,000 on (the “ISVP”) note and a BCF of $380,000 on (the “2008 RG”) note which were recognized as a decrease in the carrying value and an increase to additional paid-in capital. All related BCF expense has been fully recognized as interest expense using the effective interest method as of December 31, 2010.

Promissory Notes


Demand Notes Payable to Significant Stockholder	June 30, 2012		December 31, 2011

Unsecured demand note payable; interest rate of 7%: issued December 2009	$	350,000	$	350,000
Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010		3,310,000		3,310,000
Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011		2,240,000		2,240,000
Unsecured demand notes payable; interest rate of 7%: issued January 2012 — June 2012		285,000		—


		6,185,000		5,900,000
Accrued interest		694,946		486,691


Aggregate carrying value	$	6,879,946	$	6,386,691

Interest expense totaling $105,287 and $100,078 was incurred related to the demand notes payable for the three months ended June 30, 2012 and 2011, respectively. Interest expense totaling $208,255 and $186,224 was incurred related to the demand notes payable for the six months ended June 30, 2012 and 2011, respectively. In November 2011, the Company purchased from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. The result of this transaction was a reduction in quarterly interest expense of approximately $18,000 which has been partially offset by interest on the additional debt obligations of $2,525,000 entered into by the Company during 2011 and 2012 with Robert Gipson.

According to a Schedule D/A filed with the SEC on December 27, 2011 Robert Gipson beneficially owned approximately 50.1% of the outstanding common stock of the Company as of that date. Robert Gipson, who serves as a Senior Director of Ingalls & Snyder and a General Partner of ISVP, served as a director of the Company from June 15, 2004 until October 28, 2004. According to a Schedule D/A filed with the SEC on December 27, 2011, Thomas Gipson beneficially owned approximately 15.2% of the outstanding common stock of the Company as of that date. According to a Schedule 13G/A filed with the SEC on June 7, 2011, Arthur Koenig beneficially owned approximately 7% of the outstanding common stock of the Company on June 1, 2011. According to a Schedule 13G/A filed with the SEC on February 2, 2012, ISVP owned approximately 9.99% of the outstanding common stock of the Company as of December 31, 2011. According to a Schedule 13G/A filed with the SEC on February 7, 2012, Ingalls & Snyder LLC beneficially owned approximately 9.99% of the outstanding common stock of the Company on December 31, 2011.

7. Convertible Preferred Stock

The Company’s Series F Convertible, Redeemable Preferred Stock (“Series F Stock”) can be converted into 25 shares of common stock pursuant to the conversion terms of the Series F Stock contained in the Certificate of Designation for the Series F Stock. Each share of the Series F Stock was sold to Robert Gipson during 2009 at a price per share of $25 yielding aggregate proceeds to the Company in 2009 of $4,600,000. As of June 30, 2012, 12,000 shares of Series F Stock were outstanding and held by Robert Gipson.

8. Commitments and Contingencies

We recognize and disclose commitments when we enter into executed contractual obligations with third parties. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company does not agree that the total amounts claimed in the lawsuit are in fact owed and will pursue all legal remedies available to it to defend this claim.

On May 2, 2012 the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company believes that the total amounts claimed in the Biostorage lawsuit are significantly overstated. The Company intends to pursue all available legal and equitable remedies to defend this claim.

License Agreements

The Company has entered into license agreements (the “Harvard License Agreements”) with Harvard University and its affiliated hospitals (“Harvard and its Affiliates”) to acquire the exclusive worldwide rights to certain technologies within its molecular imaging and neurodegenerative disease programs. The Harvard License Agreements obligate the Company to pay up to an aggregate of approximately $850,000 in milestone payments in the future. The future milestone payments are generally payable only upon achievement of certain regulatory milestones.

The Company’s license agreements with Harvard and its Affiliates generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees and continuing patent prosecution costs.

9. Income taxes

The Company is subject to both federal and state income tax for the jurisdiction within which it operates. Within these jurisdictions, the Company is open to examination for tax years ended December 31, 2009 through December 31, 2011. The U.S. Internal Revenue Service (IRS) has completed an audit of tax years 2007 and 2008 and has informed us that no adjustments to the federal tax returns as filed will be proposed as a result of the audit. However, because we are carrying forward income tax attributes such as a net operating loss (“NOL”) from 2006, these attributes can still be audited when utilized on returns filed in the future.

10. Fair Value Measurements

The fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 — unadjusted quoted prices in active markets for identical securities;

Level 2 — unadjusted quoted prices in markets that are not active,

Level 3 — significant unobservable inputs, including our own assumptions in determining fair value

The following table summarizes the financial assets that we measured at fair value as of June 30, 2012 and December 31, 2011.


	June 30, 2012 Fair Value		Input Level	December 31, 2011 Fair Value		Input Level
Short-term investments	$	20,389	Level 2	$	27,446	Level 2


	$	20,389		$	27,446

As of June 30, 2012 and December 31, 2011, the Company’s short-term investments consisted of 39,209 shares of FluoroPharma Medical, Inc. stock. These shares are traded on the OTC Bulletin Board (“OTCBB”) under the symbol FPMI. The Rule 144 holding period has lapsed for these shares as of June 30, 2012, but the stock continues to trade on very thin volume in the open market. Therefore the Company continues to classify this asset as Level 2.

The Company did not have any non-financial assets or liabilities that were measured or disclosed at fair value for the period ended June 30, 2012 or December 31, 2011. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012.

11. Subsequent Events

We evaluated all events or transactions that occurred after June 30, 2012 up through the date we issued these financial statements.

In July 2012, we borrowed the principal sum of $150,000 from Robert Gipson. The funds borrowed are secured by a demand promissory note issued to Mr. Gipson that bears interest at the rate of 7% per annum.

On July 31, 2012 the Company announced that it entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, “Navidea”) to license, [¹²³I]-E-IACFT Injection (CFT), also called Altropane^®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

In January 2012, Alseres and Navidea executed an Option Agreement pursuant to which Navidea paid Alseres the non-refundable sum of $500,000 in exchange for the exclusive option to license the CFT program, to conduct its final due diligence review of the program and to prepare the paperwork necessary for the execution of the license.

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea made a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issued Alseres 300,000 shares of NAVB common stock.

The license agreement also provides for contingent milestone payments of up to $2.9 million, $2.5 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.15 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Navidea agreed to file with the Securities and Exchange Commission and use its best commercial efforts to have declared effective within 90 days a registration statement that would permit Alseres to resell the common stock issued as initial or milestone payments under the license agreement.

Under the license agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Alseres has no continuing cost obligations related to Altropane. There can be no assurances that Altropane will receive regulatory approval for sale in any jurisdiction.

On July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007 elected to exercise their existing rights under the Convertible Note Purchase Agreement to receive repayment of a total of $16 million in principal outstanding under the promissory notes purchased under the Convertible Note Purchase Agreement at a rate of 8% of the future Net Sales of the Company’s Altropane product. In a related transaction executed on July 31, 2012, Arthur Koenig and Ingalls & Snyder Value Partners LLP agreed to waive their right to receive a percentage of Altropane sales in the future in repayment of the $5,827,587 in debt remaining after their portion of the agreement mentioned above.

Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our management’s discussion and analysis of our financial condition and results of operations include the identification of certain trends and other statements that may predict or anticipate future business or financial results that are subject to important factors that could cause our actual results to differ materially from those indicated. See Item 1A, “Risk Factors” and also carefully review the risks outlined in other documents that we file from time to time with the SEC.

Overview

Description of Company

We are a biotechnology company focused on the development of diagnostic and therapeutic products primarily for disorders in the central nervous system, or CNS. Our clinical and preclinical product candidates are based on two proprietary technology platforms:

•

Molecular imaging program focused on the diagnosis of i) Parkinsonian Syndromes, or PS, including Parkinson’s Disease, or PD, and ii) Dementia with Lewy Bodies, or DLB;

•

Regenerative therapeutics program primarily focused on nerve repair in patients who have had significant loss of CNS function resulting from CNS trauma.

Product Development — Molecular Imaging Program

Altropane Molecular Imaging Agent

The Altropane molecular imaging agent is intended to be used for the differential diagnosis of PS, including PD, and non-PS in patients with an upper extremity tremor. After a series of discussions with the U.S. Food and Drug Administration, or FDA, and our expert advisors, the POET-2 program was designed as a two-part Phase III program. The first part of the program enrolled 54 subjects in a multi-center clinical study to acquire a set of Altropane images which will be used to train the expert readers in the second part of the program, as is the customary process for clinical trials of molecular imaging agents. Enrollment in the first part of POET-2 was completed in January 2009. In April 2009 we

reached agreement with the FDA under the Special Protocol Assessment, or SPA process, for the second part of the Phase III clinical trial program of Altropane. A SPA is a process by which sponsors and the FDA reach an agreement on the size, design and analysis of clinical trials that will form the primary basis of approval. The Phase III program is designed to confirm the diagnostic utility of the agent in anticipation of drug registration. The second portion of the Phase III, POET-2 program covered by the SPA consists of two clinical trials in up to 480 subjects in total to be conducted in parallel at up to 40 medical facilities throughout the United States. The subjects to be tested will be 40-80 years of age and have had a tremor in their hand(s) or arm(s) for less than three years. Each subject will be assessed by a general neurologist, an Altropane imaging procedure and a Movement Disorder Specialist considered the “gold standard”. The success of the trial will be determined by measuring the diagnostic efficacy of the neurologist diagnosis compared with the diagnosis determined by the Altropane scan versus the MDS gold standard diagnosis. Based on the trial design and scope covered by the Special Protocol Assessment Agreement for POET-2, we estimate that the total costs to complete the POET-2 program and prepare and submit a New Drug Application (“NDA”) for Altropane in the U.S. will be approximately $30 million. This funding is not available at present and there can be no assurance that such funds will be available on acceptable terms if at all.

During 2011 we focused our efforts on pursuing the capital necessary to enable us to execute the Altropane Phase III registration program and on seeking to partner our molecular imaging program with a firm or firms with the resources necessary for the completion of the Phase III clinical program, for the manufacturing and supply of Altropane, and for the launch and commercialization of Altropane. During 2011 we engaged in numerous discussions with potential capital sources as well as potential development and commercialization partners for Altropane.

On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc. (Amex NAVB), to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. The option agreement provided Navidea with a 6 month period during which it had exclusive rights to license the asset and complete further diligence and the definitive license for [123I]-E-IACFT. Under the terms of the option agreement, Navidea paid Alseres an option fee of $500,000 upon signing the agreement.

On July 31, 2012 we signed an agreement with Navidea Biopharmaceuticals, Inc. to license [¹²³I]-E-IACFT Injection (CFT), also called Altropane^®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. (See Subsequent Events)

The Altropane molecular imaging agent is a radio labeled imaging agent that contains the radioactive element iodine isotope 123 I and binds with extremely high affinity and specificity to the dopamine transporter, or DAT. The DAT is a protein that is on the surface membrane of specialized neurons in the brain that produce dopamine, a key neurotransmitter. We believe that the amount of Altropane taken up by the brain is directly proportional to the number of DATs that are present in any given area of the brain. Since DATs are on the membrane of dopamine-producing neurons, death of these neurons results in decreased numbers of DATs. Therefore, PD, which is caused by a decreased number of dopamine producing cells, is associated with a marked decrease in the number of DATs. As a result, when Altropane is administered to patients with PD, its binding is substantially diminished as compared to patients without PD. This decrease in Altropane binding in patients with PD is the theoretical basis for using Altropane imaging as a diagnostic test for PS, including PD.

Altropane is administered by intravenous injection. Since Altropane contains radioactive 123 I, it can be used as a nuclear imaging agent that can be detected using a specialized nuclear medicine instrument known as a Single Photon Emission Computed Tomography, or SPECT, camera. The strength of the SPECT signal generated by Altropane is proportional to the number of DATs present and produces images that distinguish PS and non-PS patients. SPECT cameras are widely available in both community and academic medical centers. The scanning procedure using Altropane takes less than one hour to complete. Results of these tests are usually available the same day as the scanning procedure.

We have licensed worldwide exclusive rights to develop Altropane from Harvard University and its affiliated hospitals, which we refer to as Harvard and its Affiliates, including the Massachusetts General Hospital. The license agreement provides for milestone payments and royalties based on product sales that are consistent with industry averages for such products.

Altropane Diagnostic for Parkinsonian Syndromes (PS)

PS is characterized by loss of dopamine-producing neurons resulting in a variety of movement disorders, especially tremors and gait problems. The most prevalent form of PS is PD which is a chronic, irreversible, neurodegenerative disease that generally affects people over 50 years old. PD is caused by a significant decrease in the number of dopamine producing neurons in specific areas of the brain. Inadequate production of dopamine causes, at least in part, the PD symptoms of tremor, muscle retardation and rigidity. PD can be difficult to diagnose using subjective analyses and can be confused with Essential Tremor, or ET. ET manifests with clinical symptoms very similar to those of PD. However, ET patients do not need the drugs routinely prescribed to PD patients.

Need for an Objective Diagnosis

According to published data, clinical criteria used to diagnose PS are prone to high error rates, especially in early stages of PD. This highlights the critical need for an effective diagnostic. Presently, patients who have experienced tremors and other evidence of a movement disorder may pursue diagnosis and treatment with a number of medical professionals. These include an internist or general practitioner, also known as a primary care physician, or PCP, a neurologist, or a movement disorder specialist, or MDS, whose practice is focused on movement disorders.

Patients can exhibit symptoms and/or have clinical histories that are inconclusive. A primary tool utilized to diagnose PD or PS is a clinical history and a physical exam. However, studies in the literature have reported error rates in diagnosing PD or PS from a low of 10% for MDSs to as high as 40 to 50% for PCPs.

This high error rate is driving the need for a diagnostic test that provides physicians with additional clinical information to help them make a definitive diagnosis when clinical symptoms and the patient’s history are inconclusive. Further, while the accuracy of MDSs is reported to be higher, the number of MDSs in the United States is limited with current estimates between 300 and 500. The limited availability of MDSs underscores the potential utility of a widely available diagnostic tool such as Altropane.

There are a number of important and potentially harmful results associated with misdiagnosis. These include:

•

Patients who are improperly diagnosed as having PD but actually do not (false positive) may be administered medications for PD. These drugs can have damaging effects on individuals who do not actually have PD.

•

Patients who are improperly diagnosed as not having PD but actually do (false negative), may not benefit from available treatments, thereby suffering further worsening of symptoms and progression of their disease.

Market Opportunity

It has been estimated that approximately 180,000 individuals in the United States per year present to their physician with new, undiagnosed cases of PD and ET, and are therefore candidates for a scan using the Altropane molecular imaging agent to diagnose or rule out early PS. It has also been estimated by the National Institute of Neurological Disorders and Stroke and the National Parkinson’s Foundation that the number of people in the United States with PD is between 500,000 and 1,500,000. It has been estimated by the Tremor Action Network that there are approximately 10,000,000 people in the United States with ET. In addition, a study done by the World Health Organization claims approximately 2,000,000 individuals suffer from PD in Europe. We expect the number of individuals affected by PD to grow substantially as people continue to live longer and the overall population ages.

Altropane Diagnostic for Dementia with Lewy Bodies (DLB)

DLB is a progressive brain disease and the second most common cause of neurodegenerative dementia. The symptoms of DLB are caused by the build-up of Lewy bodies inside the section of the brain that controls particular aspects of memory and motor control. The similarity of symptoms between DLB and PD, and between DLB and Alzheimer’s disease, can make it difficult to accurately diagnose. As with PD, there is no objective diagnostic tool available in the United States. We believe that the underlying basis for DLB coupled with our existing preclinical and clinical data supports the potential development of Altropane as a diagnostic for DLB. We also believe the potential use of our molecular imaging agents for the diagnosis of DLB could be strategic in our partnering efforts for our molecular imaging program.

It has been estimated by the Alzheimer’s Association that there are approximately 7,000,000 to 10,000,000 people in the United States with dementia of which the journal Age and Ageing estimates that up to approximately 3,000,000 people have DLB. According to Alzheimer Europe, there were approximately 1,800,000 people in Europe with DLB.

Regenerative Therapeutics Program — Nerve Repair

Our nerve repair program is focused on restoring movement and sensory function in patients who have had significant loss of CNS function resulting from traumas such as SCI, stroke, traumatic brain injury, or TBI, and optic nerve damage. Our efforts are aimed at the use of proprietary regenerative drugs and/or methods to induce nerve fibers to regenerate and form new connections that restore compromised abilities. Licensing or acquiring the rights to the technologies of complementary approaches for nerve repair is part of our strategy of creating competitive advantages by assembling a broad portfolio of related technologies and intellectual property.

Resource constraints have severely restricted our ability to progress our regenerative therapeutics program. On May 11, 2010, the Company was notified by Children’s Medical Center Corporation (“CMCC”) of the termination of its license agreements with the Company as a result of the Company’s lack of resources and resulting inability to comply with the performance conditions of the licenses. As of June 30, 2012 CMCC was owed approximately $77,000 in license fees and legal costs associated with the licenses and approximately $530,000 related to sponsored research contracts. Since we were unable to pay the overdue amounts within the cure periods specified in the CMCC licenses, we no longer have the rights to further develop and/or partner the axon regeneration technologies licensed from CMCC.

Brain Health Centers Opportunity

In light of the recent closing of the Navidea license, we have begun preliminary planning for the redirection of the Company.

We are presently conducting a preliminary feasibility assessment for a new business focused on organizing and operating a U.S. network of Brain Health Centers concentrating on neurodegenerative conditions. The centers will provide screening, diagnosis and on-going monitoring of both pre-symptomatic and symptomatic patients affected by neurodegenerative brain disorders. The centers will take advantage of currently available in-vitro diagnostics as well as imaging diagnostics to identify patients who are “at risk” of developing degenerative brain disorders. We are working, on a confidential basis, with industry participants to assess possible support for the development of the potential new business including capital and human resources.

The number of Americans living with neurodegenerative movement disorders such as Parkinson’s disease (PD), and dementias like Alzheimer’s (AD) and Dementia with Lewy Bodies (DLB), is expected to grow from 20 million in 2010 to 30 million by 2030. By 2050, that number is expected to grow to 40 million. Unchecked and without accounting for loss of productivity, the annual cost of care for patients with these diseases will grow from $200 billion today to $500 billion by 2030.

Today, PD, AD and DLB are diagnosed post-symptomatically. By the time diagnosable clinical symptoms appear, the disease is in an advanced stage. The disease has already progressed well beyond the point that current therapies have been shown to have disease modifying effects. Drugs in development are routinely tested in patients with advanced stage disease, where the drugs are least likely to have the disease modifying or arresting affect desired. What is needed are:

•

Early detection, definitive diagnostics and therapeutic drug monitoring tools; and

•

Comprehensive, longitudinal data to enable disease modifying treatments for early stage degenerative brain diseases

At present our work on this opportunity is extremely preliminary and is focused on identifying an initial location for a pilot site intended to demonstrate the proof of concept for the centers. We can provide no assurance that this business will ever be launched or that the capital and human resources necessary to launch and grow the new business will be available on acceptable terms if at all.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements which have been prepared by us in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Our estimates include those related to marketable securities, research contracts and the fair value and classification of financial instruments. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations

Three Months Ended June 30, 2012 and 2011

Revenue

For the three months ended June 30, 2012, the Company recognized revenue of $250,000. The Company had completed all performance obligations related to the option agreement which expired on June 30, 2012. On June 26, 2012, Navidea elected to exercise its right to extend the option exercise term until July 31, 2012 to complete its diligence efforts. (See Subsequent Events)

Our net loss was $294,908 for the three months ended June 30, 2012 compared to a net loss of $533,536 for the three months ended June 30, 2011. The net loss for the three months ended June 30, 2012 resulted from the recognition of $250,000 in revenue referenced above partially offset by operating expenses of approximately $439,000 and interest expense of approximately $106,000. The net loss of $533,536 for the three months ended June 30, 2011 was attributable to adjusted operating expenses of approximately $68,000 and interest expense of approximately $465,000.

Research and development expenses were $20,545 during the three months ended June 30, 2012 compared to $58,358 during the three months ended June 30, 2011. Our continued curtailment of spending on Altropane pending receipt of additional funds resulted in minimal expenses incurred during both periods.

General and administrative expenses were $418,676 during the three months ended June 30, 2012 compared to $571,282 during the three months ended June 30, 2011. The decrease of $152,606 or 27% for the three months ended June 30, 2012 was attributable to (i) a reduction in employee payroll and related tax and benefit costs of approximately $52,000 resulting from reduced headcount; and (ii) a reduction in overhead costs of approximately $93,000 related to the expiration of our lease in September 2011. The overhead reductions are attributable to lower rent expense and common area maintenance charges of approximately $67,000, the elimination of approximately $11,000 in non-cash charges for the amortization of leasehold improvements and the reduction of approximately $6,700 in utility expenses.

Interest expense of $105,716 was incurred during the three months ended June 30, 2012 compared to $465,258 during the three months ended June 30, 2011. The decrease of $359,542, or 77% for the three months ended June 30, 2012 was attributable to the debt reduction agreements signed in the fourth quarter of 2011. In December 2011, Robert Gipson and Thomas Gipson converted $7,172,412 of their convertible notes payable into common stock of the Company. The debt reduction agreement provided that all future interest related to these promissory notes would be waived. These transactions reduced quarterly interest expense by approximately $363,000. In November 2011, the Company further

reduced its debt obligations by purchasing from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. This transaction reduced quarterly interest expense by approximately $18,000. The savings associated with the debt reduction agreements were partially offset by $2,240,000 of new debt obligations entered into with Robert Gipson during 2011 and an additional $285,000 in the second quarter of 2012.

Six Months Ended June 30, 2012 and 2011

Revenue

Our net loss was $614,209 for the six months ended June 30, 2012 compared to a net loss of $1,610,147 for the six months ended June 30, 2011. The net loss for the six months ended June 30, 2012 resulted from the recognition of $500,000 in revenue partially offset by operating expenses of approximately $906,000 and interest expense of approximately $209,000. The net loss of $1,610,147 for the six months ended June 30, 2011 was attributable to adjusted operating expenses of approximately $691,000 and interest expense of approximately $919,000.

Research and development expenses were $41,239 during the six months ended June 30, 2012 compared to $83,954 during the six months ended June 30, 2011. Our continued curtailment of spending on Altropane pending receipt of additional funds resulted in minimal expenses incurred during both periods.

General and administrative expenses were $865,039 during the six months ended June 30, 2012 compared to $1,168,879 during the six months ended June 30, 2011. The decrease of $303,840 or 26% for the six months ended June 30, 2012 was attributable to (i) a reduction in employee payroll and related tax and benefit costs of approximately $121,000 resulting from reduced headcount; and (ii) a reduction in overhead costs of approximately $170,000 related to the expiration of our lease in September 2011. The overhead reductions are attributable to lower rent expense and common area maintenance charges of approximately $123,000, the elimination of approximately $22,000 in non-cash charges for the amortization of leasehold improvements and the reduction of approximately $14,000 in utility expenses.

Interest expense of $209,113 was incurred during the six months ended June 30, 2012 compared to $919,009 during the six months ended June 30, 2011. The decrease of $709,896, or 77% for the six months ended June 30, 2012 was attributable to the debt reduction agreements signed in the fourth quarter of 2011. In December 2011, Robert Gipson and Thomas Gipson converted $7,172,412 of their convertible notes payable into common stock of the Company. The debt reduction agreement provided that all future interest related to these promissory notes would be waived. These transactions reduced quarterly interest expense by approximately $363,000. In November 2011, the Company further reduced its debt obligations by purchasing from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. This transaction reduced quarterly interest expense by approximately $18,000. The savings associated with the debt reduction agreements were partially offset by $2,240,000 of new debt obligations entered into with Robert Gipson during 2011 and an additional $285,000 in the second quarter of 2012.

Liquidity and Capital Resources

As of June 30, 2012, we had experienced total net losses since inception of approximately $206,953,000, stockholders’ deficit of approximately $31,234,000 and a net working capital deficit of approximately $30,877,000. The cash and cash equivalents available at June 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. As of August 1, 2012, we had cash and cash equivalents of approximately $185,000 which combined with minimal additional operating capital committed by our lead investor and our ability to control certain costs, including those related to clinical trial programs, preclinical activities, and certain general and administrative expenses will enable us to meet our anticipated cash expenditures into September 2012.

For the six months ended June 30, 2012, the Company received a non-refundable option fee of $500,000 from Navidea Biopharmaceuticals, Inc. upon signing an exclusive right to negotiate a definitive license agreement by June 30, 2012. On July 31, 2012 we signed an agreement with Navidea Biopharmaceuticals, Inc. to license [¹²³I]-E-IACFT Injection (CFT), also called Altropane^®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea made a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issued Alseres 300,000 shares of NAVB common stock. The Navidea shares are currently subject to Rule 144 restrictions. Navidea agreed to file with the Securities and Exchange Commission and use its best commercial efforts to have declared effective within 90 days a registration statement that would permit Alseres to resell the common stock issued as initial or milestone payments under the license agreement.

Operating Activities

Net cash used for operating activities was $357,291 for the six months ended June 30, 2012 compared to $1,553,537 for the six months ended June 30, 2011. Net cash used for operating activities for the six months ended June 30, 2012 reflects our curtailment of operations pending additional funding, the reduction in accrued interest expense associated with the debt reduction agreements signed in the fourth quarter of 2011 and the receipt of $500,000 from Navidea Biopharmaceuticals upon the signing of an option agreement during January 2012.

Investing Activities

No cash was provided by investing activities for the six months ended June 30, 2012. Cash provided by investing activities was $88,685 for the six months ended June 30, 2011.

Financing Activities

Financing activities provided cash of $285,000 for the six months ended June 30, 2012 compared to $1,440,000 for the six months ended June 30, 2011. Cash provided by financing activities for the six months ended June 30, 2012 and 2011 reflects the proceeds from the issuance of demand notes payable issued to Robert Gipson. All notes bear interest at the rate of 7% per annum.

During the six months ended June 30, 2012, we were able to utilize the funds received from the option agreement signed with Navidea to cover operating expenses along with the additional borrowings of $285,000. In the past we had obtained all of our funding from Robert Gipson. In the event that Mr. Gipson cannot provide future funding or we cannot obtain any additional funding from other sources, we may need to cease operations or reduce, cease or delay research and development programs and/or adjust our current business plan and in any such event we may not be able to continue as a going concern.

To date, we have dedicated most of our financial resources to the research and development of our product candidates, general and administrative expenses (including costs related to obtaining and protecting patents). Since inception, we have primarily satisfied our working capital requirements from the sale of our securities through private placements. These private placements have included the sale and issuance of preferred stock, common stock, promissory notes and convertible debentures.

In the future, our working capital and capital requirements will depend on numerous factors, including the progress of our research and development activities, the level of resources that we devote to the developmental, clinical, and regulatory aspects of our technologies, and the extent to which we enter into collaborative relationships with pharmaceutical and biotechnology companies.

In order to continue as a going concern, we will need to raise additional capital through one or more of the following: a debt financing, an equity offering, or a collaboration, merger, acquisition or other transaction with one or more pharmaceutical or biotechnology companies. We are currently engaged in fundraising efforts. There can be no assurance that we will be successful in our fundraising efforts or that additional funds will be available on acceptable terms, if at all. We also cannot be sure that we will be able to obtain additional credit from, or effect additional sales of debt or equity securities to certain of our existing investors. If we are unable to raise additional or sufficient capital or if we violate a debt covenant or default under the March 2008 Amended Purchase Agreement or the June 2008 Purchase Agreement (described below) we may need to cease operations or reduce, cease or delay one or more of our research or development programs and/or adjust our current business plan and in any such event may not be able to continue as a going concern.

Item 3 — Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information.

Item 4 — Controls and Procedures

Our management evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2012. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2012, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Part II — OTHER INFORMATION

Item 1 — Legal Proceedings

The disclosure contained under the heading “Contingencies” in Note 8 to the condensed consolidated financial statements included in Part I, Item 1 hereof is incorporated herein by reference.

Statements contained or incorporated by reference in this Quarterly Report on Form 10-Q that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections, and the beliefs and assumptions of our management including, without limitation, our expectations regarding our product candidates, including the success and timing of our preclinical, clinical and development programs, the submission of regulatory filings and proposed partnering arrangements, the outcome of any litigation, collaboration, merger, acquisition and fund raising efforts, results of operations, selling, general and administrative expenses, research and development expenses and the sufficiency of our cash for future operations. Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “could,” “will,” “expect,” “estimate,” “anticipate,” “continue,” or similar terms, variations of such terms or the negative of those terms.

We cannot assure investors that our assumptions and expectations will prove to have been correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. Such factors that could cause or contribute to such differences include those factors discussed below. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 6 — Exhibits



31.1*		Certification of the Chief Executive Officer pursuant to Section 1350 of Title 18, United States Code, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Chief Financial Officer pursuant to Section 1350 of Title 18, United States Code, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema Document

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document

101.PRE**		XBRL Taxonomy Presentation Linkbase Document

101.DEF**		XBRL Taxonomy Definition Linkbase Document

*	Filed herewith.

In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposed of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


				ALSERES PHARMACEUTICALS, INC (Registrant)

DATE: August 13, 2012				/s/ PETER G. SAVAS
				Peter G. Savas
				Chief Executive Officer (Principal Executive Officer)

DATE: August 13, 2012				/s/ KENNETH L. RICE, JR.
				Kenneth L. Rice, Jr.
				Executive Vice President Finance and Administration And Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 d355656dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Peter G. Savas, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Alseres Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d355656dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Kenneth L. Rice, Jr., certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Alseres Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d355656dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Alseres Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2012 as filed with the Securities and Exchange Commission (the “Report”), I, Peter G. Savas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ PETER G. SAVAS

Peter G. Savas

Chief Executive Officer

Date: August 13, 2012

EX-32.2 5 d355656dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Alseres Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2012 as filed with the Securities and Exchange Commission (the “Report”), I, Kenneth L. Rice, Jr., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/ KENNETH L. RICE, JR.

Kenneth L. Rice, Jr.

Executive Vice President Finance and Administration and Chief Financial Officer

Date: August 13, 2012

EX-101.INS 6 alse-20120630.xml XBRL INSTANCE DOCUMENT 0000094784 us-gaap:SeriesFPreferredStockMember 2011-12-31 0000094784 us-gaap:SeriesFPreferredStockMember 2012-06-30 0000094784 alse:RangeTwoMember 2012-01-01 2012-06-30 0000094784 alse:RangeThreeMember 2012-01-01 2012-06-30 0000094784 alse:RangeOneMember 2012-01-01 2012-06-30 0000094784 alse:RangeFourMember 2012-01-01 2012-06-30 0000094784 alse:RangeTwoMember 2012-06-30 0000094784 alse:RangeThreeMember 2012-06-30 0000094784 alse:RangeOneMember 2012-06-30 0000094784 alse:RangeFourMember 2012-06-30 0000094784 alse:TwoZeroZeroFiveStockIncentivePlanMember 2012-06-30 0000094784 us-gaap:SeriesEPreferredStockMember 2012-06-30 0000094784 us-gaap:SeriesDPreferredStockMember 2012-06-30 0000094784 us-gaap:SeriesAPreferredStockMember 2012-06-30 0000094784 us-gaap:SeriesEPreferredStockMember 2011-12-31 0000094784 us-gaap:SeriesDPreferredStockMember 2011-12-31 0000094784 us-gaap:SeriesAPreferredStockMember 2011-12-31 0000094784 alse:UnsecuredDemandNoteTwoMember 2012-06-30 0000094784 alse:UnsecuredDemandNoteThreeMember 2012-06-30 0000094784 alse:UnsecuredDemandNoteFourMember 2012-06-30 0000094784 alse:UnsecuredDemandNoteFiveMember 2012-06-30 0000094784 alse:UnsecuredDemandNoteTwoMember 2011-12-31 0000094784 alse:UnsecuredDemandNoteThreeMember 2011-12-31 0000094784 alse:UnsecuredDemandNoteFourMember 2011-12-31 0000094784 alse:ChildrensHospitalBostonAndChildrensMedicalCenterCorporationMember 2012-01-01 2012-06-30 0000094784 alse:BiostorageTechnologiesIncMember 2012-01-01 2012-06-30 0000094784 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2012-06-30 0000094784 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2011-12-31 0000094784 2011-01-01 2011-12-31 0000094784 us-gaap:NotesPayableOtherPayablesMember 2012-04-01 2012-06-30 0000094784 us-gaap:NotesPayableOtherPayablesMember 2012-01-01 2012-06-30 0000094784 us-gaap:NotesPayableOtherPayablesMember 2011-04-01 2011-06-30 0000094784 us-gaap:NotesPayableOtherPayablesMember 2011-01-01 2011-06-30 0000094784 alse:RgMember 2012-01-01 2012-06-30 0000094784 alse:UnsecuredConvertiblePromissoryNoteTwoMember 2012-06-30 0000094784 alse:UnsecuredConvertiblePromissoryNoteThreeMember 2012-06-30 0000094784 alse:UnsecuredConvertiblePromissoryNoteOneMember 2012-06-30 0000094784 alse:UnsecuredConvertiblePromissoryNoteFourMember 2012-06-30 0000094784 alse:MolecularImagingAndOtherProductsMember 2012-06-30 0000094784 alse:UnsecuredConvertiblePromissoryNoteTwoMember 2011-12-31 0000094784 alse:UnsecuredConvertiblePromissoryNoteThreeMember 2011-12-31 0000094784 alse:UnsecuredConvertiblePromissoryNoteOneMember 2011-12-31 0000094784 alse:UnsecuredConvertiblePromissoryNoteFourMember 2011-12-31 0000094784 alse:RobertAndThomasGipsonMember 2011-12-31 0000094784 2011-06-30 0000094784 2010-12-31 0000094784 us-gaap:ProfessionalFeesMember 2012-06-30 0000094784 us-gaap:OtherResearchAndDevelopmentExpenseMember 2012-06-30 0000094784 us-gaap:GeneralAndAdministrativeExpenseMember 2012-06-30 0000094784 alse:CompensationRelatedExpensesMember 2012-06-30 0000094784 us-gaap:ProfessionalFeesMember 2011-12-31 0000094784 us-gaap:OtherResearchAndDevelopmentExpenseMember 2011-12-31 0000094784 us-gaap:GeneralAndAdministrativeExpenseMember 2011-12-31 0000094784 alse:CompensationRelatedExpensesMember 2011-12-31 0000094784 2011-12-31 0000094784 2012-06-30 0000094784 alse:NavbStockMember 2012-01-31 0000094784 2012-07-31 0000094784 2012-07-01 2012-07-31 0000094784 us-gaap:SeriesFPreferredStockMember 2012-01-01 2012-06-30 0000094784 alse:IsvpMember 2012-01-01 2012-06-30 0000094784 alse:IsvpMember 2011-12-31 0000094784 alse:IngallsSnyderLlcMember 2011-12-31 0000094784 us-gaap:PrincipalOwnerMember 2011-12-27 0000094784 us-gaap:MajorityShareholderMember 2011-12-27 0000094784 alse:ArthurKoenigMember 2011-06-01 0000094784 alse:TwoZeroZeroFiveStockIncentivePlanMember 2012-01-01 2012-06-30 0000094784 2012-04-01 2012-06-30 0000094784 us-gaap:FairValueMeasurementsRecurringMember 2012-06-30 0000094784 us-gaap:FairValueMeasurementsRecurringMember 2011-12-31 0000094784 2012-01-01 2012-01-31 0000094784 alse:MolecularImagingAndOtherProductsMember 2012-01-01 2012-06-30 0000094784 2012-08-01 0000094784 alse:NavideaStockMember 2012-01-31 0000094784 2012-01-31 0000094784 2011-04-01 2011-06-30 0000094784 2011-01-01 2011-06-30 0000094784 1992-10-16 2012-06-30 0000094784 2012-01-01 2012-06-30 iso4217:USD xbrli:shares alse:Number_Of_Notes xbrli:pure xbrli:shares iso4217:USD

1. Nature of Operations and Basis of Presentation Nature of Operations Alseres Pharmaceuticals, Inc. and its subsidiaries (the “Company”) is a biotechnology company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system. The Company was founded in 1992 and merged with a publicly held company in 1995 (the “Merger”) whereby the Company changed its name to Boston Life Sciences, Inc. Effective June 7, 2007, the Company changed its name to Alseres Pharmaceuticals, Inc. During the period from inception through June 30, 2012, the Company has devoted substantially all of its efforts to business planning, raising financing, furthering the research and development of its technologies, and corporate partnering efforts. Accordingly, the Company is considered to be a “development stage enterprise” as defined in Accounting Standards Codification 915 (ASC 915) Development Stage Entities and will continue to be so until the commencement of commercial operations. Our development stage started on October 16, 1992 and has continued through June 30, 2012, and is expected to continue for the foreseeable future. As of June 30, 2012, we had experienced total net losses since inception of approximately $206,953,000, stockholders’ deficit of approximately $31,234,000 and a net working capital deficit of approximately $30,877,000. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as we execute our current business plan. The cash and cash equivalents available at June 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. We believe that the approximately $185,000 in cash and cash equivalents available as of August 1, 2012 combined with minimal additional operating capital committed by our lead investor and our ability to control certain costs, including those related to clinical trial programs, preclinical activities, and certain general and administrative expenses will enable us to meet our anticipated cash expenditures into September 2012. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The interim unaudited condensed consolidated financial statements contained herein include, in management’s opinion, all adjustments necessary for a fair statement of the financial position, results of operations, and cash flows for the periods presented. The results of operations for the interim period shown on this report are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the Company’s consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The uncertainty inherent in the need to raise additional capital and the Company’s recurring losses from operations raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Reclassification Certain reclassifications have been made to the prior year’s condensed consolidated statements of comprehensive loss to conform to the current year presentation.

2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid marketable securities purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.   Short-term Investments The Company considers all marketable securities with maturities greater than three months and less than one year at the time of acquisition or purchase to be short-term investments. The Company evaluates such designation as of each balance sheet date to determine if the classification is appropriate. As of June 30, 2012 our short-term investments were classified as available-for-sale and were carried on the balance sheet at fair value. The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit. Comprehensive Loss Components of comprehensive loss are reported in the Company’s condensed consolidated statements of comprehensive loss in the period in which they are recognized. The components of comprehensive loss include net loss and net change in the unrealized gains or losses in our marketable securities during the period. Fair Value Measurements The carrying amounts of the Company’s cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values as of June 30, 2012 and December 31, 2011 due to their short-term nature. Short-term investments were considered available-for-sale as of June 30, 2012 and are carried at fair value in the condensed consolidated balance sheets. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012 and the Company currently does not have the resources to repay the convertible debt. Revenue Recognition and Deferred Revenue The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned. Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured. On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea. Recent Accounting Pronouncements In June 2011, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2011-05, “Presentation of Comprehensive Income.” ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. The Company adopted these standards as of January 1, 2012. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and six months ended June 30, 2012.

3. Accounts Payable and Accrued Expenses The Company’s accounts payable and accrued expenses consisted of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="68%"> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Research and development expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,351,940</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,316,095</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Professional fees </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">761,061</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715,672</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> General and administrative expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107,848</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">99,746</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Compensation related expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76,193</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">78,716</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,297,042</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,210,229</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

4. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders has been calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive. Stock options to purchase approximately 3.0 million shares of common stock were outstanding at June 30, 2012, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. Stock options and warrants to purchase approximately 3.6 million shares of common stock were outstanding at June 30, 2011, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. In computing diluted earnings per share, common stock equivalents in the form of convertible redeemable preferred stock were not included in the calculation of net loss per share as their inclusion would be anti-dilutive. The exercise of stock options outstanding at June 30, 2012 could potentially dilute earnings per share in the future.

5. Accounting for Stock-Based Compensation We have one stock option plan under which we can issue both nonqualified and incentive stock options to employees, officers, consultants and scientific advisors of the Company. At June 30, 2012, the 2005 Stock Incentive Plan (the “2005 Plan”) provided for the issuance of options, restricted stock, restricted stock units, stock appreciation rights or other stock-based awards to purchase 3,450,000 shares of our common stock. The 2005 Plan contains a provision that allows for an annual increase in the number of shares available for issuance under the 2005 Plan on the first day of each of the Company’s fiscal years during the period beginning in fiscal year 2006 and ending on the second day of fiscal year 2014. The annual increase in the number of shares shall be equal to the lowest of 400,000 shares; 4% of the Company’s outstanding shares on the first day of the fiscal year; and an amount determined by the Board of Directors. There was no adjustment made in January 2012. We also have outstanding stock options in three other stock option plans, the 1998 Omnibus Plan, the Amended and Restated Omnibus Stock Option Plan and the Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan. These plans have expired and no future issuance of awards is permissible. Our Board of Directors determines the term, vesting provisions, price, and number of shares for each award that is granted. The term of each option cannot exceed ten years. No stock-based compensation expense was recorded during the three and six months ended June 30, 2012. No stock-based compensation was recorded during the three months ended June 30, 2011. Stock-based compensation of $834 was recorded during the six months ended June 30, 2011. We use the Black-Scholes option-pricing model to calculate the fair value of each option grant on the date of grant. No stock options were granted during the three months ended June 30, 2012 and 2011.   A summary of our outstanding stock options for the six months ended June 30, 2012 and 2011 is presented below.   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="56%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at beginning of year </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,636,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.55</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,650,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.59</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Forfeited and expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(625,000</td> <td nowrap="nowrap" valign="bottom">)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,000</td> <td nowrap="nowrap" valign="bottom">)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.63</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at end of period </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,645,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.57</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr> <td valign="top"> Options exercisable at end of period </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,645,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.57</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> The following table summarizes information about stock options outstanding and exercisable at June 30, 2012:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="49%"> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Range of Exercise Prices </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Life</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $1.15 — $1.36 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,288,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.9 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.15</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $2.00 — $3.00 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">539,980</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3.2 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.33</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $3.10 — $4.65 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">5.3 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.17</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $4.99 — $6.96 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.47</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">2.3 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> There was no intrinsic value of outstanding options and exercisable options as of June 30, 2012. As of June 30, 2012, 809,172 shares were available for grant under the 2005 Plan.

6. Notes Payable and Debt   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Convertible Notes Payable to Significant Stockholders </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,655,173</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,655,173</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom" align="center">BCF</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom" align="center">BCF</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,172,415</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,172,415</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Aggregate carrying value </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,827,588</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,827,588</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> No interest expense was incurred related to the convertible notes payable for the three and six months ended June 30, 2012. Interest expense totaling $362,499 and $724,998 was incurred related to the convertible notes payable for the three and six months ended June 30, 2011. In December 2011, Robert Gipson and Thomas Gipson elected to convert a total of $7,172,412 of their convertible notes payable into common stock of the Company. This transaction was part of a debt reduction agreement entered into through the Fifth Amendment to Convertible Note Purchase Agreement (“Amendment”) which also provided that all interest accrued or to be accrued related to these promissory notes would be waived. The remaining unsecured convertible promissory notes may be converted, at the option of the Purchasers, into (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii). Any outstanding notes that are not converted into the Company’s common stock or into the right to receive future payments became due and payable on December 31, 2010. As of June 30, 2012, the holders of this debt have not made any formal demand for payment.   However, each Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under. There has been no demand for amounts due and the classification remains current. The Company is subject to certain debt covenants pursuant to the March 2008 Amended Purchase Agreement and the June 2008 Purchase Agreement (the “Purchase Agreements”). If the Company (i) fails to pay the principal or interest due under the Purchase Agreements, (ii) files a petition for action for relief under any bankruptcy or similar law or (iii) an involuntary petition is filed against the Company, all amounts borrowed under the Purchase Agreements may become immediately due and payable by the Company. In addition, without the consent of the Purchasers, the Company may not (i) create, incur or otherwise, permit to be outstanding any indebtedness for money borrowed, (ii) declare or pay any cash dividend, or make a distribution on, repurchase, or redeem, any class of the Company’s stock, subject to certain exceptions or sell, lease, transfer or otherwise dispose of any of the Company’s material assets or property or (iii) dissolve or liquidate. Beneficial Conversion Feature (BCF) Two of the remaining unsecured promissory notes were issued with a conversion price of $2.50 which was below the market price of the Company’s common stock on the dates the agreements were entered into and resulted in the recording of a beneficial conversion feature (“BCF”). The Company recorded a BCF of $1,400,000 on (the “ISVP”) note and a BCF of $380,000 on (the “2008 RG”) note which were recognized as a decrease in the carrying value and an increase to additional paid-in capital. All related BCF expense has been fully recognized as interest expense using the effective interest method as of December 31, 2010. Promissory Notes   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="68%"> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Demand Notes Payable to Significant Stockholder </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured demand note payable; interest rate of 7%: issued December 2009 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">350,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">350,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,310,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,310,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,240,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,240,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2012 — June 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,185,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,900,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Accrued interest </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">694,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">486,691</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Aggregate carrying value </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,879,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,386,691</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Interest expense totaling $105,287 and $100,078 was incurred related to the demand notes payable for the three months ended June 30, 2012 and 2011, respectively. Interest expense totaling $208,255 and $186,224 was incurred related to the demand notes payable for the six months ended June 30, 2012 and 2011, respectively. In November 2011, the Company purchased from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. The result of this transaction was a reduction in quarterly interest expense of approximately $18,000 which has been partially offset by interest on the additional debt obligations of $2,525,000 entered into by the Company during 2011 and 2012 with Robert Gipson. According to a Schedule D/A filed with the SEC on December 27, 2011 Robert Gipson beneficially owned approximately 50.1% of the outstanding common stock of the Company as of that date. Robert Gipson, who serves as a Senior Director of Ingalls & Snyder and a General Partner of ISVP, served as a director of the Company from June 15, 2004 until October 28, 2004. According to a Schedule D/A filed with the SEC on December 27, 2011, Thomas Gipson beneficially owned approximately 15.2% of the outstanding common stock of the Company as of that date. According to a Schedule 13G/A filed with the SEC on June 7, 2011, Arthur Koenig beneficially owned approximately 7% of the outstanding common stock of the Company on June 1, 2011. According to a Schedule 13G/A filed with the SEC on February 2, 2012, ISVP owned approximately 9.99% of the outstanding common stock of the Company as of December 31, 2011. According to a Schedule 13G/A filed with the SEC on February 7, 2012, Ingalls & Snyder LLC beneficially owned approximately 9.99% of the outstanding common stock of the Company on December 31, 2011.

7. Convertible Preferred Stock The Company’s Series F Convertible, Redeemable Preferred Stock (“Series F Stock”) can be converted into 25 shares of common stock pursuant to the conversion terms of the Series F Stock contained in the Certificate of Designation for the Series F Stock. Each share of the Series F Stock was sold to Robert Gipson during 2009 at a price per share of $25 yielding aggregate proceeds to the Company in 2009 of $4,600,000. As of June 30, 2012, 12,000 shares of Series F Stock were outstanding and held by Robert Gipson.

8. Commitments and Contingencies We recognize and disclose commitments when we enter into executed contractual obligations with third parties. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company does not agree that the total amounts claimed in the lawsuit are in fact owed and will pursue all legal remedies available to it to defend this claim. On May 2, 2012 the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company believes that the total amounts claimed in the Biostorage lawsuit are significantly overstated. The Company intends to pursue all available legal and equitable remedies to defend this claim. License Agreements The Company has entered into license agreements (the “Harvard License Agreements”) with Harvard University and its affiliated hospitals (“Harvard and its Affiliates”) to acquire the exclusive worldwide rights to certain technologies within its molecular imaging and neurodegenerative disease programs. The Harvard License Agreements obligate the Company to pay up to an aggregate of approximately $850,000 in milestone payments in the future. The future milestone payments are generally payable only upon achievement of certain regulatory milestones. The Company’s license agreements with Harvard and its Affiliates generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees and continuing patent prosecution costs.

9. Income taxes The Company is subject to both federal and state income tax for the jurisdiction within which it operates. Within these jurisdictions, the Company is open to examination for tax years ended December 31, 2009 through December 31, 2011. The U.S. Internal Revenue Service (IRS) has completed an audit of tax years 2007 and 2008 and has informed us that no adjustments to the federal tax returns as filed will be proposed as a result of the audit. However, because we are carrying forward income tax attributes such as a net operating loss (“NOL”) from 2006, these attributes can still be audited when utilized on returns filed in the future.

10. Fair Value Measurements The fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels: Level 1 — unadjusted quoted prices in active markets for identical securities; Level 2 — unadjusted quoted prices in markets that are not active, Level 3 — significant unobservable inputs, including our own assumptions in determining fair value The following table summarizes the financial assets that we measured at fair value as of June 30, 2012 and December 31, 2011.   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="54%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012 Fair Value</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Input Level</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011 Fair Value</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Input Level</td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Short-term investments </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,389</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,446</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Level 2</td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,389</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,446</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr>  </table> As of June 30, 2012 and December 31, 2011, the Company’s short-term investments consisted of 39,209 shares of FluoroPharma Medical, Inc. stock. These shares are traded on the OTC Bulletin Board (“OTCBB”) under the symbol FPMI. The Rule 144 holding period has lapsed for these shares as of June 30, 2012, but the stock continues to trade on very thin volume in the open market. Therefore the Company continues to classify this asset as Level 2. The Company did not have any non-financial assets or liabilities that were measured or disclosed at fair value for the period ended June 30, 2012 or December 31, 2011. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012.

11. Subsequent Events We evaluated all events or transactions that occurred after June 30, 2012 up through the date we issued these financial statements. In July 2012, we borrowed the principal sum of $150,000 from Robert Gipson. The funds borrowed are secured by a demand promissory note issued to Mr. Gipson that bears interest at the rate of 7% per annum. On July 31, 2012 the Company announced that it entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, “Navidea”) to license, [ 123I]-E-IACFT Injection (CFT), also called Altropane ®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. In January 2012, Alseres and Navidea executed an Option Agreement pursuant to which Navidea paid Alseres the non-refundable sum of $500,000 in exchange for the exclusive option to license the CFT program, to conduct its final due diligence review of the program and to prepare the paperwork necessary for the execution of the license. Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea made a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issued Alseres 300,000 shares of NAVB common stock. The license agreement also provides for contingent milestone payments of up to $2.9 million, $2.5 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.15 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met. Navidea agreed to file with the Securities and Exchange Commission and use its best commercial efforts to have declared effective within 90 days a registration statement that would permit Alseres to resell the common stock issued as initial or milestone payments under the license agreement. Under the license agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Alseres has no continuing cost obligations related to Altropane. There can be no assurances that Altropane will receive regulatory approval for sale in any jurisdiction. On July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007 elected to exercise their existing rights under the Convertible Note Purchase Agreement to receive repayment of a total of $16 million in principal outstanding under the promissory notes purchased under the Convertible Note Purchase Agreement at a rate of 8% of the future Net Sales of the Company’s Altropane product. In a related transaction executed on July 31, 2012, Arthur Koenig and Ingalls & Snyder Value Partners LLP agreed to waive their right to receive a percentage of Altropane sales in the future in repayment of the $5,827,587 in debt remaining after their portion of the agreement mentioned above.

The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned. Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured. On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.

<table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="56%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at beginning of year </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,636,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.55</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,650,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.59</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Forfeited and expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(625,000</td> <td nowrap="nowrap" valign="bottom">)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,000</td> <td nowrap="nowrap" valign="bottom">)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.63</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at end of period </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,645,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.57</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr> <td valign="top"> Options exercisable at end of period </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,645,443</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.57</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="49%"> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Range of Exercise Prices </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Life</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $1.15 — $1.36 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,288,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.9 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.15</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $2.00 — $3.00 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">539,980</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3.2 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.33</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $3.10 — $4.65 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">5.3 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.17</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $4.99 — $6.96 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.47</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,011,480</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">2.3 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.51</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Convertible Notes Payable to Significant Stockholders </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,655,173</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,655,173</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom" align="center">BCF</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom" align="center">BCF</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,172,415</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,172,415</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,000,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="2"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Aggregate carrying value </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,827,588</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,827,588</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="68%"> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Demand Notes Payable to Significant Stockholder </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured demand note payable; interest rate of 7%: issued December 2009 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">350,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">350,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,310,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,310,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,240,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,240,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unsecured demand notes payable; interest rate of 7%: issued January 2012 — June 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,185,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,900,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Accrued interest </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">694,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">486,691</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Aggregate carrying value </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,879,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,386,691</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

561195 561196 561196 28680 6328306 2500000 950000 185000 0.02 476837 6277100 -96425 350500 2900000 1150000 P90D 11115437 834 3966394 500000 500000 0.005 39209 39209 2 197909308 1252833 629640 906278 439221 P6M 0.04 0.07 0.501 0.152 0.0999 0.0999 0.199 0.0999 25 150000 16000000 5827587 0.08 300000 175000 P10Y 58814 Conversion Policies (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii). 30877000 false --12-31 Q2 2012 2012-06-30 10-Q 0000094784 30635720 Smaller Reporting Company ALSERES PHARMACEUTICALS INC /DE

2210229

78716

99746

1316095

715672

2297042

76193

107848

1351940

761061

-31367

-38424

166170855

166160384

834

25188

6842

3600000

3000000

170729

129531

168254

127949

27446

20389

1758037

98514

73662

135843

63552

-24852

-72291

0.01

80000000

30635720

306357

640874

21827588

7172412

5000000

4655173

2172415

10000000

21827588

1000000

5000000

4655173

2172415

10000000

7172412

1400000

380000

2.50

724998

186224

362499

100078

208225

105287

Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under.

1000000

2525000

0.07

2891559

27274

893

197048068

197662277

-3391

6277100

69679927

1168879

571282

865039

418676

-0.06

-0.02

-0.01

2001215

-769025

86813

8023052

911222

208255

-461320

24112

39043

-85

88600

14698223

919009

18000

465258

209113

105716

628406

486691

694946

7705281

499

166

277

27446

20389

30424508

31004576

170729

129531

30424508

31004576

850000

119363

642906

159916320

1440000

285000

106980

88685

-159959748

-1553537

-357291

-197660277

-1610147

-533536

-614209

-294908

-206952578

-1610147

-533536

-614209

-294908

6386691

6879946

5900000

2240000

3310000

350000

6185000

285000

2240000

3310000

350000

197348113

691637

68444

906278

439221

-195948113

-691637

-68444

-406278

-189221

206959635

1610147

533536

621266

307846

-7057

-12938

-1473159

905

1229589

26356

600564

516747

5612855

132004923

1654487

8062712

0.01

1000000

25000

500000

800

1000000

25000

500000

800

4965

44008

9000000

66731339

4600000

39922170

58770000

1440000

285000

132004923

3430

2475

1582

7750667

3500000

116082837

83954

58358

41239

20545

12146544

1400000

500000

250000

0.12

3450000

809172

3645443

3011480

1.57

1.51

5000

625000

15.63

1.75

3650443

3645443

3636480

3011480

400000

1.59

1.57

1.55

1.51

5.47

1.15

3.17

2.33

4.99

1.15

3.10

2.00

3011480

28500

2288000

155000

539980

P2Y3M18D

P1Y6M

P1Y10M24D

P5Y3M18D

P3Y2M12D

6.96

1.36

4.65

3.00

27446

20389

-30602223

-31233960

300000

0.01

200000

12000

348444

358915

27548076

28302129

30635720

EX-101.SCH 7 alse-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0611 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Convertible Preferred Stock (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Net Loss Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0503 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 06101 - Disclosure - Fair Value Measurements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0510 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 06062 - Disclosure - Notes Payable and Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06061 - Disclosure - Notes Payable and Debt (Details 1) link:presentationLink link:calculationLink link:definitionLink 0506 - Disclosure - Notes Payable and Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Notes Payable and Debt (Details) link:presentationLink link:calculationLink link:definitionLink 06052 - Disclosure - Accounting for Stock-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06051 - Disclosure - Accounting for Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 0505 - Disclosure - Accounting for Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Accounting for Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Nature of Operations and Basis of Presentation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0110 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0201 - Disclosure - Nature of Operations and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 0204 - Disclosure - Net Loss per Share link:presentationLink link:definitionLink link:calculationLink 0205 - Disclosure - Accounting for Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 0206 - Disclosure - Notes Payable and Debt link:presentationLink link:definitionLink link:calculationLink 0208 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 0209 - Disclosure - Income taxes link:presentationLink link:definitionLink link:calculationLink 0210 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 0211 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 alse-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 alse-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 alse-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and entity information. ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property and Equipment, net Property, Plant and Equipment, Net Assets, Total Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Convertible notes payable Convertible Notes Payable, Current Aggregate carrying value Liabilities, Current, Total Total current liabilities Liabilities, Total Total liabilities Commitments and Contingencies Commitments and contingencies Temporary Equity, Value, Excluding Additional Paid in Capital Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at June 30, 2012 and December 31, 2011, (liquidation preference of $300,000 at June 30, 2012) Temporary Equity, Par or Stated Value Per Share Redeemable convertible preferred stock, shares par value per share Redeemable convertible preferred stock, shares designated Temporary Equity, Shares Authorized Temporary Equity, Shares Issued Redeemable convertible preferred stock, shares issued Temporary Equity, Shares Outstanding Redeemable convertible preferred stock, shares outstanding Stockholders' deficit: Stockholders' Equity Attributable to Parent [Abstract] Preferred Stock, Value, Issued Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Convertible Preferred stock, shares designated Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common Stock, Value, Issued Common stock, $.01 par value; 80,000,000 shares authorized at June 30, 2012 and December 31, 2011; 30,635,720 issued and outstanding at June 30, 2012 and December 31, 2011 Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, shares outstanding Common Stock, Shares, Outstanding Additional paid-in capital Additional Paid in Capital, Common Stock Stockholders' Equity Attributable to Parent, Total Stockholders deficit Total stockholders' deficit Liabilities and Equity, Total Total liabilities and stockholders' deficit Revenues Revenue Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense (Excluding Acquired in Process Cost) General and Administrative Expense General and administrative Research and Development in Process Purchased in-process research and development Operating Expenses, Total Total operating expenses Operating Income (Loss) Loss from operations Gain on early extinguishment of debt Gains (Losses) on Extinguishment of Debt Other Nonoperating Income (Expense) Other income (expense), net Interest Expense Interest expense Interest expenses Investment Income, Interest and Dividend Investment income Gain on Forgiveness of Debt Forgiveness of debt Forgiveness of debt Forgiveness of debt. Preferred Stock Conversions, Inducements Preferred stock beneficial conversion feature Other Preferred Stock Dividends and Adjustments Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders Net Income (Loss) Attributable to Parent Net loss Net loss Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Write-off of acquired technology Research and Development Asset Acquired Other than Through Business Combination, Written-off Gain (Loss) on Disposition of Assets Loss on disposition of assets Interest Expense Settled Through Issuance of Notes Payable Interest expense settled through issuance of notes payable Interest expense settled through issuance of notes payable. Adjustment to Non Cash Items Issuance of Stock for Accrued Expenses Expenses satisfied with the issuance of stock Expenses satisfied with the issuance of stock. Gains Losses on Extinguishment of Debt Net Gain on early extinguishment of debt Net gain on early extinguishment of debt. Unrealized Gain Loss on Change in Fair Value of Restricted Securities Non-cash gain on restricted stock valuation Non-cash gain on restricted stock valuation. Non Cash Interest Expense Non-cash interest expense Non-cash interest expense. Non Cash Charges Related to Options Warrants and Common Stock Non-cash charges related to options, warrants and common stock Non-cash charges related to options, warrants and common stock. Amortization of financing costs Amortization of Financing Costs Amortization and depreciation Depreciation, Depletion and Amortization Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets (Increase) decrease in prepaid expenses and other current assets Increase (decrease) in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase in accrued interest payable Increase (Decrease) in Interest Payable, Net Increase Decrease in Accrued Lease Decrease in accrued lease Decrease in accrued lease. Net Cash Provided by (Used in) Operating Activities Net cash used for operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash acquired through Merger Cash Acquired from Acquisition Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sales and maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Payments for Repurchase of Common Stock Buyback of common stock Proceeds from issuance of preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of promissory notes Proceeds from Related Party Debt Proceeds from issuance of convertible debentures Proceeds from Convertible Debt Repayments of Notes Payable Principal payments of notes payable/repurchase of debt Payments of Dividends, Preferred Stock and Preference Stock Dividend payments on Series E Cumulative Convertible Preferred Stock Payments of Financing Costs Payments of financing costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Interest Paid Cash paid for interest Nature of Operations and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Operations and Basis of Presentation [Abstract] Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share [Abstract] Accounting for Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Accounting for Stock-Based Compensation [Abstract] Notes Payable and Debt Long-term Debt [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies [Abstract] Income taxes Income Tax Disclosure [Text Block] Income taxes [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements [Abstract] Subsequent Events Subsequent Events [Text Block] Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Filer Category Entity Registrant Name Document Fiscal Period Focus Document Fiscal Year Focus Condensed Consolidated Balance Sheets [Abstract] Condensed Consolidated Statements of Comprehensive Loss [Abstract] Condensed Consolidated Statements of Cash Flows [Abstract] Series A Preferred Stock [Member] Series A Preferred Stock Series D Preferred Stock [Member] Series D Preferred Stock Series E Preferred Stock [Member] Series E Preferred Stock Series F Preferred Stock [Member] Series F Preferred Stock [Member] Series F Preferred Stock Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Temporary Equity, Liquidation Preference Preferred stock, shares liquidation preference Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Organization Consolidation and Presentation of Financial Statements (Textual) [Abstract] Organization Consolidation and Presentation of Financial Statements (Textual) [Abstract] Organization consolidation and presentation of financial statements. Working Capital Deficit Net Net working capital deficit. Net working capital deficit Related Party Transactions, by Related Party [Axis] Related Party [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Summary of our outstanding stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period, Shares Outstanding at beginning of year, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of period, Weighted Average Exercise Price Outstanding at beginning of year, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options granted Granted, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited and expired, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeited and expired, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable at end of period, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable at end of period, Weighted Average Exercise Price Summary of stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Range One [Member] Range One [Member] Range one. Range Two [Member] Range Two [Member] Range two. Range Three [Member] Range Three [Member] Range three. Range Four [Member] Range Four [Member] Range four. Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Minimum Range of Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Maximum Range of Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Weighted Average Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Number Outstanding Accounting for Stock-Based Compensation (Textual) [Abstract] Accounting for Stock-Based Compensation (Textual) [Abstract] Accounting for stock-based compensation. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease) Annual increase in number of shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for grant under 2005 Plan Unsecured Convertible Promissory Note One [Member] Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member] Unsecured convertible promissory note one. Unsecured Convertible Promissory Note Two [Member] Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member] Unsecured convertible promissory note. Unsecured Convertible Promissory Note Three [Member] Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member] Unsecured convertible promissory note three. Unsecured Convertible Promissory Note Four [Member] Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member] Unsecured convertible promissory note four. Notes Payable, Current [Abstract] Convertible Notes Payable to Significant Stockholders Notes and Loans Payable, Current Aggregate carrying value Unsecured Demand Note Two [Member] Unsecured demand note payable; interest rate of 7%: issued December 2009 [Member] Unsecured demand note payable. Unsecured Demand Note Three [Member] Unsecured demand notes payable; interest rate of 7%: issued January 2010 - December 2010 [Member] Unsecured demand note payable. Unsecured Demand Note Four [Member] Unsecured demand notes payable; interest rate of 7%: issued January 2011 - December 2011 [Member] Unsecured demand note payable. Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt [Line Items] Notes and Loans Payable, Current [Abstract] Demand Notes Payable to Significant Stockholder Notes Payable and Debt (Textual) [Abstract] Notes Payable and Debt (Textual) [Abstract] Notes payable and debt. Interest expenses Related to BCF Debt Instrument, Convertible, Interest Expense Unsecured Convertible Promissory Notes Conversion Options Unsecured convertible promissory notes conversion options. Unsecured convertible promissory notes conversion options Notes Payables Additional Compensation as Percentage of Future Net Sales Notes payables additional compensation as a percentage of future net sales per $1000000 outstanding principle Notes payables additional compensation as a percentage of future net sales. Molecular Imaging and Other Products [Member] Molecular imaging and other such products. Molecular Imaging and Other Products [Member] Debt Instrument, Description Notes Payable, Description Number of Unsecured Promissory Notes Issued Number of unsecured promissory notes issued. Number of unsecured promissory notes issued Debt Instrument, Convertible, Conversion Price Unsecured convertible promissory notes conversion price per common stock share Debt Instrument, Convertible, Beneficial Conversion Feature Recorded Beneficial Conversion Feature Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Products and Services [Axis] Products and Services [Domain] Debt Instrument [Line Items] Subsequent Events (Textual) [Abstract] Subsequent Events (Textual) [Abstract] Subsequent events. Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Investments, Fair Value Disclosure Short-term investments Debt Instrument, Interest Rate, Stated Percentage Interest rate stated in the contractual debt agreement Assets, Fair Value Disclosure Fair value financial assets total Fair Value Disclosures (Textual) [Abstract] Fair Value Disclosures (Textual) [Abstract] Fair value disclosures. Arthur Koenig [Member] Arthur Koenig. Arthur Koenig [Member] Percentage of Outstanding Common Stock Percentage of outstanding common stock. Percentage of outstanding common stock EX-101.PRE 11 alse-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) (USD $)	6 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Jun. 30, 2012
Commitments and Contingencies (Textual) [Abstract]
License agreements towards Harvard License Agreements	$ 850,000
Children's hospital Boston and children's medical center corporation [Member]
Commitments and Contingencies (Textual) [Abstract]
Amount claimed	642,906
Biostorage Technologies Inc [Member]
Commitments and Contingencies (Textual) [Abstract]
Amount claimed	$ 119,363

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

ZIP 13 0001193125-12-350936-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-350936-xbrl.zip M4$L#!!0````(``4R#4&*C.WG26\``!W?!``1`!P`86QS92TR,#$R,#8S,"YX M;6Q55`D``^K3*%#JTRA0=7@+``$$)0X```0Y`0``[#W]4QM'EK]?U?T/O=Q6 M*JE"7V`;@XFW0,"&Q!@*\&WNSE>JUDQ+ZGBF6^F>02A__;[WNGMF)"3`CH4E MHJU:1S/3'^_[J]\,^_^X31-V(XR56OVXT:HW-YA0D8ZEZO^XD=L:MY&4&_]X M^Y__L?^W6HW]>GCYCOU3*&%X)F(VDMF`[IUQ\XFU]7!L9'^0L>_;/[#NF%U> MLB.ME$@2,6:U6ECDD%N8JY5;;:O>*I^="=.'9U+9C*M(L%A'>2I4ML?:>Q\_ M6(#SHS&M[9W=[9YW!Q;E*QA\Y/*EM-5M; MS5?;S3I@6NR3NGVTVF.O&ZUF`P>Q5FNON;OW8I==G+F!MUV3,)BF[(\;@RP; M[C4:H]&HCK?KVO1A5G.[$6#=<"/W$JD^W3,<'W>!`&'X[9WQHVT:W=K=W6W0 MTS`4T2E&MUT:[!_0#K5F MJ[;=*N"&]>1GD`6?QN6$ZN!7#?>P&&KE+(+`R%;CU[-W5]%`I+PVO4$LIE:W M(JKW]4T#'E3A!\8RMH]TW;.TTJ7H,:+S7C8>`H&M3(<)+DOW!D;T?MR8DB0; M;["&6P@%NJU5)FXS=B6B#/3(B3,\B_Q]&?^X<<@3A/;`GOE(81DB("8(% MS-NGOVR\;>+_=E_LO'ZQWRBGE4M9T4<-*V[`+<>./7$[3&0D,P<+BR6,509F`&>W$VX!,X+]X%;:C;?%$,+PI,"/AK@5]QLS-RI!:TS"MM^8(,/^ M$);6<84H)!'96Z1L#?B]W=IOA'MAAE48!`Y,D'-LZW0(3SE:$[IK#_)L MH(W\0\0?`$M#C#D?XO,+$%5[.#Z^%2:25EP8&0G"W+$6+=<>70,A%L-*8)K) MCD"XW@8SVP3-*^\6`X6**\,[:-?[-'Q< MN]/%N]-%X'I>+4*3/G\6JU:UAS.$4UBZ>)Z<` MLY7B5!%4K/W44L<3#_%I[:=6AE=K/_4M.36W#Z$]D$EL@`*=G[0=RHPGG4-M M,ZTZ!\"Y\NF9B&4$#]L`L3"=MC9#;>C,8LF92ER[2+C$U7JVPLH"N8"Y0QSP M+IYXK!W2%9R?3:?"7+DXE$@,P_&D6T0#I1/=Q_3[5$4KR_`2IRI*@-&S8>?L M2=N1++E&5E]?B:X!>N&6-K.)5HZ(U5_R3D>[#;B M06@4^,^#T7*AK/@:G*B8(1 MJQEDK^5O+7]/$^9#C3">"6<-,Y M37D?2W9X?.0#6*/C/,I6)8#UX)Z;*V%N9%3E8(&E1Q)P=$&LQW"E>#?CO'8= MW3R+%HEU=/-L.BC6T4&'\`5T';8.V95B7:BH?O-3OPG\OGKPUEPF_)J+>)$$3$A/6)1GGG1.Q,J4 MP?&M?JU@]GF/4H3S(7YV%'*&MK:H6<>W^-*_<)\CG>H+J.*,**]46E%PSB5_ ME$*['\@XWF$'0YZB$!V/`'^`NRD"8$.,+9"!3]M-1GLD27.'L2I5-)F2)0; M\1=B;KBIXDD2K#1GJY\DZ?@8(?#T.1M@UQ9<0=[C'E!?*6X6T>O:A3X!YQ:2 M=ZQ=Z/*XT(4P>.U"E\"%+H2S:Q?ZC5SH(KBY3%GV(C[7L$SX?=40Z&?N.V+Y M37G#J>KS)+&=*S6.A>F\2Y;]K>LOYY'#U"$*>*X2O[9VRAJ;5)$< M0BI_/H)LZ!DRJZRL>4P)T:?AUM;.U^76&?]-&]B_0]_;'N@D?M8L"^A6L%TE MOK7"VU$')AODIO.+%DH^VY=I')(.QR?@$D04S:__59GU1]R?3=0X_QWRI4MO MG^"=ZP<_L/)UF_G+.[M MG&]_-?+=@K@35`3I"M!CK`2K4E(\5"'?3?:K4/2F;L2E"!IU9SMW.\A^3Y<'5T M?'%54".6:/7+S7'<^SS%!AL]\9F_U`7E;Z75+[9:.WNPSGXCW"P]PNSYM.R1 M4#J5:M["Z&ODGJ6_/#AOY;M+[#9A!^?$@=- M[C]SV0MX>FL,8L.,U/,G^79&\`RJ/S]O7_7!RS M098F[.+#X;O3-MNH-1K_VFXW&D?71^S7GZ[/WK%6O7C5M!LG-C`T8M::AC6 M2;D!$M4R/=QK;0UOW_CKKLXRG>XUA[?%(E^\>Q=_M.KL/<^`3DSWF.\5!&(S MKF)VR*VT>+]*;@*ST;V#`ET,'T3FU0)QF8G(TH%[`"84Z,DNP&BE/!)YAE\K MMYOL5$5UHKO,++-YU\I8RQV`;:!@3JL]1Q4#E<*&X[,-&6F&VS8<$!NY.Y("-^TI;O#7T MB3C\D$`)0(_U-.9-5IM8&!M6Q3*ZX0E@;6YT#@B,+>ABG5W#,P\O&W$+DW., MNW`:1CF$,'A`A&\DLP$@,W0>M5\ ML[/)MII-^/>A]>_G]%&.E3I:Q`4HK`?2`GA&@OYL,#PQ.N\/IG;?;N+VK:W) M[0=`6>`K<#\FT<$T"@PB$!'^02XC7*('G(/_`FC=W$HE+'`51LV^[+1"R@ZLV_OBA,`X25;?R!@/.ABV/,8H% M5,F22!ZNB:IEE@' MMN)F.KP>$/!'>)3HT\L<`(H=L%ZB1]89)UT)$"PL3^B+6Q'EH-X:A!7/'U!0 M)^R+0;``73)2Y`7QE9H44.%Q[&/I M"J<"GF@T9(:8@;-#9!/!TY+'SL1KBT:>NAQH1@*01$A4@\8):-`W/+5.\(=&%,^Q1>*&;*$W^WZ+OGO1 MQ,GYQ*M"CA\H<\1(1CW\#D^X64P*2",N-RY*X"YBX-.6&@:4E+$/M M"B:;&%WG24:L*%WM9NE8O"OVKLNE#9B9D441L7.T,QL=*)7#_$N',NP.D53* M6LW:+P6M$"7P2[C0$9`BG8BTMYWG;BV7*DS8[L_1@AG6&FT-ZY+?&@TDYGS6 MYKA_$105B?U$OL.Q%-'7``&1`.Y#,*#\&E2P!,M")L=EE#SQ93X*=2$*];S$ MI_@^JNVY_DM\G$@7SDA15!X46D;<'DP["6<(/ITZY,J'(AD*,:JXRHJIPD4Y MF/N*:K`50JP`QBP!,J';)H3.TR$RK>J\8IF2@Y'/NZ!B79UG>"MFFJ!HH MZN/JSV#RM(,!UE6-%_$UQ1,RK^`.)802H`7!$LYX@4!4J+H\$5<1;%U"7`J" M5";U2Q=GM1WU:%LS!6U5&5,>BQ"K@$\'PX1&:=HPSA*`"MM=@0'T>H"]#K`T M"JP7+HPKP@8A>R.[-ZS$J?>P>+^QJ()]Y>0%B]%SSU8^Y_SE2O85T5EE927H M0F/#AK#/]51EJW*J\C@"3"W^Y/H+6=Q5GJ881H'L5F"NUN\"U,NGW`4>[5`6 MH!_'E;+`TL%>1X2='Y=MWJW% M$%Z62J<]A$",/3H0P:KX$"G!41S=G"Z"IH3NSPN@\A)F"*X8V:%#^4("=_\(C0`J%P[L]'N`@8 MA:41R)&SP"BT0=Y#;;^DIBRI.7GX)4`*4!LLJ\T&F"@P@@BY6!]4 MA5=JF#6(%FJ68S$33SEH)(<8V"4+"-@D_$!$2GX1=1'"<1?PPQ2*0F`?'4F* M6$+Z!V2=S5@\SZ"HJ*!'.!G"E$(;]!<^8C<""^+EC&I&J/'Y9$1$F'MX(,R. M0L\GDO&!\OX2AK_MB6#O':*U=$I=MM7."4^Q".'J$??G\;/#W^EBY.P]_+*^ M%B)#C@KWQG[_2$/L\4+I,^,E%#Y\,X71JRFL^F[*\DF@.Y0RADHE/,6PLJC\SA2T>6<\F\&B M^/3)E3#<$8DOR4*$Y/YFGCL'B2*3AP,I.G0K#Y=P>R!@:3:M=P]?%`2!Q(3T M44Y8?<7=P>W53$?@37MY_C[+`SP$%2B0J_]X#S'A#(JVD=G)ZX0;`4=ZFJ&/ M<^=_6`R*B)9XJFFS@FS5Y>_C8_FM>[#A73#@/^F1@%N;3-(VB?R$9WQ%E>ON MLCB-C4(I$_JS&W6D0T/\6BBA<6)+V`1:^&(374(W_8!5BD2%*EC?7!<@;I* MRJ4S1Y?`62R?73I37IR@'/D/_K`P8"GM4^"-+\9@T=%!2X6Y2">@E-J4YT*0 M$:,[0H-F#'H#P;['$"UU9?GN M&-;ZP-[K>BG@6\WF;JVU_<-FL$+,=3W'[KC88G4;+09V]UH7VQERU.)\ M'/PNJC:MDHJL>E0^&HC,:27*?@(A`$J3QYT"3TL-1@FF%$[YBS(;*&N*]J:Z M1H6@(8R@BJ\_/S=4EJ6C%[#KA'4/OB`O!-3&GXG`8N# ML0IPN4XR-WYY#J!H0V]/[V9VA<3<"*![5C/2?F*P*':K*%=#*H[F*Y)Q(Z8E M`_+YBH$I8W26#U&,H@%V[E2/6LM-J+9`O#45/01%!8E,7#[:#%G"CUR6D:#W`FS$I4#9C\8Q11/I!VM2"7]<>6$42J%C>+!<#1>,8L5 M$:9ST.Z$3/+29X,Q5J4I(.?H%+Y@2KFW-K9HV/2=&.&`5'ESFU!8.6'-NXGL MAZ8!(I\G".[5D[=H#TU1/`FFO,`:B!0.'JML'-.YKUDF0W.NV,];4(-^[4W48:=$1+L_UI; MVZ?_7SNNG1ZP+Z'.1@@>W.-FUIVD(!'!'`$A23L5$/\(&JP!#,\ MEK`J[X+#!2#=*_`@<]1"*?"W[_[U=3B01UGV\;LF?=]5QK$'$A@VD13$T@JL M4E*3O?9&L6C=K[,/Y(:ISDF:Y_53$Y5<_AHHM5E0:8@P5(G,02,F--/-9SWA M4I&7S2:UNI)YQJIGJ&&`!TQR*IZXZ`;(I41?9^@T8%5JV_YW>U_#W"B2I/U7 MB+Z9BYD(62V00%+W[D3XHSWCN^ZVS_;LW-[%&PXLE2UV$&@`V>W[]6]F5@$% M0A)"("$U&[$]MBRH_*JLK*S,IRSR'Z'@(W(P\EM:*DIM!(Y[@@2P;P%O\(Z< M#UCX,Y7!BK1/7!<-IBXVSAIG/JK=!,H$^SRP$1S&Y(BRU'$D)>[_DPSZL@W1 M_,1,@:B2#ZNM>+V]1"8Y2%Z3P1EP1_-I5$$8%QQA+(+F+HQ]M?BPQ$6RXO/+ M>PKO>?>'[)[EJG$EEC'F!W`9$-6X&*S@PCF21<5EX+%G*K(759V@>S_D>#IW MHB/OJ/;GT@6=T`[-FS\K,KH\SB^IS.[RXC31]L'7&/62$F'B8/(\I?/ MCR@@I#4@I!RT'=9T`>74OI@,;J-`DQ[#5MSQW);7HGB=(6I>X[*K:&D4M5B+ M?!'SCRQD7B0_149=GOC2,L<+<3;DT@QH>0''Y$E^)YR7/!?+]WG+4AA^J@MF M+->V+UD:(Y,FR8SIP.26%W^Z'M<\T#Q^-$=_)N)UF@&4L1DG3`P=S%ADV.)9 M"XN^!8M7IG.1T\S,CKHMQF#`$RR+XX8WFI.JS5@[3O(UW!4E'%P\/BX2+O_^ MB,Z_L#8N44\N243H/&Q8>F1O+K&$Q>"A9QJ'+I>\@._RUX7%0SPO).(<4RI+ M306G08)B>&/D5FN8.1JQ5,6!YSKN7$3F- M']J1+_H`+9Z!%-XQ;*62SF3PK,6BET=N/?F%C,._\`&Q6\.DJ1,UR5`O8UR[ M2W\.7JETRJ<]>$$./^WY'%>N'G\C?UT&8,?L[@-Q@L/O`@:N)ABYG(^O^,O'0"Y\:JTH)Y%=:7824Y(FFQJ M%F.)R;%>2A6]%K-Y,$\<]`@I4TY-!C$'8>%5*!I0_HU@FSI%/9":=*(+\4$B M@-16N_8=9)9+)(,[/>FE_0433A=C-&6N]RT6SYSQV^+;EEY?`8]N+`N M_-MHQ"!>?K>4&UBMDHX_O7SC2O$!8JP.FXHEQ,+@.OAPPC_<;A6_70:T$:[4 MZQ;CNLR@#?G^H=#D$K]2EG6[\=565U=;PUXG%QV.^^J9L[^_X_]]5ZHD:NG& M#EVWJM'J#/4#T&VA:&7//DN^P!ESJ,?JH[:,!,HSZ+ZAMCJ&>@#FW*BXJ(I5 MO67TM0-0\2J/=3AQUZ_K\6H:KU;Q,MWIMP:]P0&8?*/B@H0,AZU^SS@`#1]B M&";?Y!YA>37.:UIL>;56Z4(3$I716[X.WXS(*M=/2 MM.&A&\51!Q1=6)$0F\]FNUT)2QJWD63EDLQY.IUU\OR>"IC$2'&98L'2N"KJ M%C^9'O;E^#?,H[N6CK4RL2=5)B[E>=_X=[VV\I4%'+EGQCR%J%-6.>B]5!HB MIOF(%RA8]IQ:#$+<&Z2:KN52S"#PK,=Y$/918?\-]H%)J$HQ3-/(M/$V6-%M M0'W[6+$>P^DD7T8,9[U0W/[R2M$VX9IM!M=V*'"Z^U+4D23PD% M\\XS63Q9=T80I_S.#S`6_HP$?#N.T6>FLWG`D!1VS/^5(UY*,TF\CPD_&WN%5I(I&:11D$:XM,1\##'C ML3%C4YK[LZC'5A*+S"(Q'[*9G'M93LI/3["EDXOW7/'.N`@>+M)X'LW@91_X M[@6/PC(D%@>'M[DI,/P$NUC_FL/.@V.O(*J%@W6ZO,\KM9XAD+W[QO#.&Q>O(X+0 MHR5B$@<['LWP6@*?;BHB3`YS_((-^&FH.9#V,G?!6_FT3D<7R\M51-$-\I.^ M$H^^B7])=/)%'>K131`^PJUP$"#!$]U``1'6*`@=Z^(G'-NF)7[!A8PAR@N= M-?(F=W@_==F1).AK)QR,QWP-.\&CA;#;ZNF\1SI>[S@21KP\<)\;<15>V(&- MI<24SV_+0W0..[H@`[$2^`T/H#^/4!!"T/\H!A1#QFW^=(=,*)9Y!(X0#RU: MZYXLS\?6X;<(MU4"4LKJO7D"7V#R.S(R4!QAE0'K)U@$H%'Z+HYLD`$QOJ1$ M<$;8R!<2D'Q`[7%YY>4>_L-!2QB:?0@G!7($O>/7>AU9/Q^5WH\KP/5(`(G@ M56@U0V[\@XAT?G,>JHU`2^2&>A'-\W95>/+"`IM#B!31F$X=Q\EV9,+-MS)@ M0K:X(ZHJQ*0_\*H?WQ4N2Q9>PM]8(7@Q;V%=\&L"\T4=#@?*]=2!;9)/1LL_ M/A6(:2CD6T9MGN/H:]RM"'`4,O2P>3;S,1BB0V@\GX3_(S8BK4@&0=_ZK\B= M+HPC+HSA]',!L&\SWCA.M[F$:#VRLQ)NQ*(HB2YB@KE;'YTB2EYHJDG!Q#;M M1Z`K+051-SDVF?!EH$C"*>,`=@L3%IT4^1R2`W=\%J)&72JYH_H(C@;\ZB:6C)$<9X@:%@$P@'=JP3Q%B-?2=M!,2.*J(ZCHVXH MW<31Q\>P(UN:108A13+A[ M:"D>:O5M*=:-+5N*\SZ_XR\UY'[GY!:JO3WPYF!CO\W!WV]7]OX%7Y^VZ^]A MHNVY"Y\2O_[W.=7V+/H_Q-$K?>`I[RD$YJ>P\D>?Q!E/S/4-;LH;E36SY7L2 M_8'.EIRU6M\#DLAU\D@Z/FN`W3Y=)KL@PJ8CK,PZX&[+Z!JMWJ!!%"E?R7M' M%&GKAP`FK713AUC6^)68&HNA<5^$UL4ZVI_V1H.G;6[-VF?VZ\6.FIY7YS+'3$ M^OVIF;C'J5A5;QN'<-:W,HURZ$A[KV>,X M$4@56>*-\.Z3@'=87,2;C72Y15J(=M446!YID59SO=51SUVCIS<%ELP;G703:S>[ECJ,VTBRD>3!2#+MDJ/?-[RS;,F6L"HD MX7NZ`0;1_`FYEVCD(+7P)81"Q^MA.(JR^>C.`V7%+2Q4T9S84V8#U7Y0UFTO M:P)&.^C5%XRV-]P2C%95ZP-`NGMZ#T$JA9)+(3^I`'6E?Q03:*%^YR,)Y<.@ M-RL<5J=`SFY-YYGPQ,/&3H70RU8BSM4E\U0;I+BO=%%!S(Q4$K-*CC79$9:G MCWWJ($+KBUC(P.J[95/3.)>UL?5<71>F:A\5^*1KU'>!VXK;VJ1GM98V M&-2B:^@05LVM&%3;PY@8NN.H1HQN-W?W;,3H.@[`?@_Q^/L'#5Z2=,O==I:W M:-QRF1:M=X>M87/>7;U3[K8UY:A\<6U,6&MW#^',]TBBYVY;3;GI7MO(6!0; M-UUN7W8].NZ/WDWK[6[CIJNISVFKAU[#45NGW&L/ATFG;+2'34JCZL!CT-(; MGUR]3U;;>N.3J]G]M7N'[I,/OJ[N.%$ACDF.AT3K/G6^4>C4G)'EV>47FUO- MT]^PY9M..;1^]_Z.G@VA?REEL4<-Z6X\IKR9\P54L)_`LQ[=&*+LYU<7) M!;5AD6VZL#;ZW, M\HS72RES!]9U)9@P>+:C*S>VZ;251;V(]?QO[^?^R;-ISCY<6/[(=OVYQZZ? MSMWIC#D^51+?,ML,V/C<]0.?+IP],WTVOC'?IN`/_'OV+3BSW=&?OR!Q?PO5 M21^!4I^?V5CYZ@8,M!I_@]?.+/].2-)GUWF^9][T@CT&T4"PWCJ8*KEE3W]_ M]Q^F<])13U!*#R"\DVZ'?G[WB["MB^OS^W_>?%(FP=16;GX_^WQUKKP[>?_^ MC^[Y^_<7]Q?*?_]V_^6SHK8[RCU(S[>08]-^__[3UW?*NTD0S#Z\?__Z^MI^ M[;9=[_G]_>W[;_@N%1\6/YX$TI/M<3!^M[Q>:)%G0SE15O*;>E>FZ0_*-WU\ M\!%_,-I$J*^`RGFE..@7*>1&]1A9U(J44E,AOCSB%;09QI85XKU=%%R7.LAW M16ZA!'(%Y>%JB?7AYZ[SPKS`0FM/^HC`5>Z``^O)&N&:=(=M*!/7!OH.HGC\ ML%Y;F_+?A?`E_@57Y56:;W12D4XNV(@E&Q"Z:E(OZM[TDG-74+,2[(I21#5* M+^WIO/)WQV0S9OWXF07LO0==@D'T+-5Z/;X]7M(1:*?(^.M\RL]MGY MY;%,]=HP;"-'(^M1KLY1*LH"L0' MZ2SW]/G98\\8XXU,SWO#$D6J6R0.EYSV-F'=D9V<:&IKH/5;^F!P`"M]H]PC M5FX3QI42!QPK('CW>K=:?'7CS!3[AMT'O/'"[/@'4NZ,(CIJS05@1N` MBB%\^J%K:*W><$CO_*&O]5K#X6#'1*IM(#!*U=$G+>76A9\#Y5=KYB/R.^IX M`A+VPT^8S4:"*D&18G*V,/_W0U\D9GE_"7P"A%G>"N)!4?BF*9`;(LS30PKV MC9C.6QO&MWR%^B+,$<'1HY1F)@P,WS25,;8/@+SF_(\F1*H,VTD4.I\!2FD$ MD(T[?Y[0FR^MIV"BG,*7QO1%^'.Z^EBYF7NCB0D:.XW>]]._"_0+K?,Q>CCZ M3/WXL_(ZL4836)1]%U.E+Q9(GL003$R0DFW'5FF.1MX<:$/-N&[?P M`@%4%&]W"@TB5(GGM[A.?[)^CFU:M#(EC2?4CMK_Z">-#!4B1O1QC!GB!^,5 M>+PGBFQ9:^LP47ZRY&'PY11NH88\F#J@`^5I'@"G:-+4QY2>N5G$3%V81W/; M]!1K:H(6GDD>(!ZT8W0"BCEUY_@R]A?B1<.KM!]7<3?SV`ERB,UB\'V/O3!G MSF12_#D89S3"S)[[2J>MTTL%`PX#K9LV%V/RZ^ACF`F?_*"&^;YTTQJ(T!E9 M,Q@$M1Q4^/$>.2$8H,+740.NP&"HB^OM8-'-C*GC`Y$D+#0Y;G.BO,1T;Y' MXEC6PH>#BPX(;A+@(,D-3LP7SMK4'..8;PI=XF'#7Z=(`6I14+>!WTB$TA]S M>I%5(4B61UK1LU74(?WFOL(L\%K<<&,#M'"VN!/KT0J$@WZ"IQ7V]`2&2?>9 MR)YA<8&RGD('A<-'C+$34M6#48/&'^B?^ZSPR>]917 M*YC0BA&[M<3[`GQFPFQ:05Q\Y!51T!^9PYXL=``V6/^K`Z;]^)8:$&*1$6-C MGQA7A^WACS3-X(?AC\K5W3]N6J&;X:NZ0W<.X&?(!+P1#4F>61MZ7@M\U-@" MIP0D@LO@*V!:@','O!#O?P4G:-E+7^U+W4"*.<-EETGADB^0'8@7I.ZX\FP*O70XQVEHV_1]:ED, M>&@%EI(11(4R2KHV>BHKY,*O2F'7XE=\.0"#>#9AA,FUX+)PU30A@`BH>9?;QBCZ$99ABSV)]R)ECZ;S MIS>?!:,W'-RW0%L0"]CF:]:2AT[HQ;7!T$P(`Z,Q0&2^\,4K, M0Q]5F1'$R9K"H7'A2FALY#&@H,6W1`E/U\)0;6H%(GI.7D8%UNR@U;*Q@TX$ MY0_SG+U%8DAK;\Q@RF+01ZLCO6%D^A-E;&$,[XS)04[!0RLF"6%L^8%G/VPF^**O0M0+(FWQ%Z$S6.4O3BH1#KQAT"G+U,$X$XEA`[P?7"3(-WC(,<(PAN_U"`K*MO^;6 M&!YOQUO]37U9E2WF9]$2*#9UM`1<@B%A:/;3V?GESTK^8XLL\HWRJ:?Q[E_= M4&59VZC%C2`N2V)-YO'"XH8FW,:(K>DK+6*V^TJC`!-_0L0??3-?`,RC&[0` MGWXR8_]!%(EM-[%$L1.Z?/"LMQJ`OG9`U6,$[1#N@Z%C\UDHC.29&A\?7;[X%HI0N%:0S\RTQB?PX,B<61"> MP7;!MJ-='A(=IIJB@.5ICM%@DI"%]-CW/'G`F^D:-<28&6^),].N#J7!@Y!8J*JT"`L(8E@8! M<<&W57G1'_)/Y:9UOX%3J*%.&CB%LBO!FFJN7#7](G]%L:K8T&?4\O=__!!N M+Q8M%6+?87W=[E9RVG\ML?@F M[R#*568@2S>NLN3;CWN' M,HL:)7\'2FYBR(ZJ)1QCNNA!Y-T:IUC=?!DTEUH>N8JE"2;1M!EU]764A]#. MM+)%Y3A[G!LY'FBO^&&<$!2SN6:%R";$:*E-&'#L2M9;PZ.`H=ER9]2M:F=T M*AK4PAU0LW.IV&D->ZUA+^."[=I9/N; M35W-2\G5.H.6INN"7'";FM8K3FY.5*D5A"I?W1<9QTENK@Z;DR6PBR3,4[JS M\3?>8",W-IK.\E[45@(5@'<_+FLF?9VX,3B%/W_TK;%E>F\MY2N;>^ZC!7'H MLS7R@:-1NZ5,S''\NY;VK$=!*&HG*E,"G+$?Y"UX%1F._+?988JLK(E1\LZ:\ ML1[LAHCE$HL:-A';2D!X/#WY+,!F^^AEHO]6Z@@E@`;W$?R3*9K%L>FWI6N4 M\T["8"7;]HG]\=Q#@Z8J+F%>&N\G3MA(?6`K3D=A[S!VQBIWHPG(WY9FR\7[ M4P&,0&P@PW>?SK-A=[0^AT)+,DL\98"I)-6G=]IJA,DD0Q"L@#,33;2$0T1= M],F!$0W&57SFO2"YT1.X+-?P:%*@ M`_[WME*)GEHI.+JU2E+UMK:UDD@8:_E1N[\NY2@IQ(B94R^8S#WE/UW0\O-Z M9OH;<[(PM!I"_Q5FAX1!F`IIOZF%`%5H99D,<)2A0MI8VG>^#2_9?/0C/M;/ MM,^?S_-YBT*LKX(*4TN!\%K1?9\9J_[M_=P_>3;-V8?/KO-\S[SI!:P_]^Q; M<&8#`[_@V'\+@U#Z"$+1YV?&^WHA%HV_P9L$EW_'M'WVX9Y-9ZX'ZOGTU]P* MWBXL?V2[/D0AT9`(&8&)IEOV]/=W_V$Z)QWU!-7W`(9_TNW0S^]^$;'QQ?7Y M_3]O/BF38`I^\?>SSU?GRKN3]^__Z)Z_?W]Q?Z'\]V_W7SXK:KNCW.-"+Q;9 M]^\_?7VGO)L$P>S#^_>OKZ_MUV[;]9[?W]^^_X;O4O%A\>-)(#W9'@?C=\M; M)!>Y[RLG2D[.4V_=$:Q:E(/KMQ.XF3<>>V(4^5*3MI(_%;B7\H.@KDD8:;&'(`/0NJ\@?+?WN>8!1PP&;8\"!+Z5-[8BG3'Q%^''$9P)S?(3H#K;F%.C5"(_YVDF#,ZK=%E%!6WS9=PH`6\I.H2\F MV9Q/+'OL,2>Q5O[F^H0[I9RYL#QQ@/#,+WYA8UAB;%AM2,'GKH<^CU893.H( MX$)$//3GJ!D@UAJ/;>:S;\K='!8#W/6>NW,O:$E_.<=4SQM\8OH^+$5SGP5@ M2SYC?XK@'RWOA<6XG!".LV>>A$.7]N>2/\4V@]_,_"=$@65S"33:&`L&W/$D\%QAUCD\2(J-BGB/ M+8F;&!H?PT"$/HL,KD0#JW)Y_`RFXR113&NW(,IZP21O(B-K"P8D&,6%;+SI MO9BPYBWRFMA70&`M8^#2Z M@^MHBR.M\1DSP5&^\NUC, MT0\X:`?.RBFB_,*J)T&\B[G*XPA.D(@I,KZ,TY?S@TFB&`[>1G)P,1U-T$%, M!5YN*#<@#:03X&E+]%*_/LZ>!ERVM\XP[X2=+MJ9+"%^B09'4';?3#MXBX49 MW8N`YV#@$/%8BGD(Y`4>D_9RXO("?J4!HO$Z^$1($2*L!@AJ#6O/$V,\M.8Q MY#RZCP$(1N"45PD_SH]MML^H8LL'BZ8[9??FM^/?X`VE#=XJ MMO>]G1OB62TA;`?FMSKNWI:"PBLPP@1FRIB.E&A?A'$'GG<+=J+TT;_FGN5# M^,_/2+FCYV><$,,@RC3.<]BZ\;_P>V[D9_S60H0.I,"#>$,"+#;`AIRP@I'? MF.F%1^?+$N:=870+T*J<.@K@]_:=./S'`]9;<9?*'?->,%+]Z>KV3D+'QB4= M1#"S62`.J>=CBY\71Y3!Z'UQNMH9\-P1E0K@]1P(RRYB0@>A?O\U]\4>62#Q MTP(CY(ZO]!@L,`Z=#X8G&GS'BA#>X*G$P9Y\;LTX46TENA,#[R:9X[U8C):E MJ(H2*'I%QRRIU0PXVCGS^5:8WHYWQ7!5XE,PR_Q$'/'U^G,B8*"31&#>:`E] M2R_%W31LGSD/1"?RA%MV<+DV0A:'1TXAYYSMU-J;PR6O\@Q5..!+T_+^@66I M\7C^L7I@M2.YX)6,[]L'(U(U$J@0A2STB>DL0"U#@'EIZBDB;*$'^O-KY:;WY#1Q&577`BM>O/83?`H93JR3)KN!;'G_!8! MO!_DU<'K+.93<6<&W5V#1V3\)@7)X.NR1;RB[G&`/D/A#K;Z0^'IO2TA\HSX8\SLG MMY')%OWA#19[Q?CXCY[R'K\:AXZK@L6:=""5IZE]:N<*%_R8?@H6:BG\VMAS MSKL%&IL^,)O.V?=3_%Z&P^D%OINX7G""`3Y>C\A$TFQ=#%L7(SZPUE"MT^H. M,FY\J%U?Z/[=R/;[8,E/UXC-P[;??JO7]*S7QWY7;7$.OGW[.)%0ZB/\1F-U MT]A&&8M]H^1DNN+]CELHXW-<:*'AONB']9N@'<4,$4E2\)N?KDK#B)"RE,)J MN6]OK+-BZXQ#V\8Z2['.HPY.CQ41IS[B;W16/YWES)O6#2]I5??JFN/\!`10 MHB;;STR<8CF:;U%%"0S9';:TSC!NC"7.+^VYZ[DW\-G4#!N\1&N.S_N#[ZFV M3SR%I2>!9V)-ID"MN;X_5\[FMLT"+"%SLK^X865=.X_#NM1)8I6-@,_SGE7CA_U M35O.G+?"$!O(Q0OSPO8Q8.'%M>=3%A8B4H$J+[XA$CT&!"2;#Q(O'=FF[UM/ M;[S#ANH[D$)1[E.?`O]$XYM%#5L@Y1>L-4/\)^;L$4=2N> M5+D"WPA;0]-E+&$EL=#I2DPL1,=94=1R16V?2/,,>TK!9D477=BRR>MLXK&3 M$!R)F3.2X`X0=DFJI^7=I;;U)[-#`Q%-7HNO)L2F5W>.W>-8EP93D>.&V,PG M27%[2B*;)AX.JW=3@`"\DYYZY]MZ!PF:0*!),TB\,],?<)R!Z-E.&YW+BJFR M9^"1E<6E593QWLT???;7'+SDIQ=TE4=;PJM*);Q+F=XSZ@C.Z9@VA1.GK-I@ M[*L+GN&\I7X[;.AEG%!T;#&"G/"+[DA@!II/V"R]Q-%ARYIH8"!'@+[KE877 MS_&%+NF*J4.#5O?ZK"97B$@%OHZON4!_A.]'#C^"]?/G4X[I)_KO%F$+PW8[ M['.-00*Q15;`%#Z^(;X9QUV,(0N)8X0MC"3G*E^\=BQP@5-"FGFD]HT(?4^X M]/CVO_BI&<&N.?-2V[`_BO)'^:/MQ'_-Q;^P4B::L_DZ[CCNW!F18H!O6.`2 MC:N$QBB:^GA/WU<3N_5,;%R>48PX8G,JL@[[MW_Z^L^[3\J7_[S_H'P]_<=9 M2VYR%0\GHK^X/;:E_.^"4`N77_CS6!VJUJ47B\^V'428^/\[^71R=7I^>0]\ M8_L4KLT_P:\_MQ#:"2(_["X?*Z=VX+D@;U8:.R0^CSU_7,H4]D$J5RX8%3L! MYL&4QY9KFX^,.FK"_EM$T<`>(?QEC/$HQ+:\K0BT;D6M-V/+?'9*ZSY)E>G=Z)68_9M!"';,R,YA-%PW&;M M\L&E_G&:O6!PHCFZ11L,UZ$&6&RPQ87!5L9S5!ILF1FVO7KLQ0)IB,!2/$D, M8Y.TQV:FV+[,3/!NKZ[W)TAO!#$J2BDF*FR-%>\1%-5'M33@[]%.,H&:M="? M'"L>A.&@KD,MFDZL@);4Z.[/'R,E((X$V+LWFK3">=,2C<73*?-P8494'%`4 M8?:"@AP6MTEFR1-WAA%MQ$E(#\>G@4TI.T'V93KB=XAV::0LY"MJG/[)DKH8 MKQVF_`8&2>!F%*N\G5RBJ=U/W+E/J0:LIX?%\*[`A?L&V$-<5 M=V3A;_@=[B$XZDL8\R">!T:"89A!:A6YE["9'9R[Y0<"20>((>"`V+KB9G<> M3Z$^J,4](@L]>`P>K+95/=9>2)^D+F%LI*J6,M33^N1\$*0-#D4M:`GJ-Z.< MID5('Z6PB/MH@M'<-;%WR\+F?`$+@`D&>!GVVH(,L3657A;UOB*BPPO'K292 M8J+#I%<8PUC@,8'(MQ,">L,$53CD.,)CB&<9/$?[;L0/:$6`#O"5D>E/>(]T M)JA?*UQ`::)%+X[1'<*V+6)^BOFDNDR2R!OB!*&%`IMQ)5#5J)^.^/\DUC$. M8N:3M*A%$>2'R](C1M62$;`GF&$<-H123&,V`J<#`\$?.-RY:"@GQH<=V`6] M\69GR;BB;8_(.E&F98:=8$&\#'-7#=./YU`DQ$7APZA!VT(D;K36C)D>)R<7 MO$9]])5:_#+6NU"CY(MRZ$6L:Z1&VX0=PB0.9'F[)8+QDM,AJP@W"F/I81XP MV68,.2FF9CM2$.9Q'5="Y"#H#6)'QH234/8C*D3V-81IPZYZ4*F')(D-=TPP M<2VPJ&2D%>XS@',D$+T)L>:\)8`*ZJ/F:SXALK=VK33(>`)#.XU"C7K-`7S, MFZ<%M+BO?/Y\TQ+`96AL"_"<;E,&#"$L+("1&!!%`7I2., M:!6W'"E=(6.#QJ.F+DKPXZL8-B2-@%+#M,,@PI$66$-?8<6[PQ6/3X_E">S8 M[J/YANMM/(NDRPTBT;O+4@:E68[D(%Y-%#_7*"E1UHHI0?P@FS$[?+U/($(H M8I%(J!+__(/>&FC]EC[H\Q[A1XQ-$`Z(MKZ4@>/CS\#E21N;.";$?^`/N$@\ M0F"1"WMB:3YURXPU8I_/*2!5;EQP[V\?"#Z:#R$YTX64#P69Y<\)1&'<;'+"I?ST#_CT15^ZRW7@,%[$VPPQ/$^1"[\JAPQ70M:2I68JI:`E6?>J<0O/\J M+@!HYGBVX$(\_APRJ]OTSI[0-(W%U+4HT<7,(#XDEJ8PA?CAF32/+6"MQ6UV M>I-/:)!<.3CQ0Y\A)G]VQ4D2L30\+1,@4V,)EIZ?13/$GG\T;=I9^!/&^.4L M?%?!<3Y@S>=+M2BM0)![BM1\'L]#N$9W[JQT/8@EDDTP28!J&,+WBZ1X"*EZ M`IN%$]HL$*0O$\!:5EP!DZ0_4?3`Q3%W0!L$>L5!M6`<=\11.\,]ML^6*#:Z M02J21XA?&X20\V%B2-2F1$]P*!4>9[OX=X(T\]@$,QPO(@G#Z8$H#/\&EL!# M*MHT3^C&,%\*-A$^UAI9J[;"`@\_Q\2JS.EJE3K=;@8(?RQ4CD;&7]LXWVP! M)G'[<\EN/T[X/)P28;(OIE5,'(]VE:ZX]V-5C=$84S0$1DK-0=%-=?%Q_I(Q MQ&M%U52$N@B?O8GQ!2Z_0(L>K2-:N`5*J7(N")DW4$163PPH.:UGV$?QV`^^ MSK=DZ%"S'9:X"B2F.2^P:BY#J,QI="MU&KVE*((24EWC-59),`N)<)WP]A>[ M175^(1#\J@K$\&`AO0%JAGLFMT:G3KS=*"5"*TNH`J]'(@C# ML&29J7!?V2XW&:OY>ZDDW;Z*-.*^EI6DT3EEM'_AYFM+5VS0.1!573$?EI)1 M>'B#*.XQU;(HU_PS_#4TSTEIY0(]5)$O;A8WCA#FWCZ>"/5AG/P]A-/L.\/+T[4T[O MSI5!9]"*N+%X7"N_Z51ZEB86?:>M7$.(%Q*0>#_/-?^/-+R%!^PLWIE#<+/+[!NWY7OKI282=B@)^HW9]; MX=*@C"T\^Q05C3X6/*$;GSL67X5C$U$LGN$,C^I'$,&BOZ6W3%D@@Y&^3E@P M$6<[8V;C11RXS@K:<[3<'#SK%14!^AR30,"#'3;BX)T&< MD@"U'!V;G^70(8J[A`1*3H@!Q%_?*&O#/`0D#^M%PM4#U9-^A>7+*W-TJ1:_ M+NL1^1-76'/=XA:`;O5R[7#GP1_F9O7*HB,>_OW<]FM1HLL=\3+KJ2MV$RM5 M^4C);)&0P1(`ZAZB12N"5R83$3EM*B"QQ7(?6KD7^X38&'B>R;;$^20FK,1: MFR2HK9R.7TC,43%!=!T2+_[#)1RI%A$A,SU'%#);_IUP,(U=62I;QPM*6$5\RDMSM9EZO@FJ1[U/Y M([9*F%UQO8=(8<8T`HF19%%`Z6(`2B*()9-/MP7LBS MCN[5(2J3Y"EAL:4SP>_)+*1"NG"B@D5.T_<`F.%=*2,\KB9\?_Y'PD?&=6,U M/;P:*:2)(E5^<$Q7?5*XBI?K^$'B'?R*%Q1#=%\>2S@IS%0GZ<>O\%Q#5+]( M55BOT8T1LIS;X.43];12@9XX"@[G$9]E4956JOPRO`V0=VK$]\J(@^244XJ- M+0&T+;E%R83#*QHDFS3C-9LN.TA<$R0F?*24>&P7:RM$&XBX=D*87U1F8;^) M?LC8F\<5,[PO-+KF#*'@K6^B&T^DC4-7'G$-0N*=?&\)-;[QNIHZ.9KKJ(P[ M7O;58<;U<^E>AH5R[G4M#<0:MC6TY#+L_U6UKBC_OSQ/E/]3'6ET?S`.*I5C M_)Q9EJ]DUN7OI"Q_2;DTKSOG287%"C*J%;*8KW47=^A-CB8)W>LK4RY= MEU\8=N'-GR&"0F#_J.93[B._O#A-]Q%AD/@:#8\"$;L/K"DR<0`W4:,?!YZ4 M?(&Y8G$'&%98B>*ST&!#.7+UTPDC'6.^LL1A7)C-B2Q_^?R(`D):`T+*0=M\ MPT>78&(PF0INHT"3'O-'$S:>V_):%*\S4G'L(Y.71G]"'R[R1:_'"Y M#4%K6!+*6W$8&S^:HS\3\3K-`$JCC1,FA@YF+-*>"UTWF]';@:Q-IQDJ_AKBCAX.+Q+>H;HN^/Z.1_S.^=BGH"9(D(G8=%N8_L MS266Q'7.XM(KX7+)"\`JE[C&BB?K1)Q#,0_=&YEY255,,;PQBMN$N4OB%)L-WQ5,<.]1.*,55Q9*"7\I$%I,/'^<'+S"_%, M1UPD+):LL--".G+&HV1QTURXUB:_D%&+$CX@MM!XO."$>[ZY._>E]@^7_AR\ M4AL!O\+SA26ZXN_%KC:*6,>PU$3=]&$34'3\M;"U"/TMK/>R'"QXVP@/W!)B M=>PWVC3C:@0^DK>TA(FH_+4`TJ5`4D5`V$C!"[@H$6=]"PNY5JV5[1CI:%,G MNZNS$B,/:@2\\&LD)OO@]7%IS*^`A*$"3FV'#,JQUB?2ZS*`#N_]#;75UM37L=7+1 M\=U=`7+HNE6-5F>H'X!N"T4K>_99-Y[[Q`BZ`=OAV='ZJ"TC@?(,NF^HK8ZA M'H`Y-RHNJF)5;QG]?-=[U==C'4[<]:LHEJ/"/^GD\(4=>^15&Y-7._W6H#NN\Z^-N)FHL8Z\10W>2XT;*][VLF5SQ;\IZJF,W5;2&P:WS%7DL;]EN= MWJ9'6\TM>\=M%&JGI6D'?S'H40<4S=5Y->.H=I+,>3J]]FI`">ISBPJI=6B@ MN:O<"I5[Z6M+Y>X0T/P,.VCE?,0=`C_P%BK_%&&ZK>#M^RR8TU<5S!45WC9E MYW?\I8;<[YS<0OGE`R^`,_9;`/?]5A[N7_#U*2W\'B;: MGBM-*8CQO\^IMF?1_T%I1C:F#SSE/7YVB@W9STS^Z)-HSXVYOD%TFT9ES6SY MGD1_H+,E9S[B>ZB6OY8NU:'+>&%(P@AQGPB%?E&$3=5#F;GN;LOH&JW>H*F: M+U_)>Z^:;^N'4#!_:&JMT]S5.ZU>KRE:.LJY.SP`M1;:G.^[4)S?^MQ$%A6? MHHD_,(CALA]IA$5NXB6VJ-?6?#$U'^/*]V_3/C1]@^;8/>&UR-1Z MV>RDFYUT$XTW.^D:J[5&<[?921_QW&UVTDVLW>Q:ZC!N(\E&D@W*!!K873>-+#N-MBRVL;HO(1!=3H/)JX'R]?X=]C[>A*S-[;I^&=O86L8 MP1_=FL[S=XO>JVV"WKNU<+=!]QWTZHONVQMNB>ZKJO5!=-T]O8<@E4+9NI"? M5,2_L0E-V)81?75)YM8'>^SI/ MWD4OU1BMDF--MMCEZ6.?.HC@#R,6,L`/;]G4M!RAEO##2<="9[$VC.F+HXMN0"[?L^XLI,`#6EGR(YJ+957?GWN'%5@4^Z M&9<@UF6!VXK;VN2[M98V&-2B#>L05LVM&%3;PY@8A(S-N"GW,*UY_XE]]1`: M10^QGN`'#5Z2=,O==I:W:-QRF1:M=X>M85-`4+U3[K8UY:A\<6U,6&MW#^$0 M_4BBYVY;3;GI7MO(6!0;-UUNHWL](`R.WDWK[6[CIJLI>&JKAUX44UNGW&L/ MATFG;+2'34JCZL!CT-(;GUR]3U;;>N.3J]G]M7N'[I,/OE#Q.&$VCDF.AT3K M/G6^4>C4G)'EV>47FUO-LEEB8+$U=\@.^ M(J:L$KC*'7!@/5DC$T8@AS]Q;:#O(*J6#^NUM:D[A<5+NK.\VVG%O^"JL$KS MC4XJTLD%&[%DY7M73>I%W9M> M?/0%N#L8MI'CL14'-X=H%46!^""=Y9X^/WOL&6.\D>EY;WB7(I`X7XGTU(1U M1W9RHJFM@=9OZ8/!`:STC7*/6+E-&%=*''"LT-J-)*L*Y:+?-Z[Q+ZEBNW`! M?[KV?IL*=&U)`?\%`U\V;@KUC1AF?$,);5.0WS=J7)`_V+(@OU^?XO,#([=0 M]KV*6GEC6%JM/)]&NK.RTZ9-6FO7(>?8^YH,:A1 M9MS/9AQZ]G_\H$#@.H<'%BU5ZW2&]76[6\EIWSF+KGXHYTZ-9H]5LX==W"'Y M-S^?@X-MZ]STWA*+;Q(E-,L%UK[L8S]3OU3`DZYZ*'.F4?)WH.0C#@6W<)7J M>E>9@?W2N,J2[R?I'UAG!`<16%G;58(HZ4V8<"Q*UEO M#8^B7V?+G5&WJIW1Z6CDX2XGW`$U.Y>*G=:PUQKV,J[`J9TU-RHNBMDT,%K& M\!!!L9L=2EV&;>38[%"^HQHF?/"1PI%#;]TK*H%]U[`8K4%_V$0F1ZK;;A.2 MU&$I/=;&JT:2M6]A6]?+M&VKVG9WS:B=5,-;>,G.I6EY_\``X-3W6>!_8::/ MQ[C7SBV>YWH0'YR9ON5_=TUKD<"4$Z6HK+9I7QMJ]6U?T_/>?;*L'RSO?30[ M_M).R&UDLD4NM^F;JKB7[=%3WN-7T=4I_UBW,:S);J$J+-?=:N?*FPY9Q]@8],'9M,Y8_3B/92'D[>[F[A><`**FRJ6\\+\8`JOSKA: MM4G1E5'TV&EU!QG=F;7+X>S?C6S%('<#L9^N$9N';;_]5J_)+]?'?H\ZU7J< MIY;U$7ZCL;II[*!.M/<%@KMBW$(9G^.J[`WW13^LWP3M*&:(2)*"W_QT51I& MA)2E%%;+?7MCG15;9QS:-M99BG4>=7!ZK*?7]1%_H[/ZZ:R\VH:B)]Z%BQP6 MZA.HNH)Z)TS[%O;;GF_:EZYWRWQF>J/)J3.^P%VX.\.$Z*=O,^;X+%&;JBXF-#FDKBYL[ZMD`XGF^LI]O8*]WW$X^Q_5$^_M>PC3KI_@+^/Y""A[MOS`,W&T M:^_W&NGAZ[Z'Z:S MFNT3';2JT[(1\KTKLC-%=3@1>>C<2>OAJOEAC9CZ0T3Y\H8-9 M26Q$ER]+[NKKY;M?AGJFY*KA0A+8)Q^B>[1%G'9@^/B?3W_-03DV'K`MY;>C MGLZ?UTX$=:#'7*T92B+J_A:FH^@WP?@(B'ZV#"O`1C4)5/ZO6-0;?P^3/R+8*IZQF^RO_#]#P3O3$L,>!_78=$7=5T4N%_>B_RK$5(*Y.S M0CYMT.V52G[*JU3FR8:&T1VF2$^-G20.7@1CHP/@'%TREJN.?^463?9!V6,L M(^)N/KV")6TT,6$:PQ2`'^VY#TLR?S+7'"M&VIJ1$P3'KM\_'8]%@P'H'^5+ MDS<9]O"0"!9E"C]W&9IU*33KZ!'#6U$NRV".(X>.Z#=FPX:-"M+0T5Y%Y6@K MO#^X.IR%#YA'>J!$TH/((5'@^!"ED7)O&+I#K3,,.QCT\H`S7[?>C?$E&C7C)=(@\;(1;@&OG,AG85!T^FIZ MXWR+'TSLA_]AGOCG$A9AL3F`5\,8^/L->-Z\J8DP'LI'8B9/UT_7\\`/3`>; M\99%FO)RH(HY\G#J!9.Y]_"?+G.L#,^?37%_@>)E!)1#K=8/E^,OYK] M'FB=X;>"Y8PS](ZZ-[)O8%T=63/3?KA^=7)3K.K:CBF.XYXKY]FT;?_ASGE# M$7^V1^N)[I%Q#(?#_5'MO\QV2"V`C=`[\KU`>']3NX%H_[+M@OY',_^9CD%I3)8]ED;RB=(J.` MRRU3.*LLH&2R9>%X[(EY\#S9E'1AK!\_?(O;G'RLWL$:Q_R'RX?HO1L>8419 MT=R$)9CA*;I+")S/7,]S7V'*^'<\FCY[XZ`"R:AZ]?9X;J\/@^6D6@$"DN0G M[N@-';0T_Y>?I1"U;VO2G0;0:W0Z28K7CIDDT9]QX[IE,YYCXPET,$E,]`;W M[A\F_!7B@UO<6-R[/%_*9',^M0//G9F44\5M.6Z5MT^A#+2^/NC'?%5$J"0- ML+^%'?_B0_=N2LB;Z3`[W`DC\((DR%+K7]79J??MQPXG=EJ]R8)IF?Z&_1`R(9'+YO[2E"D329VI=.*8O1 M(#&!&0I8^!,NW'6KGGV)T^6'IG;\[$,#;UO^Q,9Z&X6'8M7-.N;LK)RI- M@MG`_,"S1B!4\EM68%57P:$/!FJXU=B"O`23:^\^C]7&!>VB M6'ZR?HYKQWQ^IN$^*<&$*9@A-!UQ#\=`4_L?<1R,WA2?(D"FQQ\U)>2('H`A'Y\/GE'3'KRPC9AJF M2Q6+ITN!`IXD52Q',:?N'%_$_H(-,KY&^W$59S./G8RB+C*Y>" M%Z9$-Z0$$Y)S%$XJ#+B&-P:ND'V`WW73`FPI,"+(718\:FOZ:#F4],7A$]K' M45%1[F_4]F>N`T+LP@7PSP MR\F)JIUT53["LE?%@UVXH_DT^@I/PES"9SFG_7]I?*"EKUDV$A*SP3CX;]9( MT6L6Q^%$;"0[_/>D8\`'R;$2KUH*PI7&+T=7[6B=! MTXI!TP3B&;9W#E)_!K>03Q!W,#P\I$!@ZWJ8U0Q=LDQ#XKWI0<."+R?X:DYS M:O;T\]VGVT]WRLUOI[=?3L\__7Y_=0Z?*5=?SY7W%Y_DL9.O3T*DG8Y&M+*( M,S4((<)J%\M\M&Q:S\6D7I]<65T>JJD=31O&]=<;#%TAS0_RV>&#.!U_"!/3 MB_'R(F/]05\U:L?6K\QA,!'IT/5T/+4<45+XPD+F\O`V'/9[]>.-'R*'A=+$ MHE0JO0E_:A>"!2Q_KQF'$)H\,=^GP^V'2Y;3$%7=Z&MUX257``0.H=_IU8[F M$IR"H0Z[M6.K'*>@=F#1']2.N3*]@JX.\>BW9AP6\PJ&VC'4SIZD!>R%>04)#80G/(&"1"POQ4P79W;-ES#&CB M=#35P<+@>`J(6I@'XE6?3,_!`[4;YI&>3BG)NBGY&=7]^KM?NH8X0"F5MJK9 M73\_EW#;V0&WU*6][6+7[_03.0AZZ68#Y5NQM*'>5?,,5$YV134&FMY+CY<= MQ^4;-B>;_6%O09XKAHV.CBXL?V2[6%M<38EUAK/K]Q*YC&7T;$WV-G74&61# MW+,@X;5D4S_FZ*^YY?'I1C_SFP0JJT#NZX-.5PK95]"00>Q"\^AI<"YN<2). MUYI)9W4F:Z"KO11MZX8LEJ`!W)PD4U22H,]TUUDMW'2U[2A6@K9L!.U.*0U]=:)QDXJ M5/CF6Q\;S\;WY0^U;$9E#"7VUS>F=^W=!;C-H:D3!F^;LO/I MYF[A&*_3[LA*6#]HB51F2Z):*GE8?3H/)JZ'-3<;R7#)4>B@DX[*5PQ8`F49 M6@K(TKBI&02 MDA5JY!X\9V719H-'I4^BCX@VX*)6BHW5RH*;7F?0E\/R=81DT4W%7')G<$D% M"RJ5,`_2U"T;KES2'FY=V!D&=(QU/W&GIO_PJS7SW8R>L:R3X+[64[4]41[5 MVCU(KWJ(J^VH\?;ATIUG=#DM:WCOU)J7:R?7N6+/T'6UWZTU*Y3\SI67(!O3 MZ\W,JYOO0'L?-I:O0&(O3FA+$(<4&[0PJ_L4\3&XI`UYJ;-+VI"5>KND39G9 MA4O"QBHIE/(LF+I84/X8\'BJLGAN(?!82\DBX5>.'WA4JRRQ?,8<*H-E5'!2PGMH0)H&N# M?KE<73!_Y%F;=/9&O8L6-EJZ$^O1PJ;*)PCT%,:Q'ISG9#,I]30FVDVM)^PX MQ?Y-O(DE:K&4GL&_)1]!Z%8$D0W;-R-*6LKKA,$3YI_XK_O,4++*JQ5,%-.V ME;@3-O&^`)^9,'N,S94N/O)J@2X?HR#`?E/<5P=8>WQ+#:BP;P2LH*C#]O!' MZLZ$'X8_*E=W_[AIA9VI@1N8MN(0/A%^9O'$.+9FRJVB&S;J6M,I&UMFP("\ MF6?!T*$\).'-'1NQX'$H"#(M>^FKZ9T<)`B^/@-]OC`A^NAE0!F*41"X1)JQ M=D"0#$:%-[:7F:ID=*ML\](<955I%2C326\FEHVSBIKPN#.NO(TQ-5+["6:_ M)%U`OH2KKNDKJ%PU_FJZN3-`;`9^)A=C2FPDUS3T0W@&N-0CK1HY3?',@_=2 M.1S\;#."*G/&`X<4` MN2E)$:6S6*R.N&\,.UK]F"FVK`S4;M6F&'65UKZYF3>>&QF6N,+@=XJ`@)0 M/65?*]Z-]`RU*Y=B%B.O=!:+)1]ZJKK2A/;"2A$SZPX[O95>J`Q.8EQ(;)TH M81D8K)P8R>'6$2F'XT-UV.D,2QB]:(99'722:BHZ?K$];\_0-7U0POC%5A=8!LM0?<$]J]K1 M$SAIN<9';(_J,D^#7B>#(!QS&34EEI?W!H8Q5+.&7U[7M2DA^=HDA[UA+U,. MJP@)KVOB.ZCP&=HEX66(3F5JZ_?Q%#@AN+6T;$=$5^7J#^IG,2"#DDUC!T2 M6#*AB8J*2L`35A-=#H-9,`H5,IB$ M6=B$P64I@B(M8SVMIW>D$&'IQC_7H/E:Q=1.IZ?+Z>0\@X(]WTFU$]@<';QM MR7X:G67=<&415PC1I3!QY80/*TTE<\TN';QSI>%DD^`ZSW@=0EA(%#>N%P(C MRMB'Z6:X?N!X\^W#/ M1A/'M=UGO(8'%H2?BVCH^>_O= M9^,K)T().\4[9RK-MJOZ<*@:B3Q7?J)*8:;8`7&OEYPJ.R:Z4#`XT*LDF:_Y MNS&:CC$:#G[Z8EHT9LGM70M<0>P"J M&:C,2C58/G1-[R^C>CUIY?%5A:7ODOY*9LLN&2A_QM5"_-O,VHT9P,8DF):? M7=,I%T3&Z*;2_"N&*H&F?`G_07^8R/AO1I/X@K@5X\;TI.T^O.2KZXQ*$9T^ M3#6M;#9ZM91+W?[\&MG-$"0T+;W[JC]ON6$8NEWU$C+!\O0U>O'6;XYKZ;W MSC6B?-EDPGMI\DRF`V3MD/W$&MX.VT^L8V[W?B+:&8?W3U66E!KVN[U!HDAD M8>Q-2"MV]P,F4_LE45`PMC<&O5ZO)!**1.?#CJ')>[MJ9+"FQ:0[U#1U6X+]9A4A:E.(9&ETIX[X%E=6P6^S@*9WY MJ1U;13L:4PFAVO%59%(;FJH9=6:JH(_HXAV6N^3K=\=CIHV`YK^Y-N*>Q,W9 M\05)IY[E8VJJ,A+*:CH*TUQL3Y".!#:AZ\83S3R4"`\+47UJ&/_7 M7!0Z5K:OU+2A/DB+-1=)259@`\TK,EWOELU$2=?UDY3BKRP:@T!,6BW6$Y*+ M\%LV9FQJ1O"5A%V6E$MES0^=CF[TUG*4@\)L3J^?(HTFOPZ4\P^8,V*5LJBK M1E^.,PN0MHRWW=S.J1NJEKB7=QD!V63>N^+RM2^F]R>CF"5VQ97-]:[6Z?2& M"&7.Y:S4/,*O)W=^53OG'+I;7HQ4_;TUK%]4\+F'^KARR7O(<[ MB.Z8_W#Z$+WI@5ZUF#Q?0GX*"G`?Q%\4)EZO@>@_%:9^L&O2\U_OM!>CCHZ$ M#M&HT\0?EE&GJ:^)48LKWK:XQC&D\GWI@ZV83#D&DZ]CVPU[148LRB/O?BGY M]LUMALAYZZ9`Y,A$XBBI&WUHZ(GYL6Z\$@G,=Q[9Z\CE?@4H=`FR6N!\A7O9 M*J$MAXN+U5(:EA.+TQ]EM9,\AV'TNVI7ACY<2TH^RO.D-Y9VH@GG?[G>^6=A M;JQ00@X*\["WKPQ'=XCGG/VUS&V8YI#>(=6JO%4Y5?1!O[]<36DJ"M);3I]< M!825T0M7C*P[DU#FON`=/U;P=OVT[US1IK2M9@U-?\>)HVZONT0K:PA:X"3[ M:VF@N0+WFO;ZB:5^^4!ED)2OMUX?:$5(NH4@($R)RB5VU6'/Z!U8(F-2EQ&0 M)M-GIC?"B^0ET'`*5D0RD8HM7-N%YQ")"ND_?1O9\3/V`?"#$I8/)A&_VJTO[JD9GH`VZ_74R MR$5E->P6:][M#O5>C9DJ6G,SZ,J`:K5CJ\C*WE,U.0"O'4]%09(Z>D_?&5O1 M`]4=:JL]/"-:QU%$2)KJ%^;,*XRMTM=8A@/F(*.(T2ZN'+F'*VI/>IX1>=#% M#V;P8LB23H$T/`.23]:6C9.B!C\Z,WTVQA(:L'1:'T\]SW2>Z?3M["W^BCAQ M/'TUO?%7ND0+!M@\\8:.5.I'9[*<&7SE0U M,@M;0B]=[U=X-D\+2-FB&W2&:E\K7W)IUC($^+A^E,?T*-=T09G_Z1OS1I9O M\GOU/,OQK1%E.3>^W34U@],V5`F-)1G3XCA="^(/A(@V+]@M#T"_Q%T;KP$;VD;G.J&VY(G5'9-=3 M5FO79)"5>N"R`A_^Q"R\ML1%)!!(4L7LIGO!%:>YY8EJ+=7[%-+Z M>':)C`SMN*64>S(6O>Q)U=M&B>O:5@S55;8%KV=2VW(6]X@D2Q%L/)%7G*1O MX/S>5TKCQHFL)?ZF1%>3I'!?&LKO>6N@H!P+PH$H2"JI2>Z&2MZP54%B99)8 MMU419V>=//LUO5/J?FV!RKT)88^;UOH((7^-==<`,92Y::V/$/:X<]^=$+CS M3=_6E*\HJ>SD8#IA7SF;E4FUV!X_P_\NV^,/*Y'2[D+Q>!2><*HQ,O$3Q-TBOU+&6W"WBI^-S_]R.9(]\7)(4GV@ MURX'D5R4L][NI0.!1LYYY7SM9,-99IFSFHXA&C'G%?-RW-!%07?;:F//A06] M!,-T4HMK* MB7Y7DMK0#ZY-&1VUK#9P9>N3:[675%CW)^V8A?/<82*W=-IK*K"5/GZ)"*DK MKQ'@>L^_3'[:8)`C"_Z=27#)BK!$AJJ>IVKI>Q-AUD*Q1(!Z=SBLAQLL*]A> M'"P5;-^RJ6DYA"?G!)XY"N:FC??F:KF25+_<:/_L?E$'%Q7M%8J37W^9;K## M^.5&_:?QI9%QV3*6%B@4L=KYHO4:4RY=S(E5[)<;O7$9%G^4_NB M:@I*M179654M# MJ704+MR_9].9ZYG>&Y?59PO^,Z;)&&..Y8?[W!SQ320RDZ64>8A:R49QW.O- M.%F/-9V3L)*Y*::7W7"#5Q1,N3O?#.!A*V8(@&(I(TMH6LE'>K$JU;:6I5M7 M3Y0T22717T`!.Z-?@.WN0/:JMIYT3DT)9)C MJ=JP=BP5P1V@JPF-KM[7.K7CIV#G;+DL_>W]MT`L``00E#@``!#D!``#M74MSXS82OF_5_@>N0/3PZ2"D(Y=Z$![\\L^__^WC/T8C MY[?/-]?.%X``<0.P<)Y@L!+??77)'\XYWFP)?%@%SH_G/SGW6^?FQKG`"`'? M!UMG-)),/KN4T6(4<3L^G.Q^^\J>O(3BUU/G_7AR-#X^FAP[D\GIY.CTZ(TS M_QHU]2'ZXYZQ<9CXB'XZ6`7!YG0\?GIZ.GR^)_XA)@^,\NAD+!L>1"U/GRG, MM'XZD6TGX]^^7M]Z*[!V1Q#1P$7>CHJS4=%-/GSX,!:_LJ84GE)!?XT]-Q`& MK93+T;;@_XUDLQ'_:C0Y'IU,#I_IXH#9P'$^$NR#&[!TA`"GP78#/AU0N-[X M7'#QW8J`Y:<#UQ<<)L=';T^../T/%]@+UP`%9VAQB0(8;*=HB`'KHX?68_S8N)Q^WE8XY"*2SY9P]DSU$<+T`@0M]:B!;&7%KR!WL27/)Z08M/]FKRR8O* M?@>>@]#=L]?LF+;6Y!L.`)V[6XXJZ_07X#XP]_,RXBXD,_;C$MH.+6;BIZ74 M'K>6\RQ"()LK]V3&VAFA`:ON MI:Z;#59S:C]N@>`:4SH'Y';E$E!_S"JG[ZZ_U9;4F-,>9%ZO82`B.T../9?W M%8`:=<`:O-K'$#:UBP:DV9+GO@2LF+/!1\`1-@D6Y?1[B''W%/P9L@=IH'/:X>89.T1RRL*A$N7WHLJ84A'#ZZ[$172 M,?`#*K\1EAL=3>)BX0_QU[^?4F_]]W(.('%H^=+`_ MEW^&\-'UQ6`2G+N$;%D0$;,1A>B&=(E**>;Q3/@%>=!>_]('9 M[0J3X`Z0]93E+#0:_A40J9O9B8A:UAB`8]L`8!GBQH4RW6:>-&,!FU3U=B,J M.^$Q$CU&ZXUM:$5B:L-O[S;/&UMMUI]M,^N7-;<,@G)A8T3>VH;(-73OH0\#ENOKHY"J42^]4E?$,-*B%G5OSJ57)>GK M=?2(_>Z#;7Z7JIVD%RGTZ%416`Q8E>@R9SRR#:24:N51P0[SY^U>TA\FU@V- M*6%9CQ9EQ!7VF;"4#R3!MAP`#8D-J)1JHX!JA]$[VS"Z`^L-)B[91DJ(*=_E ML^>'?"?6V6(!(SGG+.V=HG-W`X-=.2:%6S,V@\&RF7H)Z(>E77-#(":,:W\3 M:9.>6=H77W;2F5J6T-5EE*UZ<[=J!U/**_W'PDQGO<:H%(!B$XNM7Q16EERL MRU\TP2:E@6J:8$!D,3PFXDO`S*J4MH\WJA92PQ/;7#(]`;@!/E^*F+LDE:(R ME;]AY&GG0749V`"C9EY45Q49XDO=MO<$88H"OEX55,YH=0TM1DPGLD2FM+OU MCLP%>`0^%C6YV\!]`)=<&R85!1=@"3W(U\'#=2@<\2(D+%O-4RA0W`=3BX>3 M?:@GB_SZ?CNRP3U2FHBEBLR&DRGR\%IL._D&@MGRSGU65QCK<;`8^-JZR`IW MW>C\<9S;!-!\9T#Y_@.Y0^#$<(?`CIN#EP[GYPB&SH_?DFT!3--OPM,#[Q]@+XJ"OEU2'N)6L"P<[EU/*G?^^M6]4' M(G$NA+8#:"`66,EWB9(`OT4,94]H,2FDF*`:%7J)/%[/PS\Q(KF MF<<&`A*'^[N5B^Y6!(XB$07]E,9R%NMER:0QXFT>\&@]I M8P3I4M85N+ZX$/&H-4,7D&XP%>6'V5*[A:*B_0#!KM!(YK_Z^MBH-G3%S9?\ MFV2"%N^ZN04!2WH6L8--*0WYGL?9,CWSSB'4G,W`@&NN:/5\9E]PGBW^$T8[ MV^[P-XRXEE-F`KJ33"3R5Y@4WDLJ@MJ"V1"A;:&N!'B/FP@U`//(,4-,A@X-HN^(`->'?X'%;H@]9QG3`YBBY+W7V9(E6P&!'IN0 MWP(O)*I9;GMV0P2TE<(29_UZ_-YPEO$Y.QJK(-2U'"(Z.EVDX?>X6;3<[LPE MR`.@\1K,'9Z)!])?74)<^9J@;LFT!9\!8U934XFH=>6N8@W.BE?HE$N*3=C-$#(FZHJ7XW99S&F M*R\PV>EOY`5FC%Z%%YBI*KW`NOP5$F;K M7M_5*!&]*-YP,X22N#Q]0,L*/?)6Q9P^>'&-2"N M0SU$C.OH)T&VKEI6\%1^HCH(>!JJ77A0>KB:;HBXFFDF]X;:-^G..R;SQ*]N MP`7?SI:F\-;G,42HZVMIM"7X-67)2C-**UAW))%&B:0*WB1+5A+WW;%W6S[* M7_TSH+&MXY:`I>JX&JVDBUHW7Y?CRQ4F-V`3$F_%.F,EC`9$0\310"T)Y#[W M9G39'[.OD%]DV#4PJEWOC<*O:\Y?4O-A\X MH$6%)&SVS7M28J<.,S)`K=!ZX*`5])&86;=%@`T1\7A1NMT[>E=!UW2`:.F5 MD5#IE_][&QL3B2\@UQVWUYBB:$*`Y&:/Y93**6U>;W=7:P;4PRJ?$[.*3.Y@N_!(8 M2#T?\YONV#_?^`H$X.=SQ!M4,*+B=AC!CG^O%+NY"3/G-,@[JLQNM5+1[=V, MFN?D#?FF8$@0.)S$869TLL(U-Y;!+:C[N4NU`T,:/35OUI_S9MUQ<9:8&9;S M&457:ROE;^&8Q:L^FUT0VH53JIZ2M]W;@DMR*BX7>O(I>\+88A\OMRYV^KP.IF3;7V$75M_"4MO[_:2Y#_.T>>UX"TZ=GG=:&N=;KN?H-B<@EV(306!M&JT-CAF*F<&>E& M3>,)4FK4[.-4#_&N>Z+93F!%YRIIVT\\3^YR-9._BJ"W8%`)PBZZEVO0-,IW MWO6574>3O]7H.=TE<&5]71>M)L4)=56?[S)CJS8];55*QX2$/^_,J=`B>:B5=VV(C9./FC*_=: MD:U8,-W)_*Y8CTUHG838R:R.OKBO5(W6+3SG)6M)>E_23H&;N=1+U)'TRNBF MQTUUZ7"V#(+T&F25F^E7).=R1?)%W$G;O:L4J-/97T@3[=)1E2[U%I)>9N!+ MW^V1OHLD?25$;L7PV"`B\#\7[ MEW>8S2.90A-%KMR*6^_W?IP],A^+A$J]\Q1?8L/7,CR%RK4Y]#9?V`/4RLM$ M3)0V.Z&^]TJ2,%$N*LLMX'RH3$[\5NU6K$//:#+G=I@IK[AJ>1(C';8O-(+!XJ>8GRG M@.7+))6'[RNZA@&-?6`9"EX=O6Q`38RXWS#"\GR\2&?U"?;)$%U"8"=>55)W M'5=27?=P^3( M\CQMENW[FFQ-V`3[=V==-TTFQ*V3\0A:4V7%.%821HK^7"V@9^6?>V6LM# MGEJ-V!*7SYX?+L2KG-'9P(EZ_%`!8Y0-N;T.#S!4=ABY/5<=AVYT->D8@93]=L'_10W1T!DO59LL[][G& MNE7[1[V&U9[NK--7^I6+9N*]^Y(`ILK#:K/H/S1H$[+:NLBKPBV?4'X!B*GN MBX6I-420!MP0CYKBF2'5[\?#&IYKJ&7M'O#\6Y-56RJKWZ&T:"^E;D_EFW8[ MX^2G6+&/8\[\WJ6`_?-?4$L#!!0````(``4R#4'J"_>J%14```J2`0`5`!P` M86QS92TR,#$R,#8S,%]D968N>&UL550)``/JTRA0ZM,H4'5X"P`!!"4.```$ M.0$``.T][W/;N+'?._/^!S[WR]T'QU;2RUWRFG;D7SE/Y<@C.WV=?NE`)"2Q M1Q$Z@)2M_O4%*%(B10`$*5(`:4XFB2UA@=W%[F*QNP#^_-?7I6>M(28N\K^< M#=Y=GEG0MY'C^O,O9R$Y!\1VW;.__N5__O#G_ST__\?59&0YR`Z7T`\L&T,0 M0,>:;JS)Q+I!O@\]#VZL9S"?0YST:@TNW[$_@T^?_L^Z1JL-=N>+P/KA^L<, MU/EY/,85(+1/"A<-]O[=8/N-Y_J_?6;_3.GW%L7:)Y]?I]AS@B]GBR!8?;ZX M8+^^0WA^\?[R\J>+[9=G25,&NFOY\O+R[N5#U):B]>DB^G;7E+B\AK33P<4_ M'D9/]@(NP;GKDP#X-HRA,A!I1#Y<)$@G_>ODCU?`8RQY6D`8D$>`J9`L8.#:P#NS6*_?)_<[ M"A@TAN2=C987[+L+&?!%+>@-;1N%/NM\`Z8>'/H._02'T+E]74&?0'(#`^!Z M1`%9]:YJ19UJY1W"3P&R?XO4Y!HMV7"1;,0C#M2Q5^OMU`0\P]<@!&5FH52G M]9#S#04P-?DW.\TB; M0(RA$TE;:925>ZH+\>72#=A:32B#Z.!,5>CR[N[L4QG4E?NJ!_D[X.*_`R^$ M#Q"0$,-H:'4EDX,WCZ(Z9Y5ZJ0?AIW!*X.\A'>!V70G7H@[2:`)LJV(J\%D2 M)XXY*S]%!"QH%]@.I_#<<2F?F']Y9L4#I1'?]>+ZP05M>A&WN>!VT#36NZ'. M';0$;DF4\]`GQ!?.0.@%E1%.P!O'..+,^1(NIQ"7Q#8+VC2FP//*X17@\'`.K>>`KI1C/:,YW0+2,?QV1Z/_D20YSK1)C+N MTMKV:?V0Z?7'[?XDH<-#=@9YCVV/$.;.2,37&2#3B+ET1SL'8'7!K.(%]`*2 M?!+9R?/+0;P?^F/\\;]VF#\S-R,9P0-3Z$7[8VZC"^W87GN`D/$L\BV&KRXI M0CS?/DO#7G*&.$L-%=.D\UAB*QKA;1\SC)9BQL8#(R4*$'8@_G*V]UDO.$JP MUZN;R`Y8#Y$=(%:O.(:*X@EI2*-R$Z^]7.1Y#?49`8BI4S[,;C`>XN6-SWL9 MA&8Z;DK3(8#03,=M:3H$$)KIN"M-AP"BR04F[S)+5Q>1B4HO-#P5/UQA&B(F MZZ#R*!$;JLQ:*5/S5M(B4/68EO>MHD6@[C$M'UI%BT#E8UK^I.B1\7$A.5H22#,HF,JMIP2W ME20*5`E`M5&6]?1*F@A58$.H4S0014!&42,U#S(`HZ@H-@Z%4/JBC&BY1'X5 M]5&"-($N1<610IA#AU1EA*W-P;]86>0@F@,1:ILK9>_3F,!7);KR>F),\.L( M>A*=,2;X=00M&=4YC("UBR"![QD3]5-+B%)U.F.R/K:2+*%=^+G%Y!R8A5]: M3`K/*GQJ"3U*;F>RK%ZVCRBA[@S:XB0(G="$D+9X!W)'-*'F@V+P^R9)"[.$ M$BM,[,M\^C*?6LM\&BMC2`III:I45QU#I;SLZ*05J.H'L++Z]O'R@\4,`6&Y MM1!#^DO2E17W95'S8L6]64EWU@]QA_I4C1UK0CZ=YO%L3!4?CRF'`3N%<8U( M0!D0HRI+Z9;K0F?$0@7-K]"GGWL2:U.E(R,*7ZO,]<&Z69IP$^ME>S77*?SF M4?T-+*%\B2[?CS::(P0GD$!J'A;1"<8U]-"*K>0QFM+J2G5PC:D:-(.$F3G@ MW4%(I/2(&FO#/M$,:G2<);5G)&"BM(8JDZ,(6X&V_*D^]LF_TH>>)]!C>X;$ MJ'$150727Z9;W2!66!'3AL&8S$!EXYAF@+JYZ!;=(K-B3)ZD%BH5[8TQ"96C MB%:U78;7&_?.[1O9PR881OAFT"Y*K455FC3BJ7+DM[;DFYI MV#%..[M+S`D].)X5SM]PRI9T.^"Y\96ZT689A3B.7#!U/:H-D%R'&$=ZRIVR M4CT8Y.A4M8REZ#WT:TW)B;UQ"]6'\DX>RM.2C#,F6M&>))[:/82'5N&G@<`L MT.XB;RWJ,+Y.--WESC!8`XUY\]V2'=4UY.@^K$'Y3KFZ9=%X%=7?><`G5YO; M5SI!+H&/V+7A!/ASZ=:IZ4'UG1"MEQQ9_4(3(QF1KD9'JVR)'W8Y]?K:-VZ+FL9]?4,'8J19UCTV;%%&>:5/S M^'W13/=JBI$Y3@^FY3:I1SF7\FH:%SYBD;3,L[2UP M;S.*;,91Z6(NAD.,V8A,1:XV^R:/8,,^&KX`[&Q131^>BW(($=),,R?(\ZAP ML:;<_/))QNW(RH1>((Y%8.F*,MC-#MD-3GY?K4[-R=R0W>#DMY!M-<:SE![& MFGD*ILI&U\O?:4T4YBG[?\@>.83.<`TQF,,)9'O!*'WK1^4W(?">(5Z^E_'? M!.RZ,3^I%8?/@0S(X!234AJE+H5&Y'N01I?&;H;:3L?0W`K9S>#=Z1@J6QW- MN2WJM+PU8>4SYU*K=O*^]`)W>-V6876K??BE+]YXD\4;>JZTZ5`>OU.%N/N' MM'.F[OW1IB[NW-R,7RKD240QSV.2>R7ZUW>G`Y5^5G;9)JVH;BT]LYDC MYAEZVUV!VFT%/U)X-6`J7?X/&]67:GI^0?^$./I[YZYA-+7WODU5@?[&AA67 M!2J#ZB\7Y(D#3[&-*]'C2\>NR$AY"FKQ54PH/NJVV>K]DJJ;+H4D=2XFHK3' M*M>Q075#53A2ID:HA*P87@Y4AE.]_>MU^VBG2V&ZXZF0W091I9?V6>TD;W(8 MK*E[HL7CM(]G^7*L1VH;D4-=0PQIXQNX_;]N'JJ/6Y\NT1&8OPOF,!GEWM_- M971!MJC:316R??-_(,MK:MS90DS-Q%<*6Z["JH[AC,RL'>T?U6]I#"]:T,8Q M=;MB>)5"50Z6LE>&5Q.8HG=Y,W58"M"^S'2W=P=O*JBK)1U[;)RT!2G0;RB` MJ;O);N`T$%Y(]O%09R+@S&UD#-Z`&\C2P1J$`U;;Q#!3C07F030ZO6EDZ&C2 M:A)N6^,2D:(9R2YK7%I,3#)V5(7J%CR=N!<4$PE:U[,-D0'K52RGP4V(MO22F%/A)L99?+U.R@U-B+K^8IAR\_C2T MU,1(%P/C$M,%%F>W:2VER1VDSLS;7VJCSM#K7>JBKT7WMW34*>OFOB87X))Y M:"/MY04RS$4E`WG6&U0%P".H5TNMPGQ"[--S$E^G+\BS*T%HO(!]MVQQ$!20 M4@1DTMHM-39%A)CZ/L(;L`A]]$3;<:JZ-YBMCNAS#FI^S!W4+%`I4RXF[)#W MVT?UVQ75;[T:]6M3`S';&[BDLZP>%.>V;Q8OQ;"W`*)1W!0#VWR`9C%SU^68 ME@;H8^PZXYA<%>L$.9PX>M5L_T!TC?WU6RH2L5'R.BJ-:N3-:1:JE_4@60^?>IXY.%A`'/],N.D.92C] M.0^90,D,@7$9#[E\B;9%W%GI709#K5];789'C)S0#L;X">*U:TM/H7.;MLEE MX%-0MJ2R=QD,%;[38\Z"(C%"1'XK@KA]?64/#U1R[-`#^'X)YMO7"K>+2#RX MN/Y!%5*_4R`3&8ZJ\QANC%]0*$2[W+3J_/3N@:&6KJWN02HVOWG&P"?`CBZM MNMJDOY'8[3(=M,F5*$/78<2_=S#>@/AJHE+JA?`:UN=^3.9B!V/_77WCW9/U M2CQB^ML::42T0Y:*+=`'K5.TEB1 MI+U&!]SU;7<%O/&+7X`^OVF-]Q[C8!'BOR'HNQ(-X+6J41?\.?`\\N1OZ.2, M/%NB%X*6^EW[\L9:M"`;Y^F++?3.Q=];R#9AG;:RQM1HJ'!;9IB-J="0$Z)@ MGHVY-%6-$KZE-N8M4P6YXEGYPZ=!3<9?M#K$-/S@'O:>G&9OK?`FBO>!83T^FB87!^S"^"P7>'%%16H+M\&Y@SZ# MT!;9;S!X`A2B2)PJ==G$*RK)_?C/Z`K^"CWG:O,88GL!J-TB5%J(2ZTT=)X1 MM2T0+ZENWLYFT&;O#6YEB6U>HX>4MX\VC'WN3#8[WFGY4@7-YQ=4E2V5AS/$ MJTF9G"OHTW64*>P>ZSL(F)`K+0VJ734C#ZGG2)CE07[TA$+1M(J@C*B*Z_XA M**$`)8=0;E^9\2TM?SEPS3O8$MYXV8O43*:IHIM@3!Q+E<2C70=CXEVJ%#?K M,1@3.:N3'94]!6/B<)5C"JJ>P6&TSF1*E5V)F*A?VD!450XZ*=BE(MNT>Z2(O55F26K M,K6H66/E6*IUT":<3LB\H0-GD/KI3K0?*5++GP^U,M63M>MJ^SZM0:KY#)W/X>NL'F:G/M`4+BEYAE%0TC$5)EX:\);4[W&A/24V?H4*M(UC]=0GWF`V(7D+BMETI)R*83^2NI"4C-(UT:(D`QNLE"#J'&-?K]'A2=P9S/"T7=N"R,2#W(N[KVD`]S-3"^T M20D:$J-ZQN;:?4&;&K?Z"]=S,)767Q%9N0'PKA`)J#[0R4R^>8".:P/O&K)* MQ&N$F5_$1$=\.TH-G=9'X97+!L=@#I^AO?"1A^94GNY]R>TNA2#ZDA,2@>48 M#F,R$5)9WR%>@]RTA-)""2M96W7Z?$N;['Z[G9^&L,]M?XLH&&G.KQ13D*W^ MY4^`,5D5,3F]RK9`Z(_+KPBG0BG#H@YMB+G9W(`E7>O($PKGB^#OP,O=X5`" M3NL!"O8"57*&;C\1PR4*A>>?B\&TOZQ1W;!R9\B8H'U9RHHFJNP=Q*>+^;;) MMG=T&W[2R&L]^\`6A%GO@(LCL_(``9/02#!C(W<8_AZRM4>2Y5&"-"(:7+LK##2PO5^EL@CM M?OS5A9CJTV(S@FOHJ:U#4N`WY5U).6'BVXC=U__3R;9N=R2/:FF'2]*'?EKO M_548D(C][]4\+AZ$48Z6@F@6NB'B*3/:ZRH45R[AO!DU_%!B]TUL[V(URJ-1 M0;:RYC&T9/4;X1/7@APO3/OTC^;:@5J9UAN_MZ78I^25ZU-!=H&WO]J2[#[; MTG8%/";K3PL(@Z\8A2N*/Q&4/]37K3:.W/MK2(*L&[07?`&]14#:J-GR6IT0 M27M3'-6FEJ&B.32F9J)Q3DB$P-3ZBNXO9GTVJGHV2LN1NU,F;7HU[&.6;8Y9 MZE;0DP3[CCLJ,C(F^2BJ5!Q<#LHJM/X"]#Y29I@/TO$T9'>*O+II!GHWNR_Z M,BX7V1=]J3A@S11]Z>\_+1`.V*G.?0+F@*QRH*9X-'4;J')<:&.$N)MZWN\H^\1- MU<2-":'@IW!*(BJ"V[6*LN9T==^!M>W!("T]($ZVR^`WU?_8T_;^6_9X./*C M^P44;E;EPQ@1B)7-"/>9)SXM)D93NZU)3ZJ@G:UN@S@_54_%03 MOTFMH[L.!,4(Y%KICZ`JB63:I@CFTIAHJ50N]WN$0VEH'_XY83+\ML5N6_;V M^DA9=(K")N+F6D*=1=AGO"$NXXT)0(I(Z;71%)D^QD$91\5R;NA/P*P94$QPNON4[J8^"!_#J+L/E M[IZW((7-*B#W/@O^D?%LM,5@.,<0BL*HU?NJ]?6R].#)V&/;#O$P>*:^W7@6 MOVH_@7.7B43$9?R=^@WL]CNZMKO`>P(>).PC%;J;'U.S;Z6R6E0596../B@3 M65W,C7GR29G6YD7[\($H4Y()W5[H^X"*.*"B]Q&EFN,)(G6*/V?_3`&!])/_ M`E!+`P04````"``%,@U!2)%=BKM.``"P700`%0`<`&%L`L``00E#@``!#D!``#M?7MSY#:2Y_\7 M<=\!Y]V-;4>4W-WVS>S:GMF+TLO6K+JED.2=O7-<3%`LE,1U%5E#LM1=\^D/ M+Y)@$0`!/I!0SVW$K-42,I&_9&;BE4C\X7]]WF[0"\Z+)$O_^-7[;]Y]A7`: M9ZLD??KC5_OB)"KB)/GJ?_W;?_]O?_@?)R?H/T_OKM%/.,5Y5.(5^I24S^QW M'Z+\-W26[0YY\O1RW/WP]NVG3Y^^^?R8;[[)\B="^>Z[MU7#KWC+'SX72:OUI^^JMN_? M_N>'Z_OX&6^CDR0MRBB-&RK*1D7W_OOOOW_+_DJ:%LD/!:._SN*H9`KME0MI M6]!_G53-3NBO3MY_>_+=^V\^%ZNOB`X0^D.>;?`=7B,FP`_E88?_^%61;'<; M*CC[W7..UVHI-GG^EM*_3?$3_9:TA^]I#^]_3WOX!_'KZ^@1;[Y"M.4O=U=: M0-^W>`FBM]ZD?,C*:#-(5)E2R+NA_[HFK=)WE6V93R\>B MS*.X;.N.DIU05WGW^^_>,QAGQGEUY MLN&:Y>3K/-L.0%AF#D1_V3QNCA&UX.2XR/9YC(?JG7=`P@*AI#$2IR>_W#L9 M!5/)OU5]H2A=(=X;DKI#OU8=_M\_G*-JQ,>(MWI1%]1OF"B?OWHMP^0_BUW]9%@4NBV,# M$[!UC?RZAUE4Z@OJ%LZ&;V,E9&+PF!7X6A;3J"V-12SO[R\>[FA48:Z*8S3F,26?435#LHE]+)T;('FOGTRZ0(A9R$[VY6[1^(S>%@VQF/H.'R=1(_))BD37!#?N2^S^+?G;+/">4$= MHCST;%/:D\.8K"L\V:AM::'BMIM\'?N[OEJ>7EU?/5Q=W*/EQW-T_W!S]N\_ MWUR?7]S=_S,ZO[B\.KMZ\![-QX)JR.NH3H:I$+9()='LC@!,!.#>9'$8H&\= M@,>X'0ML&D+_9P/.4DL$89T2+.,XVZ=E<1L=HL<-77R3W^1[O.I"U(VH+AR` M9DGN(%M3*7MRL(,U5Q&[TX"Q:K(\ZDWE_Q?P@W':Y;"9=@@E1N"7AB MEZ7D4Y<)D?)C5N(*M-G]^HB`SNBLH+0.YXP48*=R%E)UAZB&"*64JO(I_\=Q M8\5G5)7KS+M17)()Y?3?8OGTE+.\0Q17!X@OL`>(U@-K...GW3#I:31TFY,#;799'^8'OP+$\JHO/\69/KQXM5ZN$IHI'F]LH65VE9]$N(9ZLT M-`:V[%I#^'CWN>%"=B-YQ4KLV"YXYMT"U?Q0PQ!1CBA)D>`)Y:P3XK_'.=VR MOJ3N6Z^',OV$7;$-3&9A:U00;?$%^@?OWGWGJST/N(>_9;\_S>;A(!=\4LL7"H2:C#*UN@?OQ,R'//Z.I@P=!OE M-_E]2?7"OM8MSN^I6NP^L)XZB!\X07W2DT"'%+)=%%"$,4)8CSH+'%$28 M(,8ED+CA"/*NB0IRL.A$".'O=8Q`.X*[4.$&=R:'X>M&$TZ(&LK`/.F*C>TN2J@H`O*@ M-HA>[^'-H0>JKBSVYL2I`AF,+(`X^GVBA`?L*3?-U-=%+RVR@'Q&`:?7<22: M,+RG(Y"]"TFD0?E1/R1'9\KT0,$\ZKI9$=[6"T([+6E(@_`L(RR#=RGICCW, MXQ5"UY3.\)(XW=(VPTO4=,YBE`G^F4R(K]F?_8]W1F5]V&C>A'Y(_KV=^J]6R1GQX@MXN4"_4ZWUZMJ?\YV-I1_66[I]A&%X$\V&[IF"N`!UW*?LV-HO=N<,''`$HX\J'5B M0>]>-*S?&#=P303A^(M^^U;?.HQQQF+K4V=/ZCU.$'>WE+_MZNII-JPO]&_1 M]E*%XQ4]&[0])"'Y1_^6ILY)#'N7()[B@J3M+H;M9K\9IUG:NW/1;0:76ZH2 M]SBA5&X#DD7:%4"9^LF9QF"@Q']^X6 M2'8KP"KYG3PEZX2F<%+:5![1;>5]_J0384SNUZQ5!?H*NPP"5.7@P11"L!:9 MUT,H5-F#013L4%9TU(#N)P,O[6&$XU))%+((B$$@R^J:H10)<4'2J1S"\`3F M.7?X!:=[;0&1YL\PGG`LGFSQU=^\6W:[8\5U"_YGJ,6\G7AP)G>SHT__DO60 M>!^C[S%%0WL8H^P%(%NIMC'40J-'H(Z]U.WKHIG^;PD,E[DB".(NP!TN,+$S M^J#8.?'"3<8>`Q`B-E4]8C*JY)BLGV[S+,9%<985.M\8Q1$JI(]60GL4&,P. MR@-'BZR(Z9PCFV&L&I[>'75F:!+/^O6G-U+Y'L&7[A\(SHBR!BP.PQ^ZW]`Z MOZMMDB8T!M';"D)ZC1I[J6!+)NQ=H)+!8<8!N6=F*S?>HLLX2+P!#ODKC M;(NO,VWH5[8$-N:NT$IS;IK!&?2Q#`:3YDW1&]JX,Y?V;-"]8M,_(?IY*K/. M4D!S_BE*TH**A(N;].(S1;!/BFT!K`%U%H%]!%!+<4M M!>M.H`D=RE)$9@&;`XF:,B&M4[HBI-X7WV/`%-R[9->$BS)"TYQ42@7,^:F?DW>1FQJXZ9VWHRZ7PCMBD1JKYNW MSSTB#9#^2.K9ED^&D2E@J5=9O*=^S#8S9A'[FU#J' M-+'1CC2$"AUF6/HR'6HZX)I/)J'ZZEL@B9B.LS4YU+1Y$F@LJ1,]$I>BZ9ST M.<.:#UKCJ-Q#7I%F:]4VS&KF4+!SX__:\VF"=J/=@0'@IHH3Q,X&BQ4US&:+ M@VB:C8IC)ZQYB(R&F@N4%X[&R1[`ID=9Z^.ZYFC5`KO-5@EQ4OZX%&G]*4$F[E[L)%[3>9)_:9\NTTE3-PG]>_&3PJ#,RB!4K M.A*^^86G/7V-FE2`AF,0&?72Q.`AN\/4`Y(-;H6?AVP:)Y^G*ZC+\_.IK7W= M?OI^X"[HSX5%<1V^[HK.-O*J,WJ\R,9,^EOZK->:;S9]-R&E78]75W^>]O`^PKJ%-!9'QT=I`WR2K==TL1U5%W1*'#^G MV29[ZCS:,7M\\H1;FPC/>FJN*O$-FI)TAD1OJ.H.2?TMD.B1JA(VG9$&U)OT M/"EV6<&JMMRL&2;=MD0/#5P:8R^0XQ1&+8'_:TS]TJA/",5PF*5((J2NR4FA M]O^&X&&)OD3X51M(I`0RXJS[*%7E'I?E!J^$L])">1&QMIOUQZS$Q6UTH'M$ MJC.Z06P`SLA'P*W/SP?P\'NV/EC`WO0O)'C5T;SB1FV3\4."(<@!]PS`16X6 M*@3P4@!/).`I`[Z;$7CO&7D(R`<=LVO"4K/X><@^9BE=W5R5>%LT4-@QRF66 ML[,1O-+<#!O+#"!$C89>!ZK!G/R&JY%B&A;.=&%,./+%,>/9"EC\N)!N+@C& M]?4VD.@UM1[JZB`%"1O%.B'X/B7E,W%DW'+B0E5\T$_8`H4\9;SJO9WR$6OS M!_OI@)();0&U,@O[B/RG&=I)I+DXQ&GUUX;H;AQ8"N((9"#WNZQ2_0:"HKNB M3Q;`IO3Z7](<1QM:#[]9XIT]$ZGP57H9)3E[2.)F?4>F4WD2DZ]YC^-]SC9@ M5>A'L0.($1/`KT/'"%Y^(\IH03N6VW!$S#.KI3_G2FM+4+[B51)BQ0UKU/`& MB4'3ZX),`D[8N4_ERGD#EF,7=5TRWBMSM@2(.*8A:Z# MB;J9WSAADD%E`V*1,NM].\N%B*OHW'P3'Y?O>OUS&MEG<#02)/(G7-SA#0VI M#]G-CA5O^+/(T%RF*_V#!2/XP#GI(,#'+NS$!,3!!TBH=W_!#`EN=/]"\$,5 M0W;D9GHVP&>(F`@\=\)8@,\;\!GGMV@2F2GZ6'I/!33*P,,'O-JTW&9YF?PM MXH=9ETD:I3%9;]&2E+K#4C,)4+:8!8Q6UI>A/5CV5J],W4U2B80N*M85$3&O M8NJC4IO$JO$0:B)6%A4P]?H<[W(<)TPP\O,&TQ_H10])8(T:[$AA/,4%ENPQ M-G10GF,OF]G\>*G$AI=W_QD!1"9=H)J8WYZ2R"'+4\1DU5W@<\S_*Z53BI>4 M>M*;71A`%:MPA=BN66%+#>5HKA)V[RBP39:";H=)J<`L'899JO04B?^TX-'H M*@;H3<7B:XJT2=T5;(+(V^VBOEQZ3LM:I';-0W-T%NMG=;3B% M,UK;2VOP^I7L]9'@6*6/\7K](A%'5Q(-(-Y-@KP5[RJ.5:XDGVD+Y!+7D%R^ MVE`7(G?36=Q(0W%G/2RS\W;IPG%5G6QZ\^3>R,RO/@F9,YW5S0'=\;3=K3Y3 M$PP6JIR=42GTBI#!`@3]EVK[N(\")#'>!H24`V]J[CO=O5\6O:V<2Y.Q.@;3 M7P!EL`_`(D.H_'@S&P2+7/0I,0"><-@7(-#$,A<&H9?,4(V+]M00I7"<1)NB M:`18R9SQ2/OOV@?GAKP"[`25;(R,@G)+"\@6[FG@$E@EFUY)>RO9)!6'$"O9 MN,/K"4HUP]`J/5"9JTOAE^2[L)_YK5:-RHP4,$YI`4+V/D-S*#?K%4GM3TUA M`W$%\`/.GW#NW8T&BE]7(V`102("+`L<'40-&2$<\6M6UA4,:(:78($J'@O$N"S8EF#-"*Q\ M\&BHXGW)@I M2Q@9!>69%I`M/-3`);!SB5Y)>\\EFNM6`9Y+N,/KB4O-S:S`SB7DN4-3"FR+ID\D_?X,30AI2/NLSO?NC#.NT_WA,8I_ MZPL&T&-0^[DXLJ;EO\#DC^X#4S^SD$8K6^C]0U@?I[#&-3MI'0:[H\?^`AGO M)H$I#X+'[S_2+9R&)_C@*"E!%`JYC?+RH'A1W(X$WE5U,'0.>=P^!+=3R^3D M7-F6_#O+#[P*-JAW#4)3%1EB5,JWU&&\A#]37":/&VSI)!T*>!_1@-"YR%'S M$#Q$*9+34JNFIX57R61MGP.[R1!($@VPCY!YKICT&M_CZ&\.]7R56?SV,U3J MMMZ73V9!%.\B5UARZ=AG""W9T8`%JU7>'`!FS_PEE&_88&K=Q>\5H,6CWXWN08#[ZBE[PZ M1?`E-T>8G5MOEO2S>.2.=75?1GEI M,EFUG$MBQWE^(#;'WG$P7HJCE9CI#[@A7Z!'_)2D*;59ND7(1)G%)3GKB]0X M`,Z$D4XCM>C\.>3]?K?;8%:)8D.EO=QDGZ[2=99O666*GIPK:VH8-W0$)WN@ M)2G4%J.3>-TD78F:FR9-JJ*OY,:;K*`;C/ZSJ"9$Q+R.TB.)01"94DT1IF2E MT4.["52%KZZ8[4I>S=\!:FD>=ZY_?96V@9,_ M1:FH4WV6I46V25:1*(%]2T2KZA75:\%H0Z8()?.[XKR.'@_X\13M\- MC)O,I2[9U:;N`VK`F@='=PE$+YVP#751N8<^^D(G8*=1D10BSZ'NS/L@YTD+ MY\@3"CUR/@2Q)SS(LKI4IKN'MP_1_VCLZ$]C'GW`I!-5ML8:N#K$4BYB M+B7VA1B%]U'*5>2J/;JM1`YDQ#@&TC,(Z)N'8?BF4*UKZSWZF@6Q,/<@@F8S M^6'9\+2,.HOH(MN/G8`Q:4G[Z3X`2Q,X81R0W(G_U[!F02NM*_@MF)IOG4O+."]X.#AY9(JH MSY7#&%FL5?,HJZ9G_!G+-/#H8%3%H."@Y.A]Q)M"W*$Q(8C!\CI+GQYPOJ6) MO7U#H*8MC.D:!9PNXB(R;7M2DL9,U$#B M/;T1F93<<>E[Q,PS<1HGV&'?VY4)4.["(*BM[`4G#F!E?`=(V3W!:9B()\4E M-OY+^\X.*;Q=82O,/1,O1QX!^Z5I6N7$P/LL:H!TCJ8;PE3I*HVS+7Z(/MN/ M&F82L"?`>F$/3*KGC@@)*J//,&_J#927T(07MQ5P^I^?UE,$ MXP<]#TSKFD,\26N6Q6C]0033RRC)6?9E`Z%W"[:'!L:,K(#(AF0D@`JH%D)U M;(K2($:$/N"(DK#1VWMP'2F[1!5(>%4!ZHFO9I)P/,,484WMO8?8?F%L_2&( M<'N_?RSP7_=$GHL7F],N0WNH=/`>`.T$<$UCN)1OHT"*E.BJ/>($`"G=(R4. M))8>X^B]%*%K'H;9FZ\]J-MZCYUF06Q,9V#$%'*LFI&#GUQBT>.C7[_S1^7/KM*;^7,XV\F\U4T2Y#OZB M9_L\IY*1\3C:_&\$`1_Q#M` MM`=T08^U2!^#S>)LX-[HO+:(X_-/W;%-^WX3/A9Z5,!W_+B[1,RL,9X9-'FZMTA3__ M.SZ,_Z@:MOZ_KA%?]9F5C<9\;P/#\1^>,T>".V+L$>$_U@::2L8L!:>XV9=% M&:6K))U@1F?3!YAU6"`_,A4#Q01VT\M].B.2*FN++,("2=V-M*G+9(/S,S+6 M/&7Y9%'EB"F4U2BQMJF(_\['?X*:$KRK3\&&TGF"*H MN4)]>#6Z]I=OMQG_Z57\)OOV#7-$N8^>%_(%!Y]M7I+?%>,MP,`:;L:HQ7D\ M?>PTG&(NJ6$ZX<12+!S%LH'U,9%MT+7H+)8A,8:VBPY&M574S::SB2.6TUL$ MVTH88`^3[C17]U"ENZFW69'8E.*Q(@7:@7:`U=J-MJ#SOS-M+90B/XTL:U*> MPU_=2\;T[O"&E?N^?\8XD+,^GNM10[7*S%&TALS*T0K?S9EN]CS![Q]Q,>3.2L*($/K!T'MC'!PD7X6\^J5H7MLRVMG+SOU MPW_E)!WCF3O98CH(T&9_[FSV&@I(LS>":)N]E?0SF[U.7(W-G`=H]F,A0)O] MA;/9:R@@S=X(HFWV5M+/;/8Z<34V-4"_LB8A['F<;:*BN%GS5X<^)[KG1@SM@2U`!Z!C#'V2SV\7"E$[ MFQJT"=VX$.&,-H.\RBY)?)YMHR35V(>J(="E=*W(E47TRSJ;*2B%Z[,!WC"$ M8'&=I/B*_-@;):2&P.&A(W(G+FAEG3\@R,(9!@O:#+%V\\QK3!NS#WB[R_(H M/]"71LK#=4+^PVO7-@_4:39H:U+$:1=(HI;>XH,JAS\"6C-G*WA*5\%3NC82 MP-V\`$T?S?VQ'OT[,>R'"_F=&)&H4#%";RI67\.\4C4!6EKS\\VJ@H&2"EJ2 M\L=(5`_F#(G'T:;`+,J^^_UW[UB,I;\95Q^:7DC;1QO-B=4,_/U&]-D41`>" MR9E[.SB;27)CX?ZA=?O?B*Z^-IS!S1WT_[^^%/I:B80C)DX("HL["ML=*6Q= M*ZRH._IFPE#\YRS_C3XH&NT2,NR,9CO+3"<8G@2$6&%:UP;+.M>YW`'%M@58F;M4$R^8(^ M*MO^,_2^F8S'N&^F:@AO:>I]LWY9O5B.=M_LR`3@M\WJ0O1R?>QE3DSWB4U< M3@^=6O7+3U&^NMDQNY;NA]UEF\UEEM,_ZK;>9NH,:/MN5M756X!>=#;?-N)< M2NIL14JO'K1*O4M]T1BL>!T!L0X72'2YD"\]HE]IMTCT"W-DZTV%^^V6[H22 M%0S!0/[7:('M(**,,_PBHM7'O2G78_I^7GV,:BMLAO"DUM1KB$RU:CP%I07B M/?I_W=V7XN0(')7M5]^KN^DSHK\OR?0L(/R/^"E)Z?M@5`L''.4Z';S*4/QG MG#P]DTGQD@R$T1.^^(SS."GP;9YT+CAZ[_W5AVT;Y9VCAUI54PT29AT%.Q9TE#)GR.>=TGOLZM0WF5`3[0Y7KW&+9=>I#]Q;`%,XZG*KXIBCU?G^YP,!5QD+A;[HX!4 MC0/:T#F`$53:Y5#(35KF6*SSA;DAX.8,954_4C0#\>@I]%+_+0"_'1FAI(%D MF:XN/N^2G'&8>X9DT>_KG#19*W2J>92S)H.=6MFH;LX0)?7/TKDD">8*6M]S MC:;XB9X&SS4-&:)804/4156!*;WP%W-RT MBKTP.WDSKQ&G_BJ:P/W%;N@)'/2.\JQG^8I^7F?DU2ILJFC:JZE@(Z1*-1X6 MQ;2_6<_R9PYA-FH334E`JMM:G^B_RF`$,)&T[OW5!RZ?D\.!6GT-00YPPM<* M?5_@M&ZXENTB9;CSN?@9K_8;?+-6JY"'^.6^?,[RY&]X]4NZPKFT\WI+E%&< M'EI:NJ-*[WTPU4/'0('3FTKKF.E=E[/[LP\=&C*I6YG3K9QJODRK?=U;`08X MK8A.6=D8S9!2/SS4](WVM'-1:(9WCUC_[$Y5._PA)H0H785&/H.KN7W+NKA) ML;):H+(%P$U;M9#U_=KVG_W>JE7UW;TGQ;XC:056+2\X67NO^SH(FZ5XR@OI MW/4_93TN(;6``>XTW>1NO<%-!5ZO:\X9"<'4Z!FO45$5[CIY".GB:1&GF0Z9)M>7Y0&FL>FP/ MCR9R3.`B2B-TV-6@L0K3+#V].K_L4]H$?FFKK1#]TJ">>?Q2[92!EK4:J,+K MOHKR,W7V!3AG1W6S^*=69Z_#1:]-%?9G]-)K?<"YUN$^W#N+-V M^25XK5J-\_BN67^OQ(,["O/GQPO$>A=.S?H/)V]J-GU^2-)DN]\*U&3]'TP: MU)1Z^&6W\QW/.EU^`?%,H\99XEF/_EY'/.LJS&<\8[U_4?&L7Y\?HL\!Q[/' MB?0@)<>*;%=3CNQ[4[P#$PDP'@)_AE:\#$3_\\93.(7[C+>2=$V>?JBI^>%\ MDG`S\:<U7[BQS5'NMOH[IJE&-/B,I%X1. MW^1*BT*65S^+=5*S4(74=L*LL64<9_NT)$PO,RYX!Z/%BX-#N`#DG@T'6Z>G MN;/PF\$V5+Z.U36,T#H3GGMRVKVX&,QK?U\N\M[,NKF@LQM7(L#'$C/(S+R1 METJE**I^,M9I+C9IOR'-PF90Z`RET>TTZ7GF-:WJO)5#]_S,L[^7>JQ5NTQ3 M$B%;KT&G]2RT8!.]5QCWJJFFF*F^1,F&KM3)0,$JYTX=[GJ[>V51SE)]HX.; MH]["BVG]BIHAE#6KQ&K%6?7+YB^LYU<5O@9JL4!1"S@K^"W6W$3HW[&U]H2K MQE_2`L?[G,)+B2K*A'1\2QPN*8HL/WS,2O.M;B=R@'7B`'CU`M&!UN_*T%FP MCJG5')#$`C4\$&4"?]-\2J"Q!'37`$T)DQ_)!*'$!$")\JAD)XV_^Z+;;PH[T0>9)317[%WH`TMRO3=(;>+ M,N"7]Z<$^O<292;1B.<(8ZX[X,@@S"ACJ%C@1!UTF2=Q'07DYUG/V>;%5SZR,-D:'L)9_^?24LT>L4!SE M^8'F8+Q$F_V@[->^:>^@*=M#3BL-`+K32$5CH&FC5A+#1('3A+;K M-03)BB-A4YP==P?%[.]?_ND'E+#G)9L)('WG+93)WT3(9UE.2K)9[EMI*`+Q M;9N=*65S>/]VV'IH>7A`>TW#T$BV7MBY^9^B=$]KO+,EWHGL]>$L^4;KPI/? M6^X;J0G"\'J;G2%5:W"?=UC]RRX?T%[/("RC'/[]D<._#\_AAZEBE+]/7\4T MR\L'G&_/\6-I6X.T2P)?050'0U7_LT_^V=:M/0*;:V\2@A/B.5M$24*HEBDC M(+T9ZUTJVT)E?!H$;](U+22>STXT(G93_%I&L4"T;0#U&H^D[ZFYJ&D=B'7H M:A]:2>W/0@PU")4V$D#Y0`G!=6_Y/W7C`&RD([K21+0R^[&0:V/YNZ.1Y3J$ MFG6&+5*;(Z<^RN"VV8U'4&YH(+;=>X^D]-OO(1Q..8.2EFDVYU,3+NWEPS0B M-HO__?>P;:@`%OGV8.J5?C^)W^6^K3SFHUKF'RS\!G-M^M4"ZUW*CT2VDY"M M""W@0IZ*?I42F1E@Z>3\2FRR7'RFEXQTBWI[-6@.Q37W6..`Y]CT MJA8(\R8%NL.;B)9&(J/.Z=FEUZ=-1^!@H:"A7 M6^Z,?7Z/)0"1SS2E+Y:K54([B#:M&\+%+29*)-;PA&_6E_N2B/P1E_<1H>B; MX@QB";P8&*$&Y4IA`#^X9<1@89+&R6ZF!^>= MUCB>K.=NRF>;)3?&R+]B'LD2@`J#=%#))[VC9HB]J[3R`UAS@F<)']Z!*.0?(Q MBP91$*A>P!PM@*Y81I5R>F!)";$$<`+5S/2MR#Q/Z!UDTE7V)7.G9GW:V8?@ M'("FF-.@V]?H.BMNGA$(,_#Y0A?*L"=MHS3[)L;W01SH0Q@6+0#VGAWT(?._ MVZZ`XK;=+NUDSO?B1$EZ<#\1L<#FOG6W8X7DZ;*=+%FWY!>LCC$OX1F@+Y[B M%*^3.*%+]PK#)8[H8MK5+8VL`O-0"]B]SNJ`U[_?F@&ZN7##2_9FP0U^HCP8 M]1V.LWQ%?-L)()33FC+GE2U#<#EEGKR%M)X#N9O=F& M-BM>;1W@2?%B8_0FO\?Y"YFK&F*&NBF,;9C$KBS#1M[9[$(CX+%5U/O2=*M: M-"W`@T8EU3)=53(9XX:A/:AYZ`$L0 MIJ@=X=735*W4GJ:JUX;K-4<3T]'7:S3'`??[QP+_=4]ZN'BA\U^+.P&])``' M`)8PZIW_GO9^M_RMA.FN9VHJQ,G"N0+PZ@#UGEN,1H09&6#*_V64Y/]!RW^= M'NH??TYP3CSL^7!-Q-L8)HVVQ#"QWPU:-10,PS3;R&`-XMC(:&O$FB]030`^ M^:PQ?,!1L<_9&S5%%YAQ0NK(`]CX7(!V;'`(POE-T1*2R2)E%@O4_$4V5?"9 M;XWM*MWMRX)YV[?*#$`K"F!#U(/HF%V_]/,;F5)$_'ZVBAEL$"T MJ_IZD?5NKXZ$QMU]U=!.>5-PF9?/^_S?,YPF3_I;@:I6`"ZL%[;VV&X3OPZJ MZ[\["+&&B+<$OJXW3&B86P@3*WB$Z\AWA6^:>\YG+(F:E3E3R6]#!>!:]F!J M5^LG\>MZMO)T4Q9:][(E4L1I><")1\#U_.\H?QX9E!39E`4->F;@J< M5T4$6"HM'<=/-QI?=Z&&2"MP!M=D&%B3>DXV<)3+F$>M+&?),Z@1Y8,8(Z`D MA+%`SQ7/$-"J:854J[/0U^KTE)@PY>=4/;P`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`T(3,0 M^JOEIRA?595(V5^+Y;Y\SO+D;YVZOC/V`_7$ZDP*:UYGG5E3\RWV9U!-]WJ/ M>KV/I&[0XZ&U+R"Z0JRO!6K*X/+^4-,AR#:G!ZV=R45%(TK,=T:G?"OHX5/V M?W#._G>9O&"V_7*5TE0A\J];(HX^M=6:%&`ZX0BKGE98TOF=7C@)U;$B0HTH M*?]_E('89*M9(,H#.)%V'$;2T>\$JJ2%"B9+;S(PEI\HG*,1*0`6N@AHRKJ9 MD'^8!R7."K(]+QFL&;!3!!=5]!XFH%/CY*)`IX=6P];L`C[I9O!THI-`,M4, M7IL\$OR4O:.2T7-TK2["FY1?&[)G;!REQT^N9RDVUR2GDP$OQZ3CJ[2>)].! MD/6N&FEM*4'OA=B`4MP-,9%!W0_IE\ET\Z"BIE?/I?4(WSG(!77-D=RC#B=L:4*:PW8/&:]3N MBF\9W61;&U'!6+-5=E6\[/1'LO)?`;:\NL+5VUK-G_QN71WWVRV->/\?M\!G MGU8RPIQDCE/?"#N_,]34NH.LI'4L6&WA=R!5L^[,I9SN?@*V[5[Y8.QZN-HF M*GO%TW\>LE/\,]ZL3@^W!.%S5."\("O6(EEALLA\R,XQ+8F^@SJA`5FH_2*."Q&'V7](%(6JF0II0FK+C^T]?=12Y+L2SD:'.;,XG);Y)H,397;5*"H0.W!@/!"#3,DN,%4]YX4 M\DZ"'$F)*13T+L:MCZ+^';^A>AIM MZ-GF_3/&Y4]YMM\EZ5.A>5=@.K9`&\L3J8/&MZEXSA+R#&%@6KFGO[P\6\B? M&7C-0GK[IT#-;\4-=L$:,=ZH9FYX&\'C]#[YZSY9)>6A>1^AK\Z"F>0M``BY M3,8=WK#'C**<%O,[V^S8^U0FI?DZM=5K3U[ZK6,B_C.-^S1^^$[)5;9FG;3V&>RQR( M`O*!S!>\R79TSG1/%U,75*)=GA3X'*^3."F)J/OMGD6;\SW-]#JFT#CN%(RA M'M2<2B7-0YM3ZV*VX#$)^.XX6C=!K`UJV"Z08(PDSHBS1AW":;WZ>ZZ+%#_1 M3G5>/9-*..A(`KWBH%<2Z$(%VN=0S6\*G>/JOM$=B59Y$HLR/-I!NX\,:OBV M@],,Y&XX9AS2>P7O#N[BDM>;BNAK>M^KH6-%JB#\:0"8JBE%D*0KO$UI+=GU M/NW<-(3TC7N:#$U7Y'B7%4FG9IL+82C^H8.D]Y`^+///P2PP:.WK374WDCE+ M(2A)2.:DK'Y85C[C7#PYZ_6`;A`T31RH*%%%"EDS(O`HO3;?LPUN)H&J M<]`/HZE@8"__;.;4([!Q=X\W65YE!]H/<#R<(?)",%R-FR> MX;`EAK$J-VB5?0W#-)NE68/HU+RJ"!&GI)N*%:V7QSQZ!IO!P`QW+J=X/V-$ MXNJ0W*R'3]G07+#!W06:MCI2?4Y9JP/["B]I=120,3FK8U)6B0#!IJS.J=#9 M,E:_#3=C]77J$[*,2[.M=4.72[0B1HZ?,<'R0JO79%M\G17%1US>K!^BSYJI MF3,7H,(NP\#6%5[&H9QMUN8.2W',46]N,A:HQ0-Q)N@-9?/U`A%.U"$(+_\' M4-."Y5L$<0OLAI!/.)>[(1-$$M/2)U%?ICC%ZRS'[&2)I]/E1:0<0&PI`698 M;J#JR9(=F=]YCXM,'5NJB:OJ007BY$C0HXK!/)Z2E=%&.P&9"!FND#UR9)%` MEL^)K'1290MUF.:N%*WV2A^PV MHADS[S5!9Q1'F``T@1+DG/<1[+Q-?R:3M3N^ZM<0E"E=.2#!%LE\T4.&!.#%5Q0BU-0UC-QH8A:C@NV%D/8\J/'SE; MN-.?*970P%H)6*G#I"6$U];_C).G9R+XDF@M>L*M]Y%NFN>PC_2A\?VAS&`< M?QSTRNNGP3R;RP\&>6SJ%2,D.'6?!)/8+;H.#^'JTX./!/C*FSERZ=WX*=]% M5V1ZW&:;)#Z8'SZW(8-XV=P>3O-T>3^-Y[?);052//]!*'G5!8D6_ZEF_W>DA1EVG8!5H^P@1+,-JK80.NL^W4O#9)+, MPT``X6`6@(!^U%VXRSN8E16$6FG6B,JM9!7$.Z M3X@QKY,X2LLNGK[YC"TQT.4V)VCU-;=!F&8S,FL0G2V=AA`IC0\X!@\'UM2, MZ\$('HJKRD?+="6JIUPGT6.R26@!)/NR:8.Y@0;QH>"/(OQ8U'.'_P$P-6-# M^Z)J56Y'XH8:=N#NZPE]E=$ZY<$2CQ\WZ]X(M(\VFAG4&$80AT]C(#?'44.X M>#Z@&B[BB'$&O1$)586A=>U!`@P9J'K"*)NYC=$F&10U(^@U8>JUM4M6M(>Q+N= M1<\;T<7]RO5,HO+4GLJ]MICX/+!&V;_D\BB70HGH"-=1+ M[0GQS[<`'P>X,Z@(=G14L9[W__K`,\*!5^SS:2*J-+&3-!$)3>#IUP#T4)'P M9-%*E"6N5AKZIQ\MB`"&7FLH]2C<2^%W0+841WDP7-'5=;OKJZ>P+T].@BD7 MF"K[AWFMK7%!2[I$&S*U5P^D M?8UA7,8L>N4C=C+/YA1:(3NE>J2&=*TZ\V#88_3#Q%Z;Q/9\'?@.%Y@8$TT) ME8IDVXP3]N2`%WT=X%6>,!37;+[A`$1]/[>B%2D=33'S$,:-$>A:N.0B[9,, M'+H3EOZ%8C6%-)ZO#&$#<;HR'&YSMN+.P_/)RE`!A^^`-&LYX$.56:`/VO+P M=(@"!QBV_%_OII;JT2J[)+L1;,/-XK!1ATLZAXL>9IM+3`!\<()'"!F!=.,F M2PF@FS6;>-0%PLZR@B(6KL_V=S4V[\8"[NJ0*TSY^M!0?+/9K2,@U7X=(Z>Q MFD^*F])PE`4SVGHZS-B$;Z75ELOG1/>RR1!&05NL`K*CW1JP0EMO&]Q(&Z9< MPC?AC]$6GV?;*#F>JXW@$[0!=P$[VJ\>*;3YMJ"-LMX%HKS0KYQ;(%9<22MJ MALG(KY,47Y5X:Q.&[=C`V[`+7)4)#\'IQ8(M@9D-N#;=J@+>! M0-+_7Z=J?#X01\0XC0J\DA,AEGE.T/*[UJ>'ILUM=*"_6WZ*\A5/CBQ^(BW+ MXBHEF))L=53+Z^(SSN.DP.S))EUVH4\)H)ZO\Z[DYC4\,.W.%N_\JK-;@XIP M/GFDK%$K>4@6@+XS(S<40B`FQ4(D:!<+Q"6ACT9R61:H4\&ODH>_R0:24`FJ M;T:,W37SBF)H!00TC#H*\4HCZ2!53Q9,1^DXW'CJJM190VHMS)<>5<=JO?K[ M/*%56RZU!W4/:*D@+%OL,S'I'O]=MME<9CEMJCPK]M(O2,%6?PJ5*K[.WZGO MDK&^$*FC'SHU1K\Z^(EVK>!7Q3ZYMK/8PJK%0+]209"0!.K6*[22^<@1RTJ. MVDHNI'8[H>2(*3D32LZ.E(P;,6!N/D!J5;IZS-Y7ME!2P/-T>T5=I66>I$42 ML]IT0Z?DP_L+=/8]5H'6$^VI-`G>-M1#--2WR9O*AO'-D0 M`"RBK2#4JU]C:[_+5@M1.@92TR!.A"@5HF1@MX4%`5-:/Y3E.[IXH5:-#I!?]JGF/\,>R=_,C6@-2&;LN33 M69:2;U@F1+.WN2@GS!Y0M2A"9T\+4IO"#9A4HL*.T'>E"A>I%.E1-3FJZ?ES MQ0%54)L0Y*X&R38QH.I7@'XT?ZN8![S=93D)O/3AF?)P>CC;1$5QL^9@#;ETH;M\I6P"XO%K(VJW;?_;KNJJ^NT5SZD::ZVQ^O,]1UBD7SPU7Y24Y31M0 M4^M>;E,V@#(WN7>CP6GNGODV.4MYIS2ZTR0C2UJ:T?6`X^)(TAIFT^/LL8Y8Q MS\EFE>.T^#DK=DD9;4YI]RF=955_^8!721QMSC#=Z3[+EXB32-N=_(MJ/^Y0!5GQ%GSN7CS9\$>N5ED'LZC+8GHQ7VV?WHN31E]%G0P M>X76@*I-0VVHA^;'Z41MHE."R0($.<;@&7ZS$$#K\$C&*R!B#N$HI; M5(\C6/E"TS@$!S@676WU.ID]F;HD9(]]-V]K`)ZF=(3O.T\Q$01B)-HS%7O9 M_1F+Z5Q%93#SG*P\X'Q+2Z_H9ASMOP,L%%0"UG-^^8]^I^_=GA6'8_F6EZ2A MC6`FC#9B/M,U/!<51_%S]>Y5'*5I1BLVQQBO2(L4'7"4`YU)C%8W=%HW^VVQ MW)?/69[\#:]^25*A/95/9,>( M-QJ9B(NC^]:(B=FZC-,DMW?N:M?2(DE<1.4-)]<]A"]EJ;CK9`UX1_$.O^!T M3W#%V5.:,-70QUL/?6\T6M#!!%!K0%5HT6+M@\.4H/F%[7J>@7J.&`&A;P M[N0(4$)!^0`_F4:GJ#E^)K/4Y`43)-D6_Y(2.!LZ1_TYV]")YT]DCDBWUV[2 MIL[G,D\*\J=S\L_TB1=?^HC+F_5#]%GCA/-U!_@DVXSJ:SWAYD%OLX6#&16E M?B*NU1?BG:$WE//7"]3TBD2WB/8K_H[(@E0J9BMZ1[S[NI8:D8!NFQ$9P!Z9 M\ZG/N*7/A.N3ZB!^IDM46F5NWVAU0S?BB1JW4?X;+MF-ZZ+N'G`2L<T8Y!PJO>H*!=4L4'KK/\)S&F#TO<<:(J?J/%KCQNFQ9L+-C!'0--B&?5B MGB9"\+W`Y5..V>X##^0J*)J&`-YN%+GV:64KOYYK$*$[0/(][+JQF"+`F.T` MP:-:\!UK#7-4.8/&QXV^8HN/.#[;H>]6WZK7<)%T[T(&;GWLIZIR^D38%?%W4['/*OS-UV$P*9M8'+R"JJM!:\YUR M#D'KZDAOI]+-**>XYD8/$,>&`*SCE@NQWSCE+EG'\!B+UANW;-LU2+^;#*[\ MFO6*<(&9ZP3S]<;RWWJ)22S`$U+!#C`73!>#*(?`2.98AQ`Y%=VH&)&J!?<42DN,L>23REQM>" MHS<^30<$\,+@A^B_LCPI>9G>YVRSPKG2CRW:PYS7]@*H#ERM)9_MQ-0DZK&I M5&V1U!C,;UV%%W;>XZ7^C/PV3](XV46;FT]ICWVKF\*8MDGLRJIMY)W-H#4" M=FB]^+HS&W$L%8]>68"H3=T0QF[7WBVU< MT2_$.^P5%:@;N&.12JHWFQ3PCD'O5WR,MEA1XD[=!"B4*\2L0[A!OOE"=UL@ M1=6N%-&_:ZK:^?_`RN)RND:P'[E;7D[6N%K&V3]T+93A4VOJR8$5-CY/BGB3 M%?L<:PXL'.B"*'6L!T2MQ)K(V\:#HT1.Q=MGV<+6"JJ[9F9-!7+AWQ:,5`:@ MC\1W<0`[>?KK:3>DTC4SJ%("`T$%]S;#)$B.''M";[Y*GZ+-IKA/#RN<7V\, MQ3UU+0&\UBQT[:GJ9GZ]TR2#XODMUACQUNCZ^@QX_W6D]#`>-Y?*Q]3BC%B9 M.W95/'G<4W6+E/B'C"6[XM65>&WJDH!-7G"*"V4]\:&<(*INC@+=E-H&9&Y(L$-EA@1#5'%$$DN8&IISH(]E]'F#?MUPH#>)(J&,ZK$V MH%*9/C5P#%E6">`QUUE4/%]NLD_T3@_Y\8K,7HJ2OPM^F:11&M.?XS)Y8=>9 MK->=X]G"+$NG4D>UMS&U'F;;#9D`>-2Z0X(IJMNRHMV:,&L[R<@8N M(7@FC=SO=[L-R^(G@6+5`"41,*9+Y! MS4)TLY$QJLI/4$T(,AX-`+,\GG3F.*9/-B;KA/V6SE93'+.YZJ>D?):S/REZ MG-,A^5+.$"4L5AAO(\56W11.J+V[0:;FZWVZHOW>[[=7Z<5G?AN?S,S)CYL] MO:NOKU'K1@]R=\,=H'1WPY[8]]T-5\D4N0)T'5WQ0(0)-=R*#;M(5#.:LY!N M_T6'*:">Y`W4@D/%,E1<0Q4U>(G/;9)X^FOP]M=5(&!/>2_L?O]8X+_NZ?WV M%_:BHT/'A#`Q8S#I M;='HY9%-L_1G:YTF$/,&M9C-U*#]=\^COZKS;O@GK:K4!]!S,U=Q@2Y43J74 M<XN`X0&SQJ8CV M&&EZGDG=%.@1!8/8]8L&%O+.MC6D$;!O)@7_*-,]<4AVA,`SDV@YCBQELR=] MHG\\Z9O'L1HTQ%?,^)HY?8UZEP;WG?KCCS7L[SN]G%/ M9S@W:_Y>R\]XL[I*[Y^SO*2/JO!#[VVW3JP;*<2DWPU6LQ*PH_.\/'`1JCNE M9=3L/(>_3T09H*L4,1;LV2#4,(&9GH\"R%J>L`?JDKIM@0J.EN"^W.RS/+LE M_]Y&U9O6K-`^T,)IHL\I`#[3SYFDY)_T5N_HD%O1*K@#V(#4AII,%RI2)(S#]_ED@8*J+C,SCDARDIZL`() M9NCT@,1=V88?NS8+5&%H*N`25&H]J%7D`:I"U.1?E4%[;*!6K^8\'M"*?]6C M]W,F/J(3AYP7GTF_[`6KZ$!50)^I2E[PZAI2N9HSAT&<8`[O1H"6 M3_(&L/%^K#=81M7,63!#-3#85%<&*24_%WIPF_G'W].-6[>J:WY-&)#;WJ@`LG\CZO2AK?&1N5\OY4QZEY.LK->/.!"(. M#87:A"!7#IZCSS#QU`_#%DV($9RD*$378(T!"VXP*0;>,-]XP]P?B:8%78>; M2(#&\H=#]#G9[K?T[A*9CA'0'Y(-6?)E*:YF;!PF/:VPG1N- MYPD0G:921!VLQC+T&[NFD59198^Q10U?5#-&]9J@8>UE.F49VF92B:2*;:T* M,?,H%FC+>X4);#-;0:R$7EE!WEC!_/,N*XC+\B'9XILU^;^XAPL0V0'CN'N/GM6[7-97%?/7N^7^X7EBEBF8-W5"(J M!)VU"#&0+`>ZR7E\;T1!3):0HGY`RNX.#RB+XWU.]5P^8U0*7>^$KG-9UUG. MHVC9IA3;ZG^>[2I+N0]AOH=T]2=LS+%.%IMLTP59!NZ&@V_R1[KCY!Y];S*E(Q MI9ZG0ZB9])QH3+,/UF\3>6^J^=P7-&_VJEK;R/[Z)\Y0%LLTVHP9C2+#GB;S MYVT?LDLRW3^GU0JX9.Q-Z@V."JHWOJI:IBMJ1;A*I#*,S6.8PDV`8] MG"/(5'JLN-JY%6>,'C)$62.)-RW+AP1W%M?%T3)-<&$]-'F4D!/LV32#UVM: M#^0%HY6DE!W@*]]S(^;86)%":@LR;%IY(&]L82?90E+9`A^X)DZSE/*RBN9A MEGU9E*1OFGZE2?JRH(-)I+0&)&=.]A)Y3Y6TE$B512OE'HH9*A!P* M2RYV38G1+1'N.9+GM-2OQ#DY^6_E0;0$*/E+&6W`\B,G^)2B`EG]*3.)>LJ` M5))A=[LM]CC_BDLT);];+39EGNXAMR-*)W$-VA$H%?#`KB,XL8L/C!\B#,7"D_RNYEFO6/$K:GGL04.SZ3O*O"_LV:UGB;_%'E99*(74Z4]X:XJJ(8T\7RVWF`F3#,K3YYF MS=25]\G9K#A4\X"J0W0G3VQ8S=6J4QI;>;?T3ZQC^BO1-6KZ5D=FVC_4I#`$ M==[HU7D3DCIM)IQP^FS-NU=4G[M*GV04^%2;9\[T*4W8=RU]=L<0.KQ,6G,+ ME]=941#(;.5N47ZOCP+BYK$5B.;"L;&YYWO&%K)T[Z.2>0:EHMXGCDG>!%-B M;C"B#45$[)_O[P`5+?+X.3R^6RERHMC.W4[,R4G4J\L*2Q/W^@4M5KCI2$=3 M,`1Z#W.T"N17$8=S\_Y) MHUK<4B7O)"6C=>>$6?Q\380C_R;_(C\\$B'(/_X?4$L#!!0````(``4R#4%- M._P732T``(3T`@`5`!P`86QS92TR,#$R,#8S,%]P&UL550)``/JTRA0 MZM,H4'5X"P`!!"4.```$.0$``.T]VW+CN'+OJ5.WH%V(<>^O73^/#HTP@@VW,@6OSZ*?0/+-^&\--__L>__LLO_W9P,/J? MR\>[T6\``6P%P!G]@,&2_>Z;A?\<77GK#8:+93#ZZ>IOHY?-Z/%Q=.TA!%P7 M;$8'!\DDEY9/8#T4S79\.,[^]HU\>0[97W\>G7\>'WT^/AH?C\;CG\='/Q]] M&3U\BX:Z$/WY0J89$?21__.;#W_]M`R"]<^?/__X\>/PQ\FAAQ<$]FC\^7^^ MW3W92["R#B#R`PO9X-.(C/_99[^\\VPK8+3GP-]>L)M,1N[ZM,3!8'^;/Y`:"`? MB6Q!,B4&LP)WG^P\`/RTM#!2P$<`UQF=BVUY(>(X6MQY^"CS[ M3V9.5]YJ#9"ORBNE69KSS@N`_V!MK!<7$%6Y!B^!"N=X4(UQ(:2M8$"5UB>3 M7GF,>.+J(/`5<))"-\8M4I1GZTT)EZW1C;]]:T'\WY8;@F_`\D,,&(T*6`C@ M&N/S%+[XX*^0S';SJHA*$:0+#W0-`@NZ*OC(@/=A_^J85IEL'Y@_4YMO"?%D MKCUR?-PJR\=[Q?T9O`6AU;+69)-VL9:HZ[D,N`O,E/58`MLAQU3T5`K=(6ZQ MRC3",)VCF]517>_DX-U@IZQ[4NA..:``TCF)^'0'&`, M'+9B*,7<0M@]2;RRNM:;MGMMJ!P1*DS5/=95H\'RF=K(!N3W\]77+#E\=_96 M&5/EF;K"3.RA-L` M.<")SMP:X-(7MX3)FT]_\(4-Z\N('V+*#9"+7>@%N-),BW.=**,:, M9"MU&S ML)U,1'[<$GDQ51^/^+PFOAL%!_82NDX"/JA*W8BP\'NH>=@#^]=/7PZ.3 M3Z/0)SAY:PJ=F5V77)X01!R*S*UK+3ALWOE[K_B\@WO&Z*\:&)T00.(!Z!$: MG&NR)$CT>F=3D'%_K(W[ M5X02;+E3LLB]_1?8"-E?&-=#_A=HR`1PK$$`5R&FA-Y"W[;<_P46%KL@\=!> MB4%,1B:)8CMB@8.4&9G'2LU0E5D>U&8<0M^9TO"9@X8WLE%0D=F;\Z MTRX,ZDC51)$;V6-!Y*C(Q'`J$,,OGW?S"\VK$UQ:Q_:T!$"I0&)G?`O5$;GY M'ABSER"`ME)620;<;D[.\I>WKO>C)QF.:*$IQ M(3]?>61J1,LER4^^YT*'U5W&LXSB:6I;^]SR7YCYA/[!PK+6D21!+!1A&LOONJ3]#$]PDK):CO#M#AOM19F'DO M'NZQTQH?%ES6.LGUWT64"Y%EF+X"_.+Y@(VEL-##Q)V2B77*,`[Q2T59&*=+ MHGS5VY9=`=E8A,>'Q8U[KV5(O2\]NB'_N_DKA*^6RPYS@BL+XPV)0EDU`$>F MBG!Z92Q0S434BC3$HC^AQ?H%T>?$UT0/=(C^:>GAX!G@U12]`C^(*TJ+:PAW MF-&"Y:,;!]>*-L)DO5E3OW0/^,8I&VYFX"3'.1;K M^="<;\03H0F:*JP$NV1G,AZ6N=U!ZP6Z9(\&:%T2RZ\N/9>0ZE.M##:2S8HZ M:)]VI.I4)1HQN)U.C@7E6U;98%URKZK4'-F+MK7CD\/B45"OI2VL42UR@^>\ MJT`;H`]E(585+.A,T96UAF3MSW&`M\E5`#)?RBI4)'(?7/:Y MR":EA;8/7([D`^;LDZ[!*W`]=A3^%%@+<$/I)UCYX!K,H0WIE?EP%3)%OPXQ1(M= M"([XVYC4_""@#2J3X._B\*RV6EU$:H7`@G[)%,7*$<]*G[:Z6F3=4.]!,)L_ M6V_\;#>DU\L$^R:.DM2; MQH!UJ%($6H_*+)7[M=W8@Z,\HHM-75V7V;DL%,^:WIT9U[D[,_II:]:_?=RE M:9,@UG=+AGH\H$^52[NX)P6][780:8'Y5Z[E^[,Y\SB3-\@MI1>/U2Z2+=TI M,+^(<'KD;(04\OA=>RL+(@[[>8.T\UVD-FD6FX.T6;Q_`I@NMMLG)M_`Z@5@ MG@W(1NN2AEA]4DN0H2V61]_2#Q&9UY5D*1AMNBP%:">WA(8BRYM*LA2,-EV6 M`K236&$HLKRM)$O!:--E*4`[N4`R`%DF2S_9K($I^5$:*N8&:8]5Y#%B#E.Q M$S4@#T)VH#/,L';8+C][+:@L]2&&U"Z:@BX)\AIB$I+T>[L&9EH2+&JS-`F# M)4'KGUE>1"ST(D1OA%U$/2WX?@="GOI^J"[@9'3/A)N@G0CV[/`]B%;<+$[( M*.VMXAH(F=<5;GS>X#RK%Z*^@^1_#A--%!*"Z#')$G$+P'HC<@'^B=@O#D^& M)O?M@+]">*8*:*[L52G(I']Z/FSQ*P1H90!]$;+PXGC\+HQ8'J650O1+S-P8C?,1 MG6_$)AS]]!U9H0/)&-V5>RF1:A5[G.%:;ON`@&+R@+U72&1[N?E.>#]%LS7` M%NT0,+$#^!K5KHK)JC.)=GN52"R]]U.#KFXJ;[3[:L**K%2=KP+YO^N2;GUU MSLD\3XA,G#V^ICMQ_A'&;8B?O4=@>\B&+MBB_=EK[ABZ^4Q_E:L;?G13(*;= MY3P2X1+!T(;HN3M44T1X8P.N$RJ%T-;ZM$-S2W2KE/B!NC(^W:R=[,3^*X0X MOG;UO+30\Q)[X6)Y&?HD6/=]$IF_0,24X'="/PEO9_.YLEXU^<3[4\0FW)(Y MN!YK[F\61)3C,W0-_75\ZV0V%S9P+AD_9)TJ(5U65EM=0;AW:ZLIB.#U[>2B M>?Q"P!,(R#[8B8V`)G[HQ;39/-]O8$ M:^/FTPU:;QIQ)FT59;HZ)6OB=J#%TQ31R$$K@8CHM#;:]-@@)H`H+EX`/^YR M]NS-&+K^[Q;&5M(Z6M3"L\$\[T$W*K(D3=<9HSDM'3VL/!S`?UK1#C[NNH$6 M5Y[/?[5*.GRH>E-.>=JA?V#J<0T(QC9D5).?7<`DBIP\-SAJH@8V9'51XT"B M-D/+I1)&DBB,=N&+_I]C7=P:2W),605XR"I4A0]IY_F!G3H6>?`0O>IZ'1/% M?=U52:G4)M*E8-4M2*PV:I2V>R#9PM:G*PU2>>U,28/4)AJ"!JE1.M"#P2([ M=CH4\]_H50,;@G;PZ&KW#+"[C397UYEFTW_QC_OD$/V2J!))QAW-[;O:ME&5 M;9]+Y*I0V8G):W]_@<^`*7HE#J]A1;9TDAY79$OI&FAY).5#4D]U2YC)?HX* M8WB79V2C#?,6"JJ>WJV1D370@D<2],1I@)ARPC_B'8/-@VNQITAHUPY6<\?1 M@RK`_56+*E2VNX+)<,)M74I,JT#W6DRID&K?!Z,B=?+/P MGR"@^RIA10#7QOAP/58.-0+-*PWJQH$08_AF!93LS6RNJB/5Y^BQOE0GMN5B M(F-\BCHS&^U=^JPM5:ALN4C([(UN>M#=9*,KG:3'&UTI7=TT%]>^TUY"XV`N(%O?6\]_`C6(;:7EE^N"PI`/58&!>K>P18WLX/M M5F@D",MZEE;S%N43]5AK:E(\U#UPCAVY!WXWG-LQN]PK#A^&5A3I,N^:4_O" MO_)(_(T#2/9I"K(OC!Z&Z`MDM9SB,$;R9,&,5T_IG5N776H7#>VOS,4TF7?) MJ=WX<3:_AI1KR/'KA`MU9NFOFM0BU[Q[36UK4.G-!?'0(>B"X#Y"6Q>=C!&X M.L\:9:?ZK!15J.SF5I/N5"8K0T`._1\],'RU7&HD#X!0Y.R6NHF*,Y3!^Y"^ MK$91)]5^9NK$A)@*QAMB%>Q:L+(R%.#ZJP4%4KK96*Z9LA%T<3!4+?AC/"`] MH,1TL]&,-.$&Z0PCGL+UVF7\LMR$7U,T]_`J$IBD9[`J9!\T09D8Z0ZTQX=9 MV7,@:>U!>*=W+V04Q+/:O4,903EMB MR?6?<>7N!0VPY%W*X\J>S35@'0K5KO05@8:D#$7JTF"/]\A!C_U"XB?O/62S M1C`)UY##V0A?0]]V/3_$0+#RMS=MCQ:1]H@>Z,50>AP3G<[XM"D(A@O"#I?^ M=K*BUV7'`BU2@-.A)FW;3EZ'%$@V+D(1W!B-+U,2:LC"^A)2)-,F0O&UR23T MRK4NW%&%1C,-13D:,6&H]\@R(XE:G$;V$1\"`T?D4Q3@AJ(V%4@>:H$,O\KL M$3@`K.B9<:YF8/MP4*`]328T+$!6/"EI@_)8NR[:B9TE9VQ[>"#LTO*ASVK. MTAE3=L7/@Q%E'!V,,MLD_[BG-RH`?00LOA'N(7]D(6?$IJ._WYI0@ZG,\,)" M<;^M[`VSJ!=7'K?T"-5RL]?-)'G`EN;5X3T:H9Z)_YDHV*7+K\EH_Q.ZO$RK M^I/LS-MG3[*//^Q\I=N#+]IJH[;[8'#FC;X4O!$(1A1D1'S1*`+28%XW%D9D M^4D1ES@1\5`=?F$7&YF!2\;JLM0ROB?&)T%]4%84]^PBI)+8AD4L9%$&M*LM M;?\F6.&_[MI4-LMH[A&KHO,+(+%BDN\?:154(Q";]0=)-` M3V*.32?4DH-2Q?DRC[/,M!O/J,L!M*,/:0/7IFP8E#/)%R2SE\2R:OS,>9P6 M%F0*-8K!V+Z``>HX\%]Z.'@&>!5E'LH\@7RX#CN_\]""(D09*+->P3AMQPX* M?$\L3H#ZWI[PW8,9T7N`,.8";3#/%E9``ORL7C4SI_-=<\I!,V/:AM?T9+R` MG-(C-5:)5`U>3SY6`46905:=0)>EUI)E6E)6DN,9\<6N$4>C M1P$;KJ=0(L)6R4*EHS75>>PB)+,^^7"-K5K+9)`KXI`0,"@[2E]G^@8L2B=S M)P6+&A_M6A2%&S'`T1:D!NU,2<@0E(69\N$ZS(N'DWFE6]=A2.>#&04PVBIU][&6UJ@+1JJI]!\&QN9+4G&ZJL: MD_,]*R07HCXH^^&/X].&QZ>"@JY& MN,3"$9#:P?R#.0CM@#=[2Q4UU+C?/?QG]BS#-9A#&XJ>`A:/U:$)G1E,JA%B M>F7W4GM<\<>.U):>2XCSZ7V\8,.+#3B#!B=_$:&QX$_.#GF55I5N(9-9NS/K M&S^`*RN^:E.\8RDM&Y@MKY5V3)Y)>$=/1E[]G+]`6/=IS&A MS7$$E6<8G`+5XD+Z/N+A<5,?8L(YDD)MAW!?4K?$(]V0:-F(?!1[L%/LI-X@ MC_&$OEB]8'9SN2F4)$Q^6-B)'[>>A8$?D!TG$?6CY[I$=^@?N>??W7QH&*4A M77&GF^U+SQ7U/ER]`-RMCB;?T%9 M$%NT%N#F#6`;^N`!0YO77V9O7_[0\%;8V-;EPZ+>:]^B-.7A;V1@X$]1U%VL M`UW?_<"'2E?A5C>O4O1140G#YP`&[&@8T4?187PFDS!KSSZ\(3X?9M`AUX_MY4OW3UTQ'.?"A[ M8P:FS?QJGVD8T]B=G3K0MX^`_V@W9@L]7>PLVN5\8^!*V3[#I.]=O%N5W7.'9UW8 M@AD5;<]T12P4M'UM4-`6S?A1SZ:MGLU>`B=T"<9\@XFVJ9,P6'H8_A,XWXD^ MX=RN]<&U$+&D+6-XI"8FO6:WAX\.I,YM#YP::!OG4M;E4B]QH]H-\T:--%=A MTG>BF0J<2)^^>%?UX./=]?/TZ&OAIFK5BO#1^&,-'=X:*GA[N^L/OA,/U9!+ MXLI;<[:OM6FR(&I7!\5?,2L9 MTHK9MJ!X8GZUI7B">[SL6S,$O@'.B1]W1`\%6*;SZ5W=75I-N*4D$]SS#Z]$ M<+D1@Q=6A,J]V7BN_5"7"*]_)#!"R]/;#>M M2WH?9=U!!*8!6+4<[$L_]!'O-^&>>`UIQ9&T>#K':B;30@KQ=?<]?G<0+J]@ MLZG7VP\3]Y:V[;-?]7X`'$MK!?D/''3Y.6T]9_;I/[IQM;NL-&&W9:"&?U^O M]ZGAA<]]:'AKK#1A6VJ@AD>5S;-Y3F"Q"+M6=MF7/_2^"ZZ:L+5OT01>6F)9 M3DHQJV15<+LO8Z<2U(;.^S,6;:Q.=P4?)K3%R**WV6'D(Z`9+-IPUT/L(#NT M7/H(UW'7UM0$LP_#TL'UI,CX?15,Q9U(>8TTCQO73>EL[?]1/:50/:52LE^W M4*K"W.^C)JH"0\190',V?@K+0O4#D&J3FGK84=FL&M^MW-\9ALI-EO)'0^K, M8M;Y0AWU3\\2ZI`?R[7S_MX]\2U)PF$W4FS3U8B_H2U$KV]^C7V,F!O)"Q;O MXM"JUG8HNN4X138&9/`UB/[?09,"A6^^1]U5YTZR?!KC9P7K,,'?IL);@(2& M*4HME/)V(JH&4(7LJ9Y4HC%95(];;@;47]^UX^63QT>()%CK@@Z7U^*G>JJ! MW3(E4=E]O/72_5YAXC@P0KZ=78-DOOYG&5I@0I)9,$9UVG%W$Y=-#AR^W=V\ MT1]Y\98JH,FNJ-2&$J>D2JQQ#TV:$<^_B][_K2M=VTQIJZ"FI<<2S5#-W,9F MB@(,D0]M]NI[MUO,W6]]**RBEG8\- M1W\[8I!QCQ0+=A[T3'\VCPCB[22V_]Y[L7-H&NA%`EKX<6^M>#T4^$,&=4;( M)U&6?C=$7-R&`Z)!.D0FTR\>Y\OOZG?@U'YX_P4[R+XJ8 M^'ZJ,J@)O!=<.U6F86_;USU48(*<:_`2")\^/AT=C+8KMACT M*`8?D9AT1"?0^]1QWC%Z.*"K%D5*I<'20E76T$(_65E$A42"B$/?6'^8Y\8!/_0<(51%Q@`(F"/!#4H>][ M>$-=BK1Y3"5P8P0@6',J$6-8T2)@>3.:BA,,0,C= MMZ+1(69YTYIJ\/T78=2M=^Y7,[HLCOW*Y"3(F7 MW"Z1CC;"]`K:E(A#BKIQ,5$[PLWY&`[Y'/F6`>@2L8*6)G(N(Z$M41MV,!N; MP)00[P=EE\3DP[7;L80(WBVFHB,NVWKJR8B)GDXYW;W!*,J':7PII1L%:Q)6 M9AI0'E(E@I`^[M#:K*;;3VN$&K=JEJK*-5@18J MB$DQ^RR`Z*.H>M+JG(.Z8@Z9#]!#40VUL?E'8MBDQ#`)D^\\"U5,$)=!&6%N M\D1Q&0G&;7U-3O,8NAENGD6: M8HE3%-#L15`J9]'`'HE81$+:Y.+P['QLSC7R]@]>XSO6#Q8.(/`3;M%`#]ER M`Z\P08\4HBIIF:(B M.(GF0@/3LD2SUGZE!),I(E8;TK!*E&7FCM+A9.\\M`C*<\O\8=HZ<8AYG#A( M/L)FA:N[.`KSR:*!NO@O4QJ1`-I.)G=AK;)\BG"DP48@Q+GCWJ*\TH[RKD`J M4&8PFYL94:9AH)F1!^PYH1W,\!/`K]`6K23\86;(E6M$?(1-OJL;(4QW%#'* MOG!ED8S5)1*9'NW(A(=V6RVW!:[M&R'`#ET+3U?6(GH?818L`4XP$F]25"$U M\UVL-JF34Z5DH(XNM]_>/&.R92=>G?;;N-SD_R)P?U6`#7:*5D*WR!ND2QK5U8TGI#W5@;_CH;N_I$Q#B4S] MU[58$OF_&BR!/)I)WU33&?\H,8#'/JC]XZZR6RUW8S4K(O(M# MGXI)DH:'/HW-MMO3'@X?*C63K@9ONIG6(,FX;@9=I&9O+1M,5K3)7FEN-C_4 M).M6;OPH)F>@HD[*&\3MO0LC>BG8`A7&=:CHPG23ESLR-EUZ&'L_(%J4'[3( M@7NI!54(-*Z]1>T6)G[T%Y^@SW\@OL$\O5.#!K0FB8>A956WK2+'DHP'W/?3 M*\/_H?-EYKH*4XO*1%5,:;$OV@#$+^6D]K!C!%/?#POO`5:"[)VX*U&7B-F< M*$(@Z-LP(&2D#^/XV>->L_D#)BJ\6M&.Y9;["%X!*KQY4',.DX1?)O+JU"7" M/S/GX3.%?;Z?6<%6+^TM@B-FW(/@R3*B M!]2>O4OP=^`ZEYN'$-M+$C#3X,B'A"3@/'O7@-::001NYG-@TT;2V8+X'9%! M4?ST_,/CZ5&GG^N3CG7*B"0=^>7PR]>3P=U6$$9FEP"!.:1..V/-+;"H;9;N M?E6GZ8F.U2?$)4@G1_7MBE1/325$-EQ;[NP' MD@B0/\QX]CW)@RG2X68*IASOKEZ[ MUGW@'U61QEL!"GNT0_QKX M-H:\%_R*VX&ML28)N^;AWA8]Z9/=IN=I5;(`N$X:8(:X.=UNOV>2&K61?ZG/ MB20!>'[XY:1Q+Q"C?4[.^9;7EJB#]D25JA'5S2:M@T)VM+!(OP&+=G)@AURB5Q#'1[M='RCXB,&/\A/H M?04QI2E#559#+A^NPW&F&%UNTA__#@$FJKW^J/=.BW-K M5R')JE/0F.;D*K@"78QH2T\*7"MQK6;=GFJ#'7>2)C@MSS]%H"$/R& MO7!-KQC)+.U0OI>XZ.M MP\G>1]K*6=NB/8K@^4[.8JDPA?9EO7K62X&JV#B/]E&/H_FP3=1J?7Q4>-.S M[-!-:Z]UC>8KNN+(^81"#QLE,-/-3IV2@>[!WL<5]@HJWO3FNBD7UUMJ-V>Q M5[3HM1=&Z0/`K,:+XZG$0_LB=CD5`^U[\W%JV=-3RX]3%-WIML:G*`8GXS]. M43Y.43Y.4=[+`OY1/V%:_41GSQS%#9JBFQKTEL84(8XLFN(29S;+T^&D\S2N?19X-%XG)^F]M,I#(#KSV39HMOK`-I+4-=!O3<46PUY(WQW6K:E#F(LUT'D8,=I<"C M"%J#-3R#U=K#)'2X^2LD.ZL,58'=5X!K)886?D=DF,I0.HRP,M?3B%B%HKUM MNHV)C,N>!F\0)YMQ@JTI;,KV^UGW5/O%U9 MAX(BK+9#ST8&4=J*H4AH6Q[^X]S;+!4H/0DWI=)!V+L;/8)YB!S6M(RA>`NX MO7Q$(_LK/RE9QA4R"`08H3Q98,`.=(C^08_[I()@8,_%)Z!J;Z_KF)#<$C5: MJ9GCTMMVY2/;E;98)/M&1-"8S5DSR=D:8"M@399]BF2UJE%M M5IV"(NZ_`41^+^K=4V<27<*OH^$5!;U%9R_%?6^M@+"ZJ,8[*7P`EIQK&5)!U#X([S_>3D^FRRJLONYZ$P(_H!",RPXA-84:%U8V%$>W9E!`F M\0OBH>TZ(THYCQN MWFPW).9X2]A(H^4P$M=L7N#FBCHBWKK5SKSZ7K%1,H`TNFN'VB'Y:&%=>IFW MKE*E;H;;-J9NO1-R+C=7KN7[<4F8Z'!>!:@W5>ZJ!)G5K>.),)25#.4Q%1RJ M2\;J6JC5U2X-B,5$F'5,FL=/?/+-&:1+%J6JE&:N.4B;Q?LG@,E2?+N]!@D/ MI*2CM>4KA>J36H(,[2X*M0U8EV3'1N*A_?%N8AHZ;A4AC-P4=H'JL(8(0ISD M5R?%N,R^Z*W<+3)R]/G9[8Y'*@>>9"L`:]NT5=7<["U;=>*2@[W#H;V$O6,8 MC\`AOPB2"S^2BS"J@+U2BRJ$);WR#_O_0,(#]FP`')^F+*:^'])^\K-YZ1WS M[4J_:C/T3BTJ4]A-8R#3'$;4'VD6!GY@(0>B1;FKX(#T3AO*2=I;*LGJK M%8Q>C9@@A_",UDX`I'+__;R8UTOG8D>Y6[.9D=F3D5N6Y8LK3:K`Z[!BFN7> M0DR4X1,-U%C%4UTVB=6*B!$>\K03@+MD[Q[`^=SGI.6X(W0Q5ZX56=R\@VY; MYCX9:RW`,["7R'.]!=&N*;+% MI:2E(`:(1U`H6HIZ7U('5Y0#A!?^WSU_#0/+O:2$(>IXD[]\`PZT+?>*,(Q6 M4F(:%5%B)#7"S2ZX"XO;7%LKLB+Y3UZX6`:L<7*IX7%A-.[5J^HWWRBY5`W6 MZZ(%[5C]$&)[:?D@XZ&PAJL)J85X;H0/UH>F.LY%H&6%X.%3` M-]DC'G\]/#HZ_E)7>A>1]!!8T'V5.?)+'K6*V)-03\,$^`K)CG"W'6O$(P4H MX^6L0,.6[+]\K9]E=B0RP`,EW<9^ENBOC@W)0)NJ6F7!9%/ MER'@S]#-&R4_A/YRQ1JCT$;P''DKP!@N<@4*\E(?7YB^[Z$$S=`M^2A\!0C0 M2P4)Y49U@\":1R\\W>#A&/OYZ>#"M\9D'%SIWW.'CT62?(?X11 MC,G=VU8`-EP5JI"24XB3BZ.S82G$EN>;O%K09;UY/'KTZ"'&F*7G$@;X]"EB MN\S3J\Q@N&I4IB>G'\TST48M%G'CP=P1:L:99^OMP<-,=$&`X4L81&QZ8#+@ M/535:#;#E:81;:D"-;BEM>U=GG-:I"=+DQ`?]9>A)1`A[609[67)DOL`,#,? MEKUP0X*SZ`I?@[D,5YH&E"4J%D+L/6^?>[BT@Y3 M.%I3=R+#5:8N6:F^M'T15+O&2%O;1UVN"$,F]E\A)!2FY\>TG:[RN;GB;,8? M\S2B+BT]H]F,H].!J9%H`?^.,+!<^$_@_)T$?80[--U#7?8,9PFA_5(^DK#CD_*RE6-D4#U3R'L>.1BA"_7%LN!I4H",MVF0G'[43=7/Y M4&U-\4HXGC[3YF2;4@(:9)=U6G\K9]'W/1!UZMRC;78B!5858N$J[#YW0Q$WM5Z?1&WY>8/ MT2DA:>B=N<1=E(V[$"L6!W2`52Z1PJA>"*6`=2(78TY;A.V;L[ZCEQ[&W@_Z MA@S+W@/G*A"+6 ME-C:T(#[$=B`A%K.]S5-G;(ADP4&;*\M6`MKS=1#C:A+:M+?N;92M'T8(E"* M;]8;7(6KM!M*\`VZ@#8=`XDM1'32D$Y5/9K/V4-%:4YTHC(&E8*(7WLH)W(2 M/,,5F,W)7YS0)N:RB`^//#3#E`.T<)/LZZ'E/EED%E7MVN/'>ZB&>^1.HJ_G M_#V;20H;&V=4GO#LW1+67`/;M2*:V?&V"RR?LB1R[A/DT#;M("[AXO;=;6'2 M'BI8"U0GBG-Q>/[EQ'C=V0[W_`<,D0W7EILKZ^.W95:"ZZ$&J!&6"?GB>'QN MS#58@9!IJGDVOPT#$NC?@X!YO=E\X@;86UO,A5)'^>SMT,Z3>^VI>J@*M6G- M:XGX_[LEME^.CHLEMFQ"VDPX-^4HFW.43#;Z*?E) M2]%MD4I)V:ULL)97J"V?EOS3_]'#LE>BKL0X&&X;:B*7+O]%/T4X755KY3)) M'ZM6(\2X8_.6Q%^\%!21KJ`!RJ`]4`)E6HPK3FM'#VXMB-E3!]^`1?TO7:%4 M%:$"K/F:4(&8M`_RL%0A;M9.`AZ/K+J4I.N8FO@O'!50@#%?]`I$I)O)P34PWMUF;OC^N4S1?G% M\@'YQ_\#4$L#!!0````(``4R#4'H>"L@I`X``-62```1`!P`86QS92TR,#$R M,#8S,"YX.R[\6=.4]ORR$KOIB\W,`E*:$A`!X"V=']]=T%2(D6* M'Y)M,5,^)):(W<4N?L`"6"RHDY\7OF<]4:F8X*>=P5&_8U%N"X?QZ6DG4%VB M;,8Z/__TU[^<_*W;M7X[']]87RBGDFCJ6,],S\RS6R*_61=BOI1L.M/6NXN_ M6X]+:SRV+@7GU//HTNIV8R'G1`&OX*&T]T>#==DMU.PR4WIL_=@;]'OO^X/W MUF!P/.@?]W^P[F]#4F7/J$\L4)ZKT\Y,Z_EQK_?\_'ST_.%(R"EP]0>]WVYO M'@Q=)R0\7CQ*CZ7(\4G,\*''N-*$VS2F]QC_5D".Q8]@RTI\AC[29O#Y\^>> M*>U8FL@IU7?$IVI.;+HB)YZBDJHC6_C&YOZG#_U8,):5$%*/^I3K:R']2^J2 MP-.GG3\"XIG6[%A$:\D>`TU3!`%/D*R;R-&KRI(&?^R%A3$I]`Z]G--U^[M$ M/1KBN,3HU^T/NA\&,1.'_A#X^8WJ:-E#OAX0=8&*2F:O^,J9(@;H'I9U0C@7 MFFCHU>8[/IG/&7=%]!4>(!['4GAT`NP6?O@Z'N8V,Y;U'@+?)W(Y+9@;<#XUJS[7S1TQB]/4!]5/2/`"R\>H+_U"75A'EJ0A<:1D8, M8B%-(6B?!H,L:+$X*Y1GO8LD6I'(%J(41&"9\6UJY%X('ZR=4:[8$[T1*AYF MA22%`('_1$QB`?#Y0G`'N&$.@D\*1HUCIKIU'3C<4K586(WU[BLG@<.`ML4O MB1\TE<^T:;DS[D";HF."-0;XHKS15IV\>.#U?]P<>`G)%N$&WK7L=A"6@,AA MD:C9HT?O)76IE-1YT,+^E@]A->(2`/^9!7`EUUH)MHSD%KY"^.ZH1A]U3^7# MC$B:!UHQ20E4/VQ"!=)"KPCR+".P1:@0H6C-IN[)DD#_!M<'3V1`G:O%'&:0&IXSLK.LTR@';S MEBU4M7UD':]8!MH>?K!%+H'<-6'RW\0+Z"TEV)+^MG!7%<*2F%<_$_1"H9:1 M:B7%MC-5?$:E`$U*(4H,Q.5031HP2D!)SD!;2\N MB3U]JHI+._O4&3%E`Z9TO-0<+BTN.1M9V(-<"VGV^2;5!0\+82MIE$_/,.F= M;1V^$AP_9J:FQ/[(%3*,0G3#3)QD/>U<]4((#^I"6SJ7?WNFCF M'+M4("^9_#[N#&0[&^XS)NL.R=(1N>^`;(%,`@D-Q=3(O4]8F0*NH+P$J.PN M@&C\(%QK-,=<5J`+DT),'?@\64L[*1;B=BGL`.,1L-2\@LZOET,.O=\W6H?( M%5(48F="(1%W\B-B%8JR$K+>"I8JK;LSG"\WG#Q,9GZ84:I7(RCYJ+#A!X.* MB7&13"L4VB*P#8%[(L'4&=7,CB-0!>4EV`QVP<9ZEZKCS9S8=X%5*H>4J-FU M)Y[STDM71<4(?=@MK12D6T;\(=))OPN<+>RX+6ES2*89##M]H M,HMPE5J84U2"S?:4PGF<4MBV?[U=4.7M3QDVN^Y[6L"*@[A;H[=E@%0,V[;M M7^U>0NE-A#(\ZMT]:&%)P!+.%!.RB&%(/BAI]L^;S1[R6AJ9VU8NRU\H2%PH M:?G*&0LM"`67#_.O&Y8U??D%P_^#1L?_\"KVF+J6N6A]C'>"3SN*^7,/+VB; M9S-)W=,.XM"-;T[_#N8>+7PO)D'Y!5>^#6Z;+115'(L@TLY(R5P$!R%BCLG! M5/5BY6,!FFED3T4@L1[U#XMXH&GOQ8R'EJ]K_`98KV3[Q;J65S+=(X]U30<6 MZKVBT30:?M)+7MN';^EK_2=@MY#:XIG7*12] MW"%\><2-L(V@`A;\UHWYNOBH.WC?_3`X6B@GUK&."NLVJ*="S+>?"IDW)532 M8I,+=?B,.@P^[:5#\A4/]?00_&Y'59(OJ)@2,D^]GV*+$D:!7,8>];2*GW37 MHJKI8N0J:A]-Q1,,-599ETT>_+!?[71ASVI7OV(RG_93P`0/Y+*V#DF^^,MN MFF1><5)Q@,8,V!4_UN^$V;>D[-X+C:QMUD>OAS$+3)P8?B\ZD3M[5%H2&UH! MM2\^O5O3DNC3:4?+`%Q<.#.95^X<0PGL=H>:^KAV`RMAB0J"`I3P18I@'A,R M((%JF>=AX"(6%9;!3,*$,S%BG4!&(:UM!GXAC(_X-307@T4P56KDAB&6T*:M MQ4FU?<&I)G+Y*HJ'98_A"@HVM)#U3#_.E,9J#$=#94 M*D`Q(S<9/(IMW8GU4.W@T,>B9CAS_ALH$TB9B#O!\<`$M5)K,TSP$8#-W"$+ M&V,/`0UM$NS*"B/C5(WXU0+C2@%3,R0*._4=377[. MU`50Y)2J,?7PG'0B1G-S&O'L3\.[/A#'!05WDH&/D7O-.$ADQ%L?E4=96)OK ME)>5V;#US*]"?H,Z+\B<:>+AMMEF2<^^O?R5>T"X/]:UG=88G>Z(TUOJ/U(9 MF['Y-%0^?&O@L2-\<-IOVNQ&G\FSR-$R\;096LXDS6O-U/-&:'HM`IFC:/+Q MH?6LDNN=[X5VX6R8K_D*ZP-8]:#2B7=A")\I)>02]PF9<5N+Y=#@EBN;&?&U M6+X#^[*^HB93\VW,>IEZ/(VQ\)+ZA#O%W3*7IHD6%'2\+50-M**@:^43'=J& MO'NZ^=-7%%(`:7CYV_K M#U;J5IB`*QJ^NZ0&-,@55.!CM!KCUQB@AC]7?P3L"69:DQH86EM*=J!@7TFT M%_8D_Z'2_+MF3]0,L2''407?[D%&VKM4)F^.RXG#\$,>3\E&Z[-G(IVLVRFF M/NRR:JB>YFDXDD\.W>+CC8EHW,CIQUQ/4A-Q3G^AGG.^O`^D/0.\)6XF%'.H MQ&.I2ZJI]!FG5ZY+;>S;ZZW&5PY$X7YCQ&G>Q/7R=1RVWX6;"_#0X8V+U,;C M7E*'9T(5J1NZ"'IPTQ(/0%DA@!&F+02_EC4,KL,JD+:@'5.M9<" M;]T>[L3!CZ@;<04'AP+JFR6R-W-(WZZ+;U$Z&A:+,BGA4I:?D"H2' MGJO7FX;2EXIG^N`NK`WK@69.R)Q*GF%VS-20GB_7)-',:M:F40`TL6?&G-`% MSJ\*E1H+S[L6,KGH?9NZ&M;`>:ACA_GX`WG"]-N75O_2C(BL`?'S M0P^?"#D7H="-9<'^@@[=%KB^'KGAQ+2*5:6>I4 MW-K`!#FFBA+8\YG#W"?JB3ER;.0(UV8[U(ZI+*LP!.)L*JDIN#QH)D6VG^@#G@NB1,=,?%M_EE^W6P82*B?7A\XR5QRV^U M&-F1NZG37BIJ]!#X0WZUL&=A4K6$CUZ`/U2=7KG4XVEJB'0C8Z1TFJC!T+`Y MXHX\/1IOGQZPF<=-&ZF@(',HR5<]4](X[>,#6C-SXAG*D.<$VS<3LDK)7W56 M+DTPN9?"IM11UU+XYT)*\0R]63V$\:CS91B12B=/K%<>.[`VUWMXS,8=S=4" M#$`140AR3&T*WL_Y.L?7GQB2U;XAX4IVXFYJ8YA>&*M^-L6KPGIE&73IE;E? M\!HE38=XZS$>MO??D@7S`W\5N-.W#!;.&J"(.W=H#%93U`'VE]/,=)U*!IWI M"?/-&;M)H!W3*4//;2"7:.WZY-VD"QIIA$<+(UH3<0VCZ)+:'@G-,.$\#Q/.P,KH MB(T[)C<\7JEL=*1]!!T\G+:9]`DK=9O-B9)BF-Z3SLA.&[2^X#B>]P`8U_ M)5`*J_`QF\[@:[0T2:9%;5J)QB?ZQ*O5T-@``M7)M[-OB[&64!UPQWS2"U^= M!1__!U!+`0(>`Q0````(``4R#4&*C.WG26\``!W?!``1`!@```````$```"D M@0````!A;'-E+3(P,3(P-C,P+GAM;%54!0`#ZM,H4'5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(``4R#4$OF(^40P\``/&[```5`!@```````$```"D@91O M``!A;'-E+3(P,3(P-C,P7V-A;"YX;6Q55`4``^K3*%!U>`L``00E#@``!#D! M``!02P$"'@,4````"``%,@U!Z@OWJA45```*D@$`%0`8```````!````I($F M?P``86QS92TR,#$R,#8S,%]D968N>&UL550%``/JTRA0=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`!3(-04B178J[3@``L%T$`!4`&````````0```*2! MBI0``&%L`Q0````(``4R#4%-._P732T``(3T`@`5`!@```````$```"D M@93C``!A;'-E+3(P,3(P-C,P7W!R92YX;6Q55`4``^K3*%!U>`L``00E#@`` M!#D!``!02P$"'@,4````"``%,@U!Z'@K(*0.``#5D@``$0`8```````!```` MI($P$0$`86QS92TR,#$R,#8S,"YX`L``00E#@``!#D! 8``!02P4&``````8`!@`:`@``'R`!```` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss Per Share (Details Textual)
In Millions, unless otherwise specified
6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Net Loss Per Share (Textual) [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3.0 3.6

X

- Details

Name: alse_NetLossPerShareTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss per Share
6 Months Ended

Jun. 30, 2012

Net Loss per Share [Abstract]

Net Loss per Share
4. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders has been calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.

Stock options to purchase approximately 3.0 million shares of common stock were outstanding at June 30, 2012, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. Stock options and warrants to purchase approximately 3.6 million shares of common stock were outstanding at June 30, 2011, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. In computing diluted earnings per share, common stock equivalents in the form of convertible redeemable preferred stock were not included in the calculation of net loss per share as their inclusion would be anti-dilutive. The exercise of stock options outstanding at June 30, 2012 could potentially dilute earnings per share in the future.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X.3!C93'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I% M>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O M=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C M8V]U;G1S7U!A>6%B;&5?86YD7T%C8W)U961?13$\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O#I7;W)K#I7;W)K#I%>&-E;%=O5]O9E]3:6=N M:69I8V%N=%]!8V-O=6YT,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8V]U;G1S7U!A>6%B;&5?86YD7T%C8W)U961?13(\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%C8V]U;G1I;F=?9F]R7U-T;V-K0F%S961? M0V]M<#0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;G9E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I7;W)K'0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C M93'0O:'1M;#L@8VAA2!);F9O2!);F9O2!296=I2!#96YT3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,#`P,#`Y-#'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)FYB'0^)FYBF5D.R`R-2PP,#`@3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYBF5D M(&%T($IU;F4@,S`L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q.R`S,"PV M,S4L-S(P(&ES7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)FYB'0^ M)FYB'0^)FYB'0^)FYBF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XX,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E M;G-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%SF%T:6]N M(&]F(&9I;F%N8VEN9R!C;W-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@86YD(&%C M8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6)A8VL@;V8@8V]M M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!N;W1E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S(&]N(%-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@ M8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$@+2!U3IT:6UEF4],T0R/CPO9F]N=#X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DYA M='5R92!O9B!/<&5R871I;VYS(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/D%L2!E;F=A9V5D(&EN('1H92!D979E;&]P;65N="!O M9B!T:&5R87!E=71I8R!A;F0-"B`@(&1I86=N;W-T:6,@<')O9'5C=',@<')I M;6%R:6QY(&9O7-T96TN(%1H92!#;VUP86YY('=A2!T:&4@0V]M<&%N>2!C M:&%N9V5D(&ET'!E8W1E9"!T;R!C;VYT:6YU92!F;W(@=&AE#0H@("!F;W)E M#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D%S(&]F M($IU;F4F(S$V,#LS,"P@,C`Q,BP@=V4@:&%D(&5X<&5R:65N8V5D('1O=&%L M(&YE="!L;W-S97,@&EM871E;'D@ M)#(P-BPY-3,L,#`P+`T*("`@&EM871E;'D@)#,Q+#(S-"PP,#`@86YD(&$@;F5T('=O&EM871E;'D@)#,P+#@W-RPP M,#`N($9O'!E8W0@=&\@ M97AP97)I96YC92!C;VYT:6YU:6YG(&]P97)A=&EN9R!L;W-S97,@86YD(&YE M9V%T:79E(&-A&5C=71E(&]U'!E;F1I='5R97,@9F]R M('1H92!N97AT('1W96QV92!M;VYT:',N(%=E(&)E;&EE=F4@=&AA="!T:&4@ M87!P2`D,3@U+#`P,`T*("`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`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$;6%R9VEN+71O<#HV M<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@2!C;VYS M:61E2!L:7%U:60@;6%R:V5T86)L92!S96-U6QE/3-$9F]N="US M:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q M-C`[/"]P/@T*("`@/'`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`Q,B!A;F0@=&AE($-O;7!A;GD@8W5R2!T:&4@8V]N M=F5R=&EB;&4@9&5B="X@/"]F;VYT/CPO<#X-"B`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`@=7!O;B!S:6=N:6YG('1H92!E>&-L=7-I=F4@2!* M=6YE)B,Q-C`[,S`L(#(P,3(@=VET:"!A(&YO+69E92!E>'1E;G-I;VX@;V8@ M=&AE(&1I;&EG96YC92!P97)I;V0@=&AR;W5G:"!*=6QY(#,Q+"`R,#$R#0H@ M("!A=F%I;&%B;&4@=&\@3F%V:61E82X@5&AE(&]P=&EO;B!A9W)E96UE;G0@ M<')O=FED960@3F%V:61E82!W:71H(&5X8VQU2!T;R!E M;G1EF%T:6]N(&%N9"!T:&4@9F5A6UE;G1S('1H870@=V]U;&0@8F4@&5R M8VES960N(%1H97)E9F]R92!T:&4@0V]M<&%N>2!R96-O9VYI>F5D('1H92!N M;VXM2`S,2P@,C`Q,B!W:&EC:"!T:&5Y(&5L96-T960@=&\@ M9&\@86AE860@;V8@97AE8W5T:6YG(&$@;&EC96YS92!O;B!*=6QY(#,Q+"`R M,#$R+B!4:&4@97AT96YS:6]N(&]F(&1I;&EG96YC92!I;B!T;R!*=6QY(&-R M96%T960@;F\@861D:71I;VYA;"!O8FQI9V%T:6]N2!.879I9&5A+B`\+V9O;G0^/"]P/@T*("`@ M/'`@6QE/3-$;6%R9VEN+71O<#HV<'@[ M;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@2!A9&]P=&5D M('1H97-E('-T86YD87)D2P@:70@ M:&%D(&YO(&5F9F5C="!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;F1E;G-E M9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@9F]R('1H92!T M:')E92!A;F0@F4Z,7!X M.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E6%B;&4@86YD($%C M8W)U960@3&EA8FEL:71I97,@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/CQB/C,N($%C8V]U;G1S(%!A>6%B;&4@ M86YD($%C8W)U960@17AP96YS97,@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S M='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,3)P>#MM87)G M:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DIU;F4F(S$V M,#LS,"PF(S$V,#LR,#$R/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#QTF4],T0R M/E)E'!E;G-E3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C$P-RPX-#@\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CDY+#6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D-O;7!E;G-A=&EO;B!R96QA M=&5D(&5X<&5N6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O"!S;VQI M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$ M)V)O7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#MM87)G:6XM8F]T=&]M M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/C0N($YE="!,;W-S('!E6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN M+6)O='1O;3HP<'@^/&9O;G0@2!D:79I9&EN9R!N970@;&]S2!D M:6QU=&EV92!C;VUM;VX@&-L=61E9"!F7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!" M96=I;B!";&]C:R!486=G960@3F]T92`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`^#0H@("`\=&%B;&4@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P M('-T>6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB M/E-H87)EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E=E:6=H=&5D/&)R("\^079EF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L2`M+3X-"B`@(#QT3IT:6UEF4] M,T0R/D]U='-T86YD:6YG(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]F;VYT/CPO M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D9O3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@V,C4L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]TF4Z M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@6QE/3-$)V)O M6QE/3-$ M)V)O'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,L,#$Q M+#0X,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N-3$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C,L-C0U+#0T,SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/C$N-3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]TF4Z,7!X/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUAF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\ M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@/'`@"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF M(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#@T)2!B;W)D97(],T0P('-T>6QE/3-$)V)O6QE M/3-$)V)O&5R8VES92!06QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1C96YT97(@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E=E M:6=H=&5D)B,Q-C`[079E2`M M+3X-"B`@(#QT'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,C@X+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@65AF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0R+C`P("8C M.#(Q,CL@)#,N,#`\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@65AF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C$U-2PP,#`\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R M/C4N,R!Y96%R3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,N,3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@ M65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$)V)O6QE/3-$)V)OF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R M/C(N,R!Y96%R3IT M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$#MM87)G:6XM8F]T=&]M.C!P M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H97)E('=A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O M:'1M;#L@8VAA6%B;&4@86YD($1E8G0\8G(^/"]S M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L M;V-K(%1A9V=E9"!.;W1E(#8@+2!U'1" M;&]C:RTM/@T*("`@/'`@F4Z M,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\ M+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#@T)2!B;W)D97(],T0P('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/DIU;F4F(S$V,#LS,"PF(S$V,#LR,#$R/"]B/CPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#QT'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,36QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E5N6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@6QE/3-$)V)O6QE/3-$)V)O M'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B M;&4^(`T*("`@/'`@'!E;G-E('=A"!M;VYT:',@96YD960@2G5N928C,38P M.S,P+"`R,#$R+@T*("`@26YT97)E6%B;&4@9F]R('1H92!T:')E92!A;F0@ M2X@5&AI2!N;W1E3IT:6UEF4],T0R/E1H92!R96UA:6YI;F<@=6YS96-U2!B92!C;VYV97)T960L(&%T('1H M92!O<'1I;VX@;V8@=&AE(%!U28C.#(Q-SMS(&UO;&5C=6QA2!F;W)M86P@9&5M86YD M(&9OF4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF M(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2`H:2DF(S$V,#MF86EL2!P971I=&EO;B!I6%B;&4@8GD@=&AE($-O;7!A;GDN M($EN(&%D9&ET:6]N+"!W:71H;W5T('1H92!C;VYS96YT(&]F('1H92!0=7)C M:&%S97)S+"!T:&4@0V]M<&%N>2!M87D@;F]T("AI*28C,38P.V-R96%T92P@ M:6YC=7(@;W(@;W1H97)W:7-E+"!P97)M:70@=&\@8F4@;W5T2!A;GD@8V%S:"!D:79I9&5N9"P@;W(@;6%K92!A M#0H@("!D:7-T&-E<'1I;VYS(&]R('-E;&PL(&QE87-E+"!T6QE/3-$;6%R9VEN M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@3IT:6UEF4],T0R/CQB/E!R;VUIF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[ M,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T3IT:6UEF4],T0R/E5N6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C,U,"PP,#`\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,L,S$P+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E5N6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C4L.3`P M+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D%C8W)U960@:6YT97)EF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L.#6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L,S@V+#8Y M,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M;6%R9VEN+71O<#HQ,G!X.VUA6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2X@26YT97)E2X@26X@3F]V96UB97(@,C`Q,2P@=&AE($-O;7!A M;GD@<'5R8VAA2P@3F5U28C,38P.S$Q+"`R,#`Y+B!4:&4@2!I;G1E6QE M/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@&EM871E;'D@-3`N,24@ M;V8@=&AE(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:R!O9B!T:&4@0V]M<&%N M>2!A2!O=VYE9"!A<'!R;WAI;6%T96QY(#$U+C(E(&]F('1H92!O M=71S=&%N9&EN9R!C;VUM;VX@&EM871E M;'D@-R4@;V8@=&AE(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:R!O9B!T:&4@ M0V]M<&%N>2!O;B!*=6YE)B,Q-C`[,2P@,C`Q,2X@06-C;W)D:6YG('1O(&$@ M4V-H961U;&4F(S$V,#LQ,T61E2!O=VYE9"!A<'!R M;WAI;6%T96QY(#DN.3DE(&]F('1H92!O=71S=&%N9&EN9R!C;VUM;VX@6QE/3-$9F]N="US:7IE.C%P>#MM87)G M:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#<@+2!A;'-E M.E1E;7!O45Q=6ET>41I6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2!I;B`R,#`Y(&]F("0T+#8P,"PP,#`N($%S(&]F M($IU;F4F(S$V,#LS,"P@,C`Q,BP@,3(L,#`P('-H87)E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M M+2!"96=I;B!";&]C:R!486=G960@3F]T92`X("T@=7,M9V%A<#I#;VUM:71M M96YT3IT:6UEF4],T0R/CQB/C@N($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S M(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/E=E(')E8V]G;FEZ92!A;F0@ M9&ES8VQO'!E;F1I='5R97,@8V%N(&)E(')E87-O;F%B M;'D@97-T:6UA=&5D+B`\+V9O;G0^/"]P/@T*("`@/'`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`D.#4P+#`P,"!I M;B!M:6QE6QE/3-$;6%R9VEN+71O M<#HQ,G!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C.#(Q-SMS(&QI8V5N2!P6UE;G1S(&5Q=6%L('1O('-P96-I9FEE9"!P97)C96YT86=E'1087)T7S@Y,&-E-SED7V1A-#%?-#0X.5]A,&9E7S4Y-#!F.#`P M8SDV.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X.3!C93'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO&5S(%M!8G-T&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA M;"\O14XB(")H='1P.B\O=W=W+G'1";&]C:RTM/@T*("`@/'`@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@"!Y96%R65A"!R971U6EN9R!F;W)W87)D(&EN8V]M92!T M87@@871T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!" M96=I;B!";&]C:R!486=G960@3F]T92`Q,"`M('5S+6=A87`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`^#0H@("`\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)OF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/DIU;F4F M(S$V,#LS,"PF(S$V,#LR,#$R/&)R("\^1F%IF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0Q/CQB/DEN<'5T)B,Q M-C`[3&5V96P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DEN<'5T)B,Q-C`[3&5V96P\+V(^/"]F;VYT/CPO=&0^#0H@ M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@ M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QTF4],T0R M/E-H;W)T+71EF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/CQB/C(P+#,X.3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/CQB/B8C,38P.SPO8CX\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/CQB M/C(W+#0T-CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/CQB/B8C,38P.SPO8CX\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$)V)O M6QE/3-$;6%R9VEN+71O M<#HQ,G!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C.#(Q-SMS('-H;W)T+71E2!C;VYT:6YU97,@=&\@8VQA28C.#(Q-SMS('-T;V-K('!R:6-E(&]F("0P+C$R(&%S(&]F($IU M;F4F(S$V,#LS,"P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$ M9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP M<'@^)B,Q-C`[/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM M($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$Q("T@=7,M9V%A<#I3=6)S97%U M96YT179E;G1S5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E=E(&5V M86QU871E9"!A;&P@979E;G1S(&]R('1R86YS86-T:6]N#MM M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/DEN($IU;'D@,C`Q,BP@=V4@8F]R M0T*("`@;F]T92!I#MM87)G:6XM8F]T=&]M.C!P>#MP861D:6YG+6)O M='1O;3HP<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@28C,38P.S,Q+"`R,#$R('1H92!# M;VUP86YY#0H@("!A;FYO=6YC960@=&AA="!I="!E;G1E6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$;6%R M9VEN+71O<#HQ,G!X.VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`R,#$R+"!!;'-E&-H86YG90T*("`@9F]R('1H92!E>&-L=7-I=F4@;W!T:6]N('1O(&QI M8V5N2!F;W(@=&AE(&5X96-U=&EO M;B!O9B!T:&4@;&EC96YS92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$ M;6%R9VEN+71O<#HQ,G!X.VUA6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@&-L=7-I=F4L('=O&5C=71I;VX@<&%Y;65N="!T;R!!;'-E6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6UE M;G1S(&]F('5P('1O("0R+CD@;6EL;&EO;BP@)#(N-2!M:6QL:6]N(&]F('=H M:6-H('=I;&P@<')I;F-I<&%L;'D@;V-C=7(@870@=&AE('1I;64@;V8-"B`@ M('!R;V1U8W0@2!N970@2US=&%N9&%R9"!T97)M#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T* M("`@56YD97(@=&AE(&QI8V5N2!J=7)I3IT:6UEF4],T0R/D]N#0H@("!*=6QY)B,Q-C`[,S$L(#(P,3(L(%)O8F5R M="!':7!S;VXL(%1H;VUA&5R8VES92!T:&5I&ES=&EN9PT* M("`@2!N;W1E'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$51E>'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!#;VUP M86YY(&-O;G-I9&5R6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O M;G0@2!C;VYS:61E65A2!E=F%L=6%T97,@5!O M;&EC>51E>'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/D-O;7!O;F5N=',@;V8@8V]M M<')E:&5N28C M.#(Q-SMS(&-O;F1E;G-E9"!C;VYS;VQI9&%T960-"B`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`R,#$R('1H92!# M;VUP86YY(&5N=&5R960@:6YT;R!A;B!/<'1I;VX@06=R965M96YT('=I=&@@ M3F%V:61E82!":6]P:&%R;6%C975T:6-A;',L#0H@("!);F,N+"!T;R!L:6-E M;G-E(%LQ,C-)72U%+4E!1D-4($EN:F5C=&EO;B`H86QS;R!R969E2`S,2P@,C`Q,@T*("`@879A:6QA8FQE('1O M($YA=FED96$N(%1H92!O<'1I;VX@86=R965M96YT('!R;W9I9&5D($YA=FED M96$@=VET:"!E>&-L=7-I=F4@&5R8VES:6YG('1H92!L:6-E;G-E(&]P=&EO;BX@07,@2!O=F5R M('1H92!O<'1I;VX@<&5R:6]D('=H:6-H(&5N9&5D($IU;F4F(S$V,#LS,"P@ M,C`Q,B!A2!H860@8V]N=&EN=6EN9R!P97)F;W)M86YC M92!O8FQI9V%T:6]N0T* M("`@9F5E9&)A8VL@'1E;F0@=&AE:7(@9&EL:6=E;F-E(')E=FEE=R!T:')O=6=H($IU;'D@ M,S$L(#(P,3(@=VAI8V@@=&AE>2!E;&5C=&5D('1O(&1O(&%H96%D(&]F(&5X M96-U=&EN9R!A(&QI8V5N2`S,2P@,C`Q,BX@5&AE(&5X=&5N M2!C2!*=6YE(#,P+"!S;R!N;R!A9&IU'1E;G-I M;VX@8GD@3F%V:61E82X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`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`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(%1A8FQE.B!A;'-E+3(P,3(P-C,P7VYO=&4S7W1A8FQE,2`M('5S M+6=A87`Z4V-H961U;&5/9D%C8V]U;G1S4&%Y86)L94%N9$%C8W)U961,:6%B M:6QI=&EE6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DIU;F4F(S$V,#LS,"PF(S$V,#LR,#$R M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/E)E3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$ M)VUAF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/CF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]T6QE/3-$)VUAF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/C$P-RPX-#@\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CDY M+#6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D-O;7!E;G-A=&EO;B!R96QA=&5D(&5X<&5N6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M/"]T6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X- M"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E-H87)EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E=E:6=H=&5D/&)R("\^ M079E'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/BD\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/BD\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@/'`@6QE/3-$)VUA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/D]P=&EO;G,@97AE3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,L,#$Q+#0X,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N-3$\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C,L-C0U+#0T M,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N-3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]TF4Z,7!X M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@3F]T92!486)L93H@86QS92TR,#$R,#8S,%]N;W1E-5]T M86)L93(@+2!U6QE/3-$)V)O6QE/3-$)V)O&5R M8VES92!06QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E=E:6=H=&5D)B,Q-C`[079E2`M+3X-"B`@(#QT'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C(L,C@X+#`P,#PO9F]N=#X\+W1D M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B0R+C`P("8C.#(Q,CL@)#,N,#`\+V9O;G0^/"]P/@T*("`@ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C$U-2PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/C4N,R!Y96%R3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,N,3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1C96YT97(^/&9O;G0@65AF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M/'`@6QE/3-$)V)O6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/C(N,R!Y96%R3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M'1087)T7S@Y,&-E-SED7V1A-#%?-#0X.5]A,&9E7S4Y-#!F.#`P M8SDV.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X.3!C93'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@ M86YD($1E8G0@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!A M;'-E+3(P,3(P-C,P7VYO=&4V7W1A8FQE,2`M(&%L4YO=&5S4&%Y86)L951A8FQE M5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#@T)2!B;W)D97(],T0P('-T>6QE/3-$)V)O M6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/DIU;F4F(S$V,#LS,"PF(S$V,#LR,#$R/"]B/CPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X- M"B`@(#QT'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C(L,36QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E5N M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE M/3-$)V)O6QE/3-$)V)O'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@2`M+3X- M"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@ M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!A;'-E+3(P M,3(P-C,P7VYO=&4V7W1A8FQE,B`M(&%L6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6%B;&4@=&\@4VEG;FEF:6-A;G0@4W1O M8VMH;VQD97(\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)VUA3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E5N6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,C0P+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(X-2PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]TF4Z,7!X/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA M6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE M/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92!486)L93H@ M86QS92TR,#$R,#8S,%]N;W1E,3!?=&%B;&4Q("T@=7,M9V%A<#I&86ER5F%L M=65!6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4],T0R/DQE=F5L)B,Q M-C`[,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/DQE=F5L)B,Q-C`[,CPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/CQB/B0\+V(^/"]F;VYT/CPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O M6QE/3-$)V)O2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@8VAA MF%T:6]N($-O;G-O;&ED M871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!N;W1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B M;&4@86YD($%C8W)U960@17AP96YS97,@*$1E=&%I;',I("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S M,"P@,C`Q,CQB6%B;&4@86YD(&%C M8W)U960@97AP96YS97,\+W-T'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@ M86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X.3!C93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S65A&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)FYB'0^)FYB M&5R8VES92!0'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S&5R M8VES92!0'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES86)L92!A="!E;F0@;V8@<&5R M:6]D+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES86)L92!A="!E;F0@;V8@<&5R:6]D+"!796EG:'1E9"!!=F5R86=E M($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#$N-3$\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA65A&5R8VES92!0&5R8VES92!0'0^,2!Y96%R(#$P(&UO;G1H'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^,R!Y96%R2!O9B!S=&]C:R!O M<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L93PO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!065A&5R8VES92!0 M2!O9B!S=&]C:R!O<'1I;VYS(&]U='-T M86YD:6YG(&%N9"!E>&5R8VES86)L93PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T@4F%N9V4@;V8@17AE65A&5R8VES92!03X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^)FYB M'0^)FYB&5R8VES86)L92!O<'1I;VYS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T M7S@Y,&-E-SED7V1A-#%?-#0X.5]A,&9E7S4Y-#!F.#`P8SDV.0T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X.3!C93'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@=&\@4VEG;FEF:6-A;G0@4W1O8VMH;VQD97)S/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6EN9R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6%B;&4@=&\@ M4VEG;FEF:6-A;G0@4W1O8VMH;VQD97)S/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\6EN9R!V86QU M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!N;W1E M.R!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6EN9R!V86QU93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;&4[(&EN=&5R97-T(')A=&4@ M;V8@-R4Z(&ES6%B;&4@=&\@4VEG;FEF:6-A;G0@4W1O8VMH M;VQD97(\+W-T6%B;&4@=F%L=64\+W1D/@T*("`@("`@("`\ M=&0@8VQA6%B;&4@=&\@4VEG;FEF:6-A;G0@4W1O8VMH;VQD97(\+W-T6%B;&4@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6%B;&4@86YD($1E8G0@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB M61E6%B;&4@6TUE;6)E6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&5S(&%D9&ET:6]N86P@8V]M<&5N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!N;W1E28C.#(Q-SMS(&UO;&5C=6QA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!N;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O M:'1M;#L@8VAA'1U86PI("A397)I97,@1B!0'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3!C93'0O:'1M;#L@8VAA'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'1U M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB'1U86PI(%M!8G-T'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&-H M86YG92!F;W(@97AC;'5S:79E(&]P=&EO;B!T;R!L:6-E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA&EM=6T@969F96-T:79E(&1E8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^.3`@9&%Y6UE;G0@;V8@82!T;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X.3!C93&UL M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'10 L87)T7S@Y,&-E-SED7V1A-#%?-#0X.5]A,&9E7S4Y-#!F.#`P8SDV.2TM#0H` ` end XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Notes Payable and Debt (Details) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Convertible Notes Payable to Significant Stockholders

Aggregate carrying value $ 21,827,588 $ 21,827,588

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]

Convertible Notes Payable to Significant Stockholders

Aggregate carrying value 4,655,173 4,655,173

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]

Convertible Notes Payable to Significant Stockholders

Aggregate carrying value 10,000,000 10,000,000

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]

Convertible Notes Payable to Significant Stockholders

Aggregate carrying value 2,172,415 2,172,415

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]

Convertible Notes Payable to Significant Stockholders

Aggregate carrying value $ 5,000,000 $ 5,000,000

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_NotesPayableCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting for Stock-Based Compensation (Details Textual) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Accounting for Stock Based Compensation (Additional Textual) [Abstract]

Term of Option 10 years

Stock-Based Employee Compensation Expense $ 0 $ 0 $ 0 $ 834

Stock options granted 0 0

Intrinsic value of outstanding options 0 0

Intrinsic value of exercisable options $ 0 $ 0

2005 Stock Incentive Plan [Member]

Accounting for Stock-Based Compensation (Textual) [Abstract]

Common stock award shares 3,450,000 3,450,000

Annual increase in number of shares 400,000

Annual increase in number of shares percentage 4.00%

Shares available for grant under 2005 Plan 809,172 809,172

X

- Details

Name: alse_AccountingForStockBasedCompensationAdditionalTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: alse_AccountingForStockBasedCompensationTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage increase in number of stock award.

+ References

No definition available.

+ Details

Name: alse_PercentageIncreaseInNumberOfStockAward

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The term of each option cannot exceed ten years.

+ References

No definition available.

+ Details

Name: alse_TermOfOption

Namespace Prefix: alse_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Notes Payable and Debt (Details 1) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Demand Notes Payable to Significant Stockholder

Demand notes payable value $ 6,185,000 $ 5,900,000

Accrued interest 694,946 486,691

Aggregate carrying value 6,879,946 6,386,691

Unsecured demand note payable; interest rate of 7%: issued December 2009 [Member]

Demand Notes Payable to Significant Stockholder

Demand notes payable value 350,000 350,000

Unsecured demand notes payable; interest rate of 7%: issued January 2010 - December 2010 [Member]

Demand Notes Payable to Significant Stockholder

Demand notes payable value 3,310,000 3,310,000

Unsecured demand notes payable; interest rate of 7%: issued January 2011 - December 2011 [Member]

Demand Notes Payable to Significant Stockholder

Demand notes payable value 2,240,000 2,240,000

Unsecured demand notes payable; interest rate of 7%: issued January 2012 - June 2012 [Member]

Demand Notes Payable to Significant Stockholder

Demand notes payable value $ 285,000

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesAndLoansPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_NotesAndLoansPayableCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

Notes Payable and Debt (Details Textual) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended 236 Months Ended 6 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Number_Of_Notes

Jun. 30, 2011

Dec. 31, 2011

Jun. 30, 2012

Jun. 30, 2012

RG [Member]

Jun. 30, 2012

ISVP [Member]

Dec. 31, 2011

ISVP [Member]

Dec. 31, 2011

Robert and Thomas Gipson [Member]

Dec. 27, 2011

Robert Gipson [Member]

Dec. 27, 2011

Thomas Gipson [Member]

Jun. 01, 2011

Arthur Koenig [Member]

Dec. 31, 2011

Ingalls Snyder LLC [Member]

Jun. 30, 2012

Molecular Imaging and Other Products [Member]

Jun. 30, 2012

Demand Notes Payable [Member]

Jun. 30, 2011

Demand Notes Payable [Member]

Jun. 30, 2012

Demand Notes Payable [Member]

Jun. 30, 2011

Demand Notes Payable [Member]

Notes Payable and Debt (Textual) [Abstract]

Convertible notes payable $ 21,827,588 $ 21,827,588 $ 21,827,588 $ 21,827,588 $ 7,172,412 $ 1,000,000

Future payments as a percentage of pre-commercial revenue 2.00%

Notes payables additional compensation as a percentage of future net sales per $1000000 outstanding principle 0.50%

Percentage of shares to be held by purchases considered to determine effective conversion under option 1 19.90%

Percentage of shares to be held by purchases considered to determine effective conversion under option 2 9.99%

Recorded Beneficial Conversion Feature 380,000 1,400,000

Percentage of outstanding common stock 9.99% 50.10% 15.20% 7.00% 9.99%

Demand notes payable value 6,185,000 6,185,000 5,900,000 6,185,000

Interest expenses Related to BCF 0 362,499 0 724,998 105,287 100,078 208,225 186,224

Notes Payable and Debt (Additional Textual) [Abstract]

Unsecured promissory note 1,000,000 1,000,000 1,000,000

Interest expenses 105,716 465,258 209,113 919,009 18,000 14,698,223

Additional Debt $ 2,525,000

Unsecured convertible promissory notes conversion options Conversion Policies (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii).

Unsecured convertible promissory notes conversion price per common stock share $ 2.50 $ 2.50 $ 2.50

Notes Payable, Description Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under.

Number of unsecured promissory notes issued 2

X

- Definition

Future payments as percentage of pre commercial revenue.

+ References

No definition available.

+ Details

Name: alse_FuturePaymentsAsPercentageOfPreCommercialRevenue

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: alse_NotesPayableAndDebtAdditionalTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: alse_NotesPayableAndDebtTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Notes payables additional compensation as a percentage of future net sales.

+ References

No definition available.

+ Details

Name: alse_NotesPayablesAdditionalCompensationAsPercentageOfFutureNetSales

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of unsecured promissory notes issued.

+ References

No definition available.

+ Details

Name: alse_NumberOfUnsecuredPromissoryNotesIssued

Namespace Prefix: alse_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of outstanding common stock.

+ References

No definition available.

+ Details

Name: alse_PercentageOfOutstandingCommonStock

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Percentage of shares to be held by purchasers considered to determine effective conversion under option 1.

+ References

No definition available.

+ Details

Name: alse_PercentageOfSharesToBeHeldByPurchasersConsideredToDetermineEffectiveConversionUnderOptionOne

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of shares to be held by purchases considered to determine effective conversion under option 2.

+ References

No definition available.

+ Details

Name: alse_PercentageOfSharesToBeHeldByPurchasesConsideredToDetermineEffectiveConversionUnderOptionTwo

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Unsecured convertible promissory notes conversion options.

+ References

No definition available.

+ Details

Name: alse_UnsecuredConvertiblePromissoryNotesConversionOptions

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 98-5

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-27

-Paragraph 56

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 32

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Interest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6036836-161870

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 33

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentConvertibleInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Increase of additional borrowings on existing and new debt instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_DebtInstrumentIncreaseAdditionalBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses
6 Months Ended

Jun. 30, 2012

Accounts Payable and Accrued Liabilities [Abstract]

Accounts Payable and Accrued Expenses
3. Accounts Payable and Accrued Expenses

The Company’s accounts payable and accrued expenses consisted of the following:

June 30, 2012 December 31, 2011

Research and development expenses
$ 1,351,940 $ 1,316,095

Professional fees
761,061 715,672

General and administrative expenses
107,848 99,746

Compensation related expenses
76,193 78,716

$ 2,297,042 $ 2,210,229

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6

Convertible Preferred Stock (Details Textual) (Series F Preferred Stock [Member], USD $)
6 Months Ended

Jun. 30, 2012

Dec. 31, 2011

Series F Preferred Stock [Member]

Convertible Preferred Stock (Textual) [Abstract]

Preferred Stock Convertibles Conversion Ratio 25

Convertible Preferred Stock price per share $ 25

Proceeds from sale of convertible preferred stock $ 4,600,000

Redeemable convertible preferred stock, shares outstanding 12,000 12,000

X

- Details

Name: alse_ConvertiblePreferredStockTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Preferred stock convertibles conversion ratio.

+ References

No definition available.

+ Details

Name: alse_PreferredStockConvertiblesConversionRatio

Namespace Prefix: alse_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2,3,4,5,6,7,8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TemporaryEquityRedemptionPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (USD $)

Jun. 30, 2012

Dec. 31, 2011

Current assets:

Cash and cash equivalents $ 63,552 $ 135,843

Short-term investments 20,389 27,446

Prepaid expenses and other current assets 44,008 4,965

Total current assets 127,949 168,254

Property and Equipment, net 1,582 2,475

Total assets 129,531 170,729

Current liabilities:

Accounts payable and accrued expenses 2,297,042 2,210,229

Convertible notes payable 21,827,588 21,827,588

Notes payable 6,185,000 5,900,000

Accrued interest payable on notes payable 694,946 486,691

Total current liabilities 31,004,576 30,424,508

Total liabilities 31,004,576 30,424,508

Commitments and contingencies

Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at June 30, 2012 and December 31, 2011, (liquidation preference of $300,000 at June 30, 2012) 358,915 348,444

Stockholders' deficit:

Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively

Common stock, $.01 par value; 80,000,000 shares authorized at June 30, 2012 and December 31, 2011; 30,635,720 issued and outstanding at June 30, 2012 and December 31, 2011 306,357 306,357

Additional paid-in capital 166,160,384 166,170,855

Accumulated other comprehensive loss (38,424) (31,367)

Deficit accumulated during development stage (197,662,277) (197,048,068)

Total stockholders' deficit (31,233,960) (30,602,223)

Total liabilities and stockholders' deficit $ 129,531 $ 170,729

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-98

-Paragraph 2,4,5,6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2,3,4,5,6,7,8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Nature of Operations and Basis of Presentation
6 Months Ended

Jun. 30, 2012

Nature of Operations and Basis of Presentation [Abstract]

Nature of Operations and Basis of Presentation
1. Nature of Operations and Basis of Presentation

Nature of Operations

Alseres Pharmaceuticals, Inc. and its subsidiaries (the “Company”) is a biotechnology company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system. The Company was founded in 1992 and merged with a publicly held company in 1995 (the “Merger”) whereby the Company changed its name to Boston Life Sciences, Inc. Effective June 7, 2007, the Company changed its name to Alseres Pharmaceuticals, Inc. During the period from inception through June 30, 2012, the Company has devoted substantially all of its efforts to business planning, raising financing, furthering the research and development of its technologies, and corporate partnering efforts. Accordingly, the Company is considered to be a “development stage enterprise” as defined in Accounting Standards Codification 915 (ASC 915) Development Stage Entities and will continue to be so until the commencement of commercial operations. Our development stage started on October 16, 1992 and has continued through June 30, 2012, and is expected to continue for the foreseeable future.

As of June 30, 2012, we had experienced total net losses since inception of approximately $206,953,000, stockholders’ deficit of approximately $31,234,000 and a net working capital deficit of approximately $30,877,000. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as we execute our current business plan. The cash and cash equivalents available at June 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. We believe that the approximately $185,000 in cash and cash equivalents available as of August 1, 2012 combined with minimal additional operating capital committed by our lead investor and our ability to control certain costs, including those related to clinical trial programs, preclinical activities, and certain general and administrative expenses will enable us to meet our anticipated cash expenditures into September 2012.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

The interim unaudited condensed consolidated financial statements contained herein include, in management’s opinion, all adjustments necessary for a fair statement of the financial position, results of operations, and cash flows for the periods presented. The results of operations for the interim period shown on this report are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the Company’s consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The uncertainty inherent in the need to raise additional capital and the Company’s recurring losses from operations raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Reclassification

Certain reclassifications have been made to the prior year’s condensed consolidated statements of comprehensive loss to conform to the current year presentation.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Details Textual) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Fair Value Disclosures (Textual) [Abstract]

Unsecured convertible promissory notes conversion price per common stock share 2.50

Sale of stock, price per share 0.12

Fair Value, Measurements, Recurring [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Short-term investments shares of FluoroPharma Medical, Inc 39,209 39,209

X

- Details

Name: alse_FairValueDisclosuresTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares held in short term investment.

+ References

No definition available.

+ Details

Name: alse_NumberOfSharesHeldInShortTermInvestment

Namespace Prefix: alse_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 32

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section H

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Nature of Operations and Basis of Presentation (Details Textual) (USD $)
3 Months Ended 6 Months Ended 236 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Aug. 01, 2012

Dec. 31, 2011

Organization Consolidation and Presentation of Financial Statements (Textual) [Abstract]

Net losses since inception $ (294,908) $ (533,536) $ (614,209) $ (1,610,147) $ (206,952,578)

Stockholders deficit (31,233,960) (31,233,960) (31,233,960) (30,602,223)

Net working capital deficit 30,877,000 30,877,000 30,877,000

Estimated cash and cash equivalents $ 185,000

X

- Definition

Estimated cash and cash equivalents.

+ References

No definition available.

+ Details

Name: alse_EstimatedCashAndCashEquivalents

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: alse_OrganizationConsolidationAndPresentationOfFinancialStatementsTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net working capital deficit.

+ References

No definition available.

+ Details

Name: alse_WorkingCapitalDeficitNet

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 28 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events (Details Textual) (USD $)
1 Months Ended 6 Months Ended

Jul. 31, 2012

Jan. 31, 2012

Jun. 30, 2012

Subsequent Events (Additional Textual) [Abstract]

Borrowings from Robert Gipson $ 150,000

Interest rate stated in the contractual debt agreement 7.00%

Non-refundable sum in exchange for exclusive option to license 500,000

Sublicense execution payment (175,000)

Contingent milestone payments, maximum 2,900,000

Contingent milestone payments occur at the time of product registration or upon commercial sales 2,500,000

Maximum effective declaration period 90 days

Convertible Note Purchase Agreement to receive repayment of a total 16,000,000

Convertible Note Purchase Agreement at a rate 8.00%

Prospective Repayment Of Debt Pursuant To Waiver Of Right To Receive Percentage of Altropane Product Sale $ 5,827,587

Navb Stock [Member]

Subsequent Events (Textual) [Abstract]

Shares Received Against Execution Of Sublicense Granted 300,000

Navidea stock [Member]

Subsequent Events (Textual) [Abstract]

Issuance common shares of Navidea stock maximum 1,150,000

Issuance common shares of Navidea stock occur at the time of product registration or upon commercial sales 950,000

X

- Definition

Contingent milestone proceeds receivable at time of product registration or upon commercial sales upon license agreement.

+ References

No definition available.

+ Details

Name: alse_ContingentMilestoneProceedsReceivableAtTimeOfProductRegistrationOrUponCommercialSalesUponLicenseAgreement

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Contingent share receipts occur at time of product registration or upon commercial sales upon license agreement.

+ References

No definition available.

+ Details

Name: alse_ContingentShareReceiptsOccurAtTimeOfProductRegistrationOrUponCommercialSalesUponLicenseAgreement

Namespace Prefix: alse_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Maximum contingent milestone proceeds receivable upon license agreement.

+ References

No definition available.

+ Details

Name: alse_MaximumContingentMilestoneProceedsReceivableUponLicenseAgreement

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Maximum contingent shares receipts in terms of license agreement.

+ References

No definition available.

+ Details

Name: alse_MaximumContingentSharesReceiptsInTermsOfLicenseAgreement

Namespace Prefix: alse_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Maximum period to file declaration for release of payment and issue of shares.

+ References

No definition available.

+ Details

Name: alse_MaximumPeriodToFileDeclarationForReleaseOfPaymentAndIssueOfShares

Namespace Prefix: alse_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Non-refundable sum in exchange for exclusive option.

+ References

No definition available.

+ Details

Name: alse_NonRefundableSumInExchangeForExclusiveOption

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from borrowings secured by demand promissory note.

+ References

No definition available.

+ Details

Name: alse_ProceedsFromBorrowingsSecuredByDemandPromissoryNote

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Promissory notes principal outstandings.

+ References

No definition available.

+ Details

Name: alse_PromissoryNotesPrincipalOutstandings

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Prospective repayment of debt pursuant to waiver of right to receive percentage of altropane product sale.

+ References

No definition available.

+ Details

Name: alse_ProspectiveRepaymentOfDebtPursuantToWaiverOfRightToReceivePercentageOfAltropaneProductSale

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Rate of future net sales of altropane product to promissory notes.

+ References

No definition available.

+ Details

Name: alse_RateOfFutureNetSalesOfAltropaneProductToPromissoryNotes

Namespace Prefix: alse_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Shares received against execution of sublicense granted.

+ References

No definition available.

+ Details

Name: alse_SharesReceivedAgainstExecutionOfSublicenseGranted

Namespace Prefix: alse_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Sublicense execution payment received upon license agreement.

+ References

No definition available.

+ Details

Name: alse_SublicenseExecutionPaymentReceivedUponLicenseAgreement

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: alse_SubsequentEventsAdditionalTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: alse_SubsequentEventsTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Interest rate stated in the contractual debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses (Details) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses $ 2,297,042 $ 2,210,229

Research and development expenses [Member]

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses 1,351,940 1,316,095

Professional fees [Member]

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses 761,061 715,672

General and administrative expenses [Member]

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses 107,848 99,746

Compensation related expenses [Member]

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses $ 76,193 $ 78,716

X

- Details

Name: alse_ScheduleOfAccountsPayableAndAccruedExpensesAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid marketable securities purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.

Short-term Investments

The Company considers all marketable securities with maturities greater than three months and less than one year at the time of acquisition or purchase to be short-term investments. The Company evaluates such designation as of each balance sheet date to determine if the classification is appropriate. As of June 30, 2012 our short-term investments were classified as available-for-sale and were carried on the balance sheet at fair value. The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.

Comprehensive Loss

Components of comprehensive loss are reported in the Company’s condensed consolidated statements of comprehensive loss in the period in which they are recognized. The components of comprehensive loss include net loss and net change in the unrealized gains or losses in our marketable securities during the period.

Fair Value Measurements

The carrying amounts of the Company’s cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values as of June 30, 2012 and December 31, 2011 due to their short-term nature. Short-term investments were considered available-for-sale as of June 30, 2012 and are carried at fair value in the condensed consolidated balance sheets. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012 and the Company currently does not have the resources to repay the convertible debt.

Revenue Recognition and Deferred Revenue

The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.

Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.

On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.

Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2011-05, “Presentation of Comprehensive Income.” ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. The Company adopted these standards as of January 1, 2012. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and six months ended June 30, 2012.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Preferred stock, par value $ 0.01 $ 0.01

Convertible Preferred stock, shares designated 1,000,000 1,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 80,000,000 80,000,000

Common stock, shares issued 30,635,720 30,635,720

Common stock, shares outstanding 30,635,720 30,635,720

Series A Preferred Stock

Convertible Preferred stock, shares designated 25,000 25,000

Series D Preferred Stock

Convertible Preferred stock, shares designated 500,000 500,000

Series E Preferred Stock

Convertible Preferred stock, shares designated 800 800

Series F Preferred Stock

Redeemable convertible preferred stock, shares par value per share $ 0.01 $ 0.01

Redeemable convertible preferred stock, shares designated 200,000 200,000

Redeemable convertible preferred stock, shares issued 12,000 12,000

Redeemable convertible preferred stock, shares outstanding 12,000 12,000

Preferred stock, shares liquidation preference $ 300,000

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Cash and Cash Equivalents
The Company considers all highly liquid marketable securities purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.

Short-term Investments
The Company considers all marketable securities with maturities greater than three months and less than one year at the time of acquisition or purchase to be short-term investments. The Company evaluates such designation as of each balance sheet date to determine if the classification is appropriate. As of June 30, 2012 our short-term investments were classified as available-for-sale and were carried on the balance sheet at fair value. The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.

Comprehensive Loss
Components of comprehensive loss are reported in the Company’s condensed consolidated statements of comprehensive loss in the period in which they are recognized. The components of comprehensive loss include net loss and net change in the unrealized gains or losses in our marketable securities during the period.

Fair Value Measurements
The carrying amounts of the Company’s cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values as of June 30, 2012 and December 31, 2011 due to their short-term nature. Short-term investments were considered available-for-sale as of June 30, 2012 and are carried at fair value in the condensed consolidated balance sheets. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012 and the Company currently does not have the resources to repay the convertible debt.

Revenue Recognition and Deferred Revenue
The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.

Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.

On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.

Recent Accounting Pronouncements
In June 2011, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2011-05, “Presentation of Comprehensive Income.” ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. The Company adopted these standards as of January 1, 2012. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and six months ended June 30, 2012.

X

- Definition

Short-term investments.

+ References

No definition available.

+ Details

Name: alse_ShortTermInvestmentsPolicyTextBlock

Namespace Prefix: alse_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Technical Practice Aid (TPA)

-Number 2110

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for fair value measurements, which may include, but is not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 35

-Paragraph 18G

-URI http://asc.fasb.org/extlink&oid=15229074&loc=SL7494712-110257

+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197196

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_RevenueRecognitionDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
6 Months Ended

Jun. 30, 2012

Jul. 31, 2012

Document and Entity Information [Abstract]

Entity Registrant Name ALSERES PHARMACEUTICALS INC /DE

Entity Central Index Key 0000094784

Document Type 10-Q

Document Period End Date Jun. 30, 2012

Amendment Flag false

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q2

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 30,635,720

X

- Details

Name: alse_DocumentAndEntityInformationAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2012

Accounts Payable and Accrued Liabilities [Abstract]

Schedule of accounts payable and accrued expenses

June 30, 2012 December 31, 2011

Research and development expenses
$ 1,351,940 $ 1,316,095

Professional fees
761,061 715,672

General and administrative expenses
107,848 99,746

Compensation related expenses
76,193 78,716

$ 2,297,042 $ 2,210,229

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)
3 Months Ended 6 Months Ended 236 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Condensed Consolidated Statements of Comprehensive Loss [Abstract]

Revenue $ 250,000 $ 500,000 $ 1,400,000

Operating expenses:

General and administrative 418,676 571,282 865,039 1,168,879 69,679,927

Research and development 20,545 58,358 41,239 83,954 116,082,837

Purchased in-process research and development 12,146,544

Operating expenses before accrual reversal 439,221 629,640 906,278 1,252,833 197,909,308

Accrual reversal (561,196) (561,196) (561,195)

Total operating expenses 439,221 68,444 906,278 691,637 197,348,113

Loss from operations (189,221) (68,444) (406,278) (691,637) (195,948,113)

Interest expense (105,716) (465,258) (209,113) (919,009) (14,698,223)

Investment income 29 166 277 499 7,705,281

Other income (expense), net 905 (1,473,159)

Gain on early extinguishment of debt 6,277,100

Forgiveness of debt 476,837

Net loss (294,908) (533,536) (614,209) (1,610,147) (197,660,277)

Preferred stock beneficial conversion feature (8,062,712)

Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders (1,229,589)

Net loss attributable to common stockholders (294,908) (533,536) (614,209) (1,610,147) (206,952,578)

Other comprehensive income Net change in unrealized loss on marketable securities (12,938) (7,057) (7,057)

Comprehensive loss $ (307,846) $ (533,536) $ (621,266) $ (1,610,147) $ (206,959,635)

Basic and diluted net loss attributable to common stockholders per share $ (0.01) $ (0.02) $ (0.02) $ (0.06)

Weighted average common shares outstanding 30,635,720 28,302,129 30,635,720 27,548,076

X

- Definition

Accrual expenses.

+ References

No definition available.

+ Details

Name: alse_AccrualReversalForResearchAndDevelopmentExpense

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Forgiveness of debt.

+ References

No definition available.

+ Details

Name: alse_GainOnForgivenessOfDebt

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Operating expenses before accrual reversal.

+ References

No definition available.

+ Details

Name: alse_OperatingExpensesBeforeAccrualReversal

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 26

-Paragraph 20, 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt and equity securities and on cash and cash equivalents. Interest income represents earnings which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Dividend income represents a distribution of earnings to shareholders by investee companies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(a),(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Subparagraph a, b

-Article 5

+ Details

Name: us-gaap_InvestmentIncomeInterestAndDividend

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Tax effect of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 17, 22

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other preferred stock dividends and adjustments, not otherwise defined in the taxonomy, that are necessary to adjust net income to obtain net income applicable to common stockholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section Q

+ Details

Name: us-gaap_OtherPreferredStockDividendsAndAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section S99

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6802175&loc=d3e42851-122695

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockConversionsInducements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 4

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Convertible Preferred Stock
6 Months Ended

Jun. 30, 2012

Convertible Preferred Stock [Abstract]

Convertible Preferred Stock
7. Convertible Preferred Stock

The Company’s Series F Convertible, Redeemable Preferred Stock (“Series F Stock”) can be converted into 25 shares of common stock pursuant to the conversion terms of the Series F Stock contained in the Certificate of Designation for the Series F Stock. Each share of the Series F Stock was sold to Robert Gipson during 2009 at a price per share of $25 yielding aggregate proceeds to the Company in 2009 of $4,600,000. As of June 30, 2012, 12,000 shares of Series F Stock were outstanding and held by Robert Gipson.

X

- Definition

Convertible preferred stock.

+ References

No definition available.

+ Details

Name: alse_TemporaryEquityDisclosureTextBlock

Namespace Prefix: alse_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Notes Payable and Debt
6 Months Ended

Jun. 30, 2012

Notes Payable and Debt [Abstract]

Notes Payable and Debt
6. Notes Payable and Debt

Convertible Notes Payable to Significant Stockholders
June 30, 2012 December 31, 2011

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
$ 4,655,173 $ 4,655,173

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
BCF 10,000,000 10,000,000

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
BCF 2,172,415 2,172,415

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
5,000,000 5,000,000

Aggregate carrying value
$ 21,827,588 $ 21,827,588

No interest expense was incurred related to the convertible notes payable for the three and six months ended June 30, 2012. Interest expense totaling $362,499 and $724,998 was incurred related to the convertible notes payable for the three and six months ended June 30, 2011. In December 2011, Robert Gipson and Thomas Gipson elected to convert a total of $7,172,412 of their convertible notes payable into common stock of the Company. This transaction was part of a debt reduction agreement entered into through the Fifth Amendment to Convertible Note Purchase Agreement (“Amendment”) which also provided that all interest accrued or to be accrued related to these promissory notes would be waived.

The remaining unsecured convertible promissory notes may be converted, at the option of the Purchasers, into (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii). Any outstanding notes that are not converted into the Company’s common stock or into the right to receive future payments became due and payable on December 31, 2010. As of June 30, 2012, the holders of this debt have not made any formal demand for payment.

However, each Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under. There has been no demand for amounts due and the classification remains current.

The Company is subject to certain debt covenants pursuant to the March 2008 Amended Purchase Agreement and the June 2008 Purchase Agreement (the “Purchase Agreements”). If the Company (i) fails to pay the principal or interest due under the Purchase Agreements, (ii) files a petition for action for relief under any bankruptcy or similar law or (iii) an involuntary petition is filed against the Company, all amounts borrowed under the Purchase Agreements may become immediately due and payable by the Company. In addition, without the consent of the Purchasers, the Company may not (i) create, incur or otherwise, permit to be outstanding any indebtedness for money borrowed, (ii) declare or pay any cash dividend, or make a distribution on, repurchase, or redeem, any class of the Company’s stock, subject to certain exceptions or sell, lease, transfer or otherwise dispose of any of the Company’s material assets or property or (iii) dissolve or liquidate.

Beneficial Conversion Feature (BCF)

Two of the remaining unsecured promissory notes were issued with a conversion price of $2.50 which was below the market price of the Company’s common stock on the dates the agreements were entered into and resulted in the recording of a beneficial conversion feature (“BCF”). The Company recorded a BCF of $1,400,000 on (the “ISVP”) note and a BCF of $380,000 on (the “2008 RG”) note which were recognized as a decrease in the carrying value and an increase to additional paid-in capital. All related BCF expense has been fully recognized as interest expense using the effective interest method as of December 31, 2010.

Promissory Notes

Demand Notes Payable to Significant Stockholder
June 30, 2012 December 31, 2011

Unsecured demand note payable; interest rate of 7%: issued December 2009
$ 350,000 $ 350,000

Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010
3,310,000 3,310,000

Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011
2,240,000 2,240,000

Unsecured demand notes payable; interest rate of 7%: issued January 2012 — June 2012
285,000 —

6,185,000 5,900,000

Accrued interest
694,946 486,691

Aggregate carrying value
$ 6,879,946 $ 6,386,691

Interest expense totaling $105,287 and $100,078 was incurred related to the demand notes payable for the three months ended June 30, 2012 and 2011, respectively. Interest expense totaling $208,255 and $186,224 was incurred related to the demand notes payable for the six months ended June 30, 2012 and 2011, respectively. In November 2011, the Company purchased from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. The result of this transaction was a reduction in quarterly interest expense of approximately $18,000 which has been partially offset by interest on the additional debt obligations of $2,525,000 entered into by the Company during 2011 and 2012 with Robert Gipson.

According to a Schedule D/A filed with the SEC on December 27, 2011 Robert Gipson beneficially owned approximately 50.1% of the outstanding common stock of the Company as of that date. Robert Gipson, who serves as a Senior Director of Ingalls & Snyder and a General Partner of ISVP, served as a director of the Company from June 15, 2004 until October 28, 2004. According to a Schedule D/A filed with the SEC on December 27, 2011, Thomas Gipson beneficially owned approximately 15.2% of the outstanding common stock of the Company as of that date. According to a Schedule 13G/A filed with the SEC on June 7, 2011, Arthur Koenig beneficially owned approximately 7% of the outstanding common stock of the Company on June 1, 2011. According to a Schedule 13G/A filed with the SEC on February 2, 2012, ISVP owned approximately 9.99% of the outstanding common stock of the Company as of December 31, 2011. According to a Schedule 13G/A filed with the SEC on February 7, 2012, Ingalls & Snyder LLC beneficially owned approximately 9.99% of the outstanding common stock of the Company on December 31, 2011.

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Details Textual) (USD $)
6 Months Ended

Jun. 30, 2012

Summary of Significant Accounting Policies (Textual) [Abstract]

Unsecured convertible promissory notes conversion price per common stock share $ 2.50

Stock price $ 0.12

Non refundable option fee $ 500,000

Option Agreement Period 6 months

X

- Definition

Non refundable option fee.

+ References

No definition available.

+ Details

Name: alse_NonRefundableOptionFee

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Option agreement period.

+ References

No definition available.

+ Details

Name: alse_OptionAgreementPeriod

Namespace Prefix: alse_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: alse_SummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 32

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section H

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting for Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2012

Accounting for Stock-Based Compensation [Abstract]

Summary of our outstanding stock options

2012 2011

Shares Weighted
Average
Exercise Price Shares Weighted
Average
Exercise Price

Outstanding at beginning of year
3,636,480 $ 1.55 3,650,443 $ 1.59

Granted
— — — —

Exercised
— — — —

Forfeited and expired
(625,000 ) 1.75 (5,000 ) 15.63

Outstanding at end of period
3,011,480 $ 1.51 3,645,443 $ 1.57

Options exercisable at end of period
3,011,480 $ 1.51 3,645,443 $ 1.57

Summary of stock options outstanding and exercisable

Range of Exercise Prices
Number Outstanding Weighted Average
Remaining
Contractual Life Weighted Average
Exercise Price

$1.15 — $1.36
2,288,000 1.9 years $ 1.15

$2.00 — $3.00
539,980 3.2 years 2.33

$3.10 — $4.65
155,000 5.3 years 3.17

$4.99 — $6.96
28,500 1.5 years 5.47

3,011,480 2.3 years $ 1.51

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements
6 Months Ended

Jun. 30, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements
10. Fair Value Measurements

The fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 — unadjusted quoted prices in active markets for identical securities;

Level 2 — unadjusted quoted prices in markets that are not active,

Level 3 — significant unobservable inputs, including our own assumptions in determining fair value

The following table summarizes the financial assets that we measured at fair value as of June 30, 2012 and December 31, 2011.

June 30, 2012
Fair Value Input Level December 31, 2011
Fair Value Input Level

Short-term investments
$ 20,389 Level 2 $ 27,446 Level 2

$ 20,389 $ 27,446

As of June 30, 2012 and December 31, 2011, the Company’s short-term investments consisted of 39,209 shares of FluoroPharma Medical, Inc. stock. These shares are traded on the OTC Bulletin Board (“OTCBB”) under the symbol FPMI. The Rule 144 holding period has lapsed for these shares as of June 30, 2012, but the stock continues to trade on very thin volume in the open market. Therefore the Company continues to classify this asset as Level 2.

The Company did not have any non-financial assets or liabilities that were measured or disclosed at fair value for the period ended June 30, 2012 or December 31, 2011. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
6 Months Ended

Jun. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies
8. Commitments and Contingencies

We recognize and disclose commitments when we enter into executed contractual obligations with third parties. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company does not agree that the total amounts claimed in the lawsuit are in fact owed and will pursue all legal remedies available to it to defend this claim.

On May 2, 2012 the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company believes that the total amounts claimed in the Biostorage lawsuit are significantly overstated. The Company intends to pursue all available legal and equitable remedies to defend this claim.

License Agreements

The Company has entered into license agreements (the “Harvard License Agreements”) with Harvard University and its affiliated hospitals (“Harvard and its Affiliates”) to acquire the exclusive worldwide rights to certain technologies within its molecular imaging and neurodegenerative disease programs. The Harvard License Agreements obligate the Company to pay up to an aggregate of approximately $850,000 in milestone payments in the future. The future milestone payments are generally payable only upon achievement of certain regulatory milestones.

The Company’s license agreements with Harvard and its Affiliates generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees and continuing patent prosecution costs.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income taxes
6 Months Ended

Jun. 30, 2012

Income taxes [Abstract]

Income taxes
9. Income taxes

The Company is subject to both federal and state income tax for the jurisdiction within which it operates. Within these jurisdictions, the Company is open to examination for tax years ended December 31, 2009 through December 31, 2011. The U.S. Internal Revenue Service (IRS) has completed an audit of tax years 2007 and 2008 and has informed us that no adjustments to the federal tax returns as filed will be proposed as a result of the audit. However, because we are carrying forward income tax attributes such as a net operating loss (“NOL”) from 2006, these attributes can still be audited when utilized on returns filed in the future.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
6 Months Ended

Jun. 30, 2012

Subsequent Events [Abstract]

Subsequent Events
11. Subsequent Events

We evaluated all events or transactions that occurred after June 30, 2012 up through the date we issued these financial statements.

In July 2012, we borrowed the principal sum of $150,000 from Robert Gipson. The funds borrowed are secured by a demand promissory note issued to Mr. Gipson that bears interest at the rate of 7% per annum.

On July 31, 2012 the Company announced that it entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, “Navidea”) to license, [¹²³I]-E-IACFT Injection (CFT), also called Altropane^®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

In January 2012, Alseres and Navidea executed an Option Agreement pursuant to which Navidea paid Alseres the non-refundable sum of $500,000 in exchange for the exclusive option to license the CFT program, to conduct its final due diligence review of the program and to prepare the paperwork necessary for the execution of the license.

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea made a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issued Alseres 300,000 shares of NAVB common stock.

The license agreement also provides for contingent milestone payments of up to $2.9 million, $2.5 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.15 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Navidea agreed to file with the Securities and Exchange Commission and use its best commercial efforts to have declared effective within 90 days a registration statement that would permit Alseres to resell the common stock issued as initial or milestone payments under the license agreement.

Under the license agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Alseres has no continuing cost obligations related to Altropane. There can be no assurances that Altropane will receive regulatory approval for sale in any jurisdiction.

On July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007 elected to exercise their existing rights under the Convertible Note Purchase Agreement to receive repayment of a total of $16 million in principal outstanding under the promissory notes purchased under the Convertible Note Purchase Agreement at a rate of 8% of the future Net Sales of the Company’s Altropane product. In a related transaction executed on July 31, 2012, Arthur Koenig and Ingalls & Snyder Value Partners LLP agreed to waive their right to receive a percentage of Altropane sales in the future in repayment of the $5,827,587 in debt remaining after their portion of the agreement mentioned above.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)

Jun. 30, 2012

Dec. 31, 2011

Summary of financial asset measured at fair value

Fair value financial assets total $ 20,389 $ 27,446

Level 2 [Member]

Summary of financial asset measured at fair value

Short-term investments $ 20,389 $ 27,446

X

- Definition

This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents investment securities as of the balance sheet date which may include marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Trading Securities

-URI http://asc.fasb.org/extlink&oid=6526789

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a, f, g

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 12

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=16383099&loc=d3e24584-111560

+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 46 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Tables)
6 Months Ended

Jun. 30, 2012

Fair Value Measurements [Abstract]

Summary of financial asset measured at fair value

June 30, 2012
Fair Value Input Level December 31, 2011
Fair Value Input Level

Short-term investments
$ 20,389 Level 2 $ 27,446 Level 2

$ 20,389 $ 27,446

X

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 6

-Footnote 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting for Stock-Based Compensation (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Summary of our outstanding stock options

Outstanding at beginning of year, Shares 3,636,480 3,650,443

Outstanding at beginning of year, Weighted Average Exercise Price $ 1.55 $ 1.59

Granted, Shares 0 0

Granted, Weighted Average Exercise Price

Exercised, Shares

Exercised, Weighted Average Exercise Price

Forfeited and expired, Shares (625,000) (5,000)

Forfeited and expired, Weighted Average Exercise Price $ 1.75 $ 15.63

Outstanding at end of period, Shares 3,011,480 3,645,443 3,011,480 3,645,443

Outstanding at end of period, Weighted Average Exercise Price $ 1.51 $ 1.57 $ 1.51 $ 1.57

Options exercisable at end of period, Shares 3,011,480 3,645,443 3,011,480 3,645,443

Options exercisable at end of period, Weighted Average Exercise Price $ 1.51 $ 1.57 $ 1.51 $ 1.57

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended 236 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Cash flows from operating activities:

Net loss $ (614,209) $ (1,610,147) $ (197,660,277)

Adjustments to reconcile net loss to net cash used for operating activities:

Purchased in-process research and development 12,146,544

Write-off of acquired technology 3,500,000

Loss on disposition of assets 3,391

Interest expense settled through issuance of notes payable 350,500

Expenses satisfied with the issuance of stock 28,680

Forgiveness of debt (476,837)

Gain on early extinguishment of debt (6,277,100)

Non-cash gain on restricted stock valuation (58,814)

Non-cash interest expense 3,966,394

Non-cash charges related to options, warrants and common stock 834 11,115,437

Amortization of financing costs 6,842 25,188

Amortization and depreciation 893 27,274 2,891,559

Changes in operating assets and liabilities:

(Increase) decrease in prepaid expenses and other current assets (39,043) (24,112) 461,320

Increase (decrease) in accounts payable and accrued expenses 86,813 (769,025) 2,001,215

Increase in accrued interest payable 208,255 911,222 8,023,052

Decrease in accrued lease (96,425)

Net cash used for operating activities (357,291) (1,553,537) (159,959,748)

Cash flows from investing activities:

Cash acquired through Merger 1,758,037

Purchases of property and equipment (1,654,487)

Proceeds from the sale of property and equipment 3,430

Decrease (increase) in security deposits and other assets 88,600

Decrease in indemnity fund 85

Purchases of marketable securities (132,004,923)

Sales and maturities of marketable securities 132,004,923

Net cash provided by investing activities 88,685 106,980

Cash flows from financing activities:

Proceeds from issuance of common stock 66,731,339

Buyback of common stock (26,356)

Proceeds from issuance of preferred stock 39,922,170

Preferred stock conversion inducement (600,564)

Proceeds from issuance of promissory notes 285,000 1,440,000 58,770,000

Proceeds from issuance of convertible debentures 9,000,000

Principal payments of notes payable/repurchase of debt (7,750,667)

Dividend payments on Series E Cumulative Convertible Preferred Stock (516,747)

Payments of financing costs (5,612,855)

Net cash provided by financing activities 285,000 1,440,000 159,916,320

Net (decrease) increase in cash and cash equivalents (72,291) (24,852) 63,552

Cash and cash equivalents, beginning of period 135,843 98,514

Cash and cash equivalents, end of period 63,552 73,662 63,552

Supplemental cash flow disclosures:

Cash paid for interest 628,406

Supplemental disclosure of non-cash financing activity:

Conversion of notes payable to common stock 7,172,412

Capital contribution related to forgiveness of accrued interest 6,328,306

Accrued interest reclassified in connection with conversion of Series F convertible redeemable preferred stock to common stock $ 640,874

X

- Definition

Expenses satisfied with the issuance of stock.

+ References

No definition available.

+ Details

Name: alse_AdjustmentToNonCashItemsIssuanceOfStockForAccruedExpenses

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Capital contribution related to accrued interest forgiveness.

+ References

No definition available.

+ Details

Name: alse_CapitalContributionRelatedToAccruedInterestForgiveness

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Forgiveness of debt.

+ References

No definition available.

+ Details

Name: alse_GainOnForgivenessOfDebt

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net gain on early extinguishment of debt.

+ References

No definition available.

+ Details

Name: alse_GainsLossesOnExtinguishmentOfDebtNet

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Decrease in accrued lease.

+ References

No definition available.

+ Details

Name: alse_IncreaseDecreaseInAccruedLease

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Interest expense settled through issuance of notes payable.

+ References

No definition available.

+ Details

Name: alse_InterestExpenseSettledThroughIssuanceOfNotesPayable

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Non-cash charges related to options, warrants and common stock.

+ References

No definition available.

+ Details

Name: alse_NonCashChargesRelatedToOptionsWarrantsAndCommonStock

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Non-cash interest expense.

+ References

No definition available.

+ Details

Name: alse_NonCashInterestExpense

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Non-cash gain on restricted stock valuation.

+ References

No definition available.

+ Details

Name: alse_UnrealizedGainLossOnChangeInFairValueOfRestrictedSecurities

Namespace Prefix: alse_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in security deposits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInSecurityDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow in the form of ordinary dividends to preferred shareholders, generally out of earnings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 4

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting for Stock-Based Compensation
6 Months Ended

Jun. 30, 2012

Accounting for Stock-Based Compensation [Abstract]

Accounting for Stock-Based Compensation
5. Accounting for Stock-Based Compensation

We have one stock option plan under which we can issue both nonqualified and incentive stock options to employees, officers, consultants and scientific advisors of the Company. At June 30, 2012, the 2005 Stock Incentive Plan (the “2005 Plan”) provided for the issuance of options, restricted stock, restricted stock units, stock appreciation rights or other stock-based awards to purchase 3,450,000 shares of our common stock. The 2005 Plan contains a provision that allows for an annual increase in the number of shares available for issuance under the 2005 Plan on the first day of each of the Company’s fiscal years during the period beginning in fiscal year 2006 and ending on the second day of fiscal year 2014. The annual increase in the number of shares shall be equal to the lowest of 400,000 shares; 4% of the Company’s outstanding shares on the first day of the fiscal year; and an amount determined by the Board of Directors. There was no adjustment made in January 2012.

We also have outstanding stock options in three other stock option plans, the 1998 Omnibus Plan, the Amended and Restated Omnibus Stock Option Plan and the Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan. These plans have expired and no future issuance of awards is permissible.

Our Board of Directors determines the term, vesting provisions, price, and number of shares for each award that is granted. The term of each option cannot exceed ten years.

No stock-based compensation expense was recorded during the three and six months ended June 30, 2012. No stock-based compensation was recorded during the three months ended June 30, 2011. Stock-based compensation of $834 was recorded during the six months ended June 30, 2011.

We use the Black-Scholes option-pricing model to calculate the fair value of each option grant on the date of grant. No stock options were granted during the three months ended June 30, 2012 and 2011.

A summary of our outstanding stock options for the six months ended June 30, 2012 and 2011 is presented below.

2012 2011

Shares Weighted
Average
Exercise Price Shares Weighted
Average
Exercise Price

Outstanding at beginning of year
3,636,480 $ 1.55 3,650,443 $ 1.59

Granted
— — — —

Exercised
— — — —

Forfeited and expired
(625,000 ) 1.75 (5,000 ) 15.63

Outstanding at end of period
3,011,480 $ 1.51 3,645,443 $ 1.57

Options exercisable at end of period
3,011,480 $ 1.51 3,645,443 $ 1.57

The following table summarizes information about stock options outstanding and exercisable at June 30, 2012:

Range of Exercise Prices
Number Outstanding Weighted Average
Remaining
Contractual Life Weighted Average
Exercise Price

$1.15 — $1.36
2,288,000 1.9 years $ 1.15

$2.00 — $3.00
539,980 3.2 years 2.33

$3.10 — $4.65
155,000 5.3 years 3.17

$4.99 — $6.96
28,500 1.5 years 5.47

3,011,480 2.3 years $ 1.51

There was no intrinsic value of outstanding options and exercisable options as of June 30, 2012. As of June 30, 2012, 809,172 shares were available for grant under the 2005 Plan.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting for Stock-Based Compensation (Details 1) (USD $)
6 Months Ended

Jun. 30, 2012

Summary of stock options outstanding and exercisable

Number Outstanding 3,011,480

Weighted Average Remaining Contractual Life 2 years 3 months 18 days

Weighted Average Exercise Price $ 1.51

Range One [Member]

Summary of stock options outstanding and exercisable

Minimum Range of Exercise Price $ 1.15

Maximum Range of Exercise Price $ 1.36

Number Outstanding 2,288,000

Weighted Average Remaining Contractual Life 1 year 10 months 24 days

Weighted Average Exercise Price $ 1.15

Range Two [Member]

Summary of stock options outstanding and exercisable

Minimum Range of Exercise Price $ 2.00

Maximum Range of Exercise Price $ 3.00

Number Outstanding 539,980

Weighted Average Remaining Contractual Life 3 years 2 months 12 days

Weighted Average Exercise Price $ 2.33

Range Three [Member]

Summary of stock options outstanding and exercisable

Minimum Range of Exercise Price $ 3.10

Maximum Range of Exercise Price $ 4.65

Number Outstanding 155,000

Weighted Average Remaining Contractual Life 5 years 3 months 18 days

Weighted Average Exercise Price $ 3.17

Range Four [Member]

Summary of stock options outstanding and exercisable

Minimum Range of Exercise Price $ 4.99

Maximum Range of Exercise Price $ 6.96

Number Outstanding 28,500

Weighted Average Remaining Contractual Life 1 year 6 months

Weighted Average Exercise Price $ 5.47

X

- Details

Name: alse_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableRollForward

Namespace Prefix: alse_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a, b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 79 190 1 false 36 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://alseres.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Consolidated Balance Sheets Sheet http://alseres.com/role/BalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://alseres.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://alseres.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) false false R5.htm 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://alseres.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 0201 - Disclosure - Nature of Operations and Basis of Presentation Sheet http://alseres.com/role/BasisOfPresentation Nature of Operations and Basis of Presentation false false R7.htm 0202 - Disclosure - Summary of Significant Accounting Policies Sheet http://alseres.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R8.htm 0203 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://alseres.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R9.htm 0204 - Disclosure - Net Loss per Share Sheet http://alseres.com/role/NetIncomeLossPerShare Net Loss per Share false false R10.htm 0205 - Disclosure - Accounting for Stock-Based Compensation Sheet http://alseres.com/role/AccountingForStockBasedCompensation Accounting for Stock-Based Compensation false false R11.htm 0206 - Disclosure - Notes Payable and Debt Notes http://alseres.com/role/NotesPayableAndDebt Notes Payable and Debt false false R12.htm 0207 - Disclosure - Convertible Preferred Stock Sheet http://alseres.com/role/ConvertiblePreferredStock Convertible Preferred Stock false false R13.htm 0208 - Disclosure - Commitments and Contingencies Sheet http://alseres.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 0209 - Disclosure - Income taxes Sheet http://alseres.com/role/IncomeTaxes Income taxes false false R15.htm 0210 - Disclosure - Fair Value Measurements Sheet http://alseres.com/role/FairValueMeasurements Fair Value Measurements false false R16.htm 0211 - Disclosure - Subsequent Events Sheet http://alseres.com/role/SubsequentEvents Subsequent Events false false R17.htm 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://alseres.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R18.htm 0503 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://alseres.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) false false R19.htm 0505 - Disclosure - Accounting for Stock-Based Compensation (Tables) Sheet http://alseres.com/role/AccountingForStockBasedCompensationTables Accounting for Stock-Based Compensation (Tables) false false R20.htm 0506 - Disclosure - Notes Payable and Debt (Tables) Notes http://alseres.com/role/NotesPayableAndDebtTables Notes Payable and Debt (Tables) false false R21.htm 0510 - Disclosure - Fair Value Measurements (Tables) Sheet http://alseres.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) false false R22.htm 0601 - Disclosure - Nature of Operations and Basis of Presentation (Details Textual) Sheet http://alseres.com/role/BasisOfPresentationDetails Nature of Operations and Basis of Presentation (Details Textual) false false R23.htm 0602 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://alseres.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R24.htm 0603 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://alseres.com/role/AccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R25.htm 0604 - Disclosure - Net Loss Per Share (Details Textual) Sheet http://alseres.com/role/NetLossPerShareDetailsTextual Net Loss Per Share (Details Textual) false false R26.htm 0605 - Disclosure - Accounting for Stock-Based Compensation (Details) Sheet http://alseres.com/role/AccountingForStockBasedCompensationDetails Accounting for Stock-Based Compensation (Details) false false R27.htm 06051 - Disclosure - Accounting for Stock-Based Compensation (Details 1) Sheet http://alseres.com/role/AccountingForStockBasedCompensationDetails1 Accounting for Stock-Based Compensation (Details 1) false false R28.htm 06052 - Disclosure - Accounting for Stock-Based Compensation (Details Textual) Sheet http://alseres.com/role/AccountingForStockBasedCompensationDetailsTextuals Accounting for Stock-Based Compensation (Details Textual) false false R29.htm 0606 - Disclosure - Notes Payable and Debt (Details) Notes http://alseres.com/role/NotesPayableAndDebtDetails Notes Payable and Debt (Details) false false R30.htm 06061 - Disclosure - Notes Payable and Debt (Details 1) Notes http://alseres.com/role/NotesPayableAndDebtDetails1 Notes Payable and Debt (Details 1) false false R31.htm 06062 - Disclosure - Notes Payable and Debt (Details Textual) Notes http://alseres.com/role/NotesPayableAndDebtDetailsTextual Notes Payable and Debt (Details Textual) false false R32.htm 0607 - Disclosure - Convertible Preferred Stock (Details Textual) Sheet http://alseres.com/role/ConvertiblePreferredStockDetailsTextual Convertible Preferred Stock (Details Textual) false false R33.htm 0608 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://alseres.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R34.htm 0610 - Disclosure - Fair Value Measurements (Details) Sheet http://alseres.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) false false R35.htm 06101 - Disclosure - Fair Value Measurements (Details Textual) Sheet http://alseres.com/role/FairValueMeasurementsDetailsTextual Fair Value Measurements (Details Textual) false false R36.htm 0611 - Disclosure - Subsequent Events (Details Textual) Sheet http://alseres.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element alse_PercentageOfOutstandingCommonStock had a mix of decimals attribute values: 2 3 4. Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) alse-20120630.xml alse-20120630.xsd alse-20120630_cal.xml alse-20120630_def.xml alse-20120630_lab.xml alse-20120630_pre.xml true true XML 52 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Notes Payable and Debt (Tables)
6 Months Ended

Jun. 30, 2012

Notes Payable and Debt [Abstract]

Convertible notes payable to significant stockholders

Convertible Notes Payable to Significant Stockholders
June 30, 2012 December 31, 2011

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
$ 4,655,173 $ 4,655,173

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
BCF 10,000,000 10,000,000

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
BCF 2,172,415 2,172,415

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010
5,000,000 5,000,000

Aggregate carrying value
$ 21,827,588 $ 21,827,588

Demand notes payable to significant stockholder

Demand Notes Payable to Significant Stockholder
June 30, 2012 December 31, 2011

Unsecured demand note payable; interest rate of 7%: issued December 2009
$ 350,000 $ 350,000

Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010
3,310,000 3,310,000

Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011
2,240,000 2,240,000

Unsecured demand notes payable; interest rate of 7%: issued January 2012 — June 2012
285,000 —

6,185,000 5,900,000

Accrued interest
694,946 486,691

Aggregate carrying value
$ 6,879,946 $ 6,386,691

X

- Definition

Schedule of demand notes payable debt.

+ References

No definition available.

+ Details

Name: alse_ScheduleOfDemandNotesPayableTableTextBlock

Namespace Prefix: alse_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Schedule of unsecured convertible promissory notes payable.

+ References

No definition available.

+ Details

Name: alse_ScheduleOfUnsecuredConvertiblePromissoryNotesPayableTableTextBlock

Namespace Prefix: alse_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Net Loss Per Share (Details Textual) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Net Loss Per Share (Textual) [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3.0	3.6

Notes Payable and Debt (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Convertible Notes Payable to Significant Stockholders
Aggregate carrying value	$ 21,827,588	$ 21,827,588
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]
Convertible Notes Payable to Significant Stockholders
Aggregate carrying value	4,655,173	4,655,173
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]
Convertible Notes Payable to Significant Stockholders
Aggregate carrying value	10,000,000	10,000,000
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]
Convertible Notes Payable to Significant Stockholders
Aggregate carrying value	2,172,415	2,172,415
Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010 [Member]
Convertible Notes Payable to Significant Stockholders
Aggregate carrying value	$ 5,000,000	$ 5,000,000

Notes Payable and Debt (Details 1) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Demand Notes Payable to Significant Stockholder
Demand notes payable value	$ 6,185,000	$ 5,900,000
Accrued interest	694,946	486,691
Aggregate carrying value	6,879,946	6,386,691
Unsecured demand note payable; interest rate of 7%: issued December 2009 [Member]
Demand Notes Payable to Significant Stockholder
Demand notes payable value	350,000	350,000
Unsecured demand notes payable; interest rate of 7%: issued January 2010 - December 2010 [Member]
Demand Notes Payable to Significant Stockholder
Demand notes payable value	3,310,000	3,310,000
Unsecured demand notes payable; interest rate of 7%: issued January 2011 - December 2011 [Member]
Demand Notes Payable to Significant Stockholder
Demand notes payable value	2,240,000	2,240,000
Unsecured demand notes payable; interest rate of 7%: issued January 2012 - June 2012 [Member]
Demand Notes Payable to Significant Stockholder
Demand notes payable value	$ 285,000

Notes Payable and Debt (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	236 Months Ended	6 Months Ended								6 Months Ended	3 Months Ended		6 Months Ended
Notes Payable and Debt (Details Textual) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Number_Of_Notes	Jun. 30, 2011	Dec. 31, 2011	Jun. 30, 2012	Jun. 30, 2012 RG [Member]	Jun. 30, 2012 ISVP [Member]	Dec. 31, 2011 ISVP [Member]	Dec. 31, 2011 Robert and Thomas Gipson [Member]	Dec. 27, 2011 Robert Gipson [Member]	Dec. 27, 2011 Thomas Gipson [Member]	Jun. 01, 2011 Arthur Koenig [Member]	Dec. 31, 2011 Ingalls Snyder LLC [Member]	Jun. 30, 2012 Molecular Imaging and Other Products [Member]	Jun. 30, 2012 Demand Notes Payable [Member]	Jun. 30, 2011 Demand Notes Payable [Member]	Jun. 30, 2012 Demand Notes Payable [Member]	Jun. 30, 2011 Demand Notes Payable [Member]
Notes Payable and Debt (Textual) [Abstract]
Convertible notes payable	$ 21,827,588		$ 21,827,588		$ 21,827,588	$ 21,827,588				$ 7,172,412					$ 1,000,000
Future payments as a percentage of pre-commercial revenue															2.00%
Notes payables additional compensation as a percentage of future net sales per $1000000 outstanding principle															0.50%
Percentage of shares to be held by purchases considered to determine effective conversion under option 1								19.90%
Percentage of shares to be held by purchases considered to determine effective conversion under option 2								9.99%
Recorded Beneficial Conversion Feature							380,000	1,400,000
Percentage of outstanding common stock									9.99%		50.10%	15.20%	7.00%	9.99%
Demand notes payable value	6,185,000		6,185,000		5,900,000	6,185,000
Interest expenses Related to BCF	0	362,499	0	724,998												105,287	100,078	208,225	186,224
Notes Payable and Debt (Additional Textual) [Abstract]
Unsecured promissory note	1,000,000		1,000,000			1,000,000
Interest expenses	105,716	465,258	209,113	919,009	18,000	14,698,223
Additional Debt					$ 2,525,000
Unsecured convertible promissory notes conversion options			Conversion Policies (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii).
Unsecured convertible promissory notes conversion price per common stock share	$ 2.50		$ 2.50			$ 2.50
Notes Payable, Description			Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under.
Number of unsecured promissory notes issued			2

Convertible Preferred Stock (Details Textual) (Series F Preferred Stock [Member], USD $)	6 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Series F Preferred Stock [Member]
Convertible Preferred Stock (Textual) [Abstract]
Preferred Stock Convertibles Conversion Ratio	25
Convertible Preferred Stock price per share	$ 25
Proceeds from sale of convertible preferred stock	$ 4,600,000
Redeemable convertible preferred stock, shares outstanding	12,000	12,000

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 63,552	$ 135,843
Short-term investments	20,389	27,446
Prepaid expenses and other current assets	44,008	4,965
Total current assets	127,949	168,254
Property and Equipment, net	1,582	2,475
Total assets	129,531	170,729
Current liabilities:
Accounts payable and accrued expenses	2,297,042	2,210,229
Convertible notes payable	21,827,588	21,827,588
Notes payable	6,185,000	5,900,000
Accrued interest payable on notes payable	694,946	486,691
Total current liabilities	31,004,576	30,424,508
Total liabilities	31,004,576	30,424,508
Commitments and contingencies
Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at June 30, 2012 and December 31, 2011, (liquidation preference of $300,000 at June 30, 2012)	358,915	348,444
Stockholders' deficit:
Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively
Common stock, $.01 par value; 80,000,000 shares authorized at June 30, 2012 and December 31, 2011; 30,635,720 issued and outstanding at June 30, 2012 and December 31, 2011	306,357	306,357
Additional paid-in capital	166,160,384	166,170,855
Accumulated other comprehensive loss	(38,424)	(31,367)
Deficit accumulated during development stage	(197,662,277)	(197,048,068)
Total stockholders' deficit	(31,233,960)	(30,602,223)
Total liabilities and stockholders' deficit	$ 129,531	$ 170,729

Fair Value Measurements (Details Textual) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Fair Value Disclosures (Textual) [Abstract]
Unsecured convertible promissory notes conversion price per common stock share	2.50
Sale of stock, price per share	0.12
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments shares of FluoroPharma Medical, Inc	39,209	39,209

Subsequent Events (Details Textual) (USD $)	1 Months Ended		6 Months Ended
Subsequent Events (Details Textual) (USD $)	Jul. 31, 2012	Jan. 31, 2012	Jun. 30, 2012
Subsequent Events (Additional Textual) [Abstract]
Borrowings from Robert Gipson	$ 150,000
Interest rate stated in the contractual debt agreement			7.00%
Non-refundable sum in exchange for exclusive option to license		500,000
Sublicense execution payment		(175,000)
Contingent milestone payments, maximum		2,900,000
Contingent milestone payments occur at the time of product registration or upon commercial sales		2,500,000
Maximum effective declaration period		90 days
Convertible Note Purchase Agreement to receive repayment of a total	16,000,000
Convertible Note Purchase Agreement at a rate	8.00%
Prospective Repayment Of Debt Pursuant To Waiver Of Right To Receive Percentage of Altropane Product Sale			$ 5,827,587
Navb Stock [Member]
Subsequent Events (Textual) [Abstract]
Shares Received Against Execution Of Sublicense Granted		300,000
Navidea stock [Member]
Subsequent Events (Textual) [Abstract]
Issuance common shares of Navidea stock maximum		1,150,000
Issuance common shares of Navidea stock occur at the time of product registration or upon commercial sales		950,000

Accounts Payable and Accrued Expenses (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses	$ 2,297,042	$ 2,210,229
Research and development expenses [Member]
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses	1,351,940	1,316,095
Professional fees [Member]
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses	761,061	715,672
General and administrative expenses [Member]
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses	107,848	99,746
Compensation related expenses [Member]
Schedule of accounts payable and accrued expenses
Accounts payable and accrued expenses	$ 76,193	$ 78,716

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.01	$ 0.01
Convertible Preferred stock, shares designated	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	30,635,720	30,635,720
Common stock, shares outstanding	30,635,720	30,635,720
Series A Preferred Stock
Convertible Preferred stock, shares designated	25,000	25,000
Series D Preferred Stock
Convertible Preferred stock, shares designated	500,000	500,000
Series E Preferred Stock
Convertible Preferred stock, shares designated	800	800
Series F Preferred Stock
Redeemable convertible preferred stock, shares par value per share	$ 0.01	$ 0.01
Redeemable convertible preferred stock, shares designated	200,000	200,000
Redeemable convertible preferred stock, shares issued	12,000	12,000
Redeemable convertible preferred stock, shares outstanding	12,000	12,000
Preferred stock, shares liquidation preference	$ 300,000

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2012
Accounting Policies [Abstract]
Cash and Cash Equivalents	The Company considers all highly liquid marketable securities purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.
Short-term Investments	The Company considers all marketable securities with maturities greater than three months and less than one year at the time of acquisition or purchase to be short-term investments. The Company evaluates such designation as of each balance sheet date to determine if the classification is appropriate. As of June 30, 2012 our short-term investments were classified as available-for-sale and were carried on the balance sheet at fair value. The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.
Comprehensive Loss	Components of comprehensive loss are reported in the Company’s condensed consolidated statements of comprehensive loss in the period in which they are recognized. The components of comprehensive loss include net loss and net change in the unrealized gains or losses in our marketable securities during the period.
Fair Value Measurements	The carrying amounts of the Company’s cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values as of June 30, 2012 and December 31, 2011 due to their short-term nature. Short-term investments were considered available-for-sale as of June 30, 2012 and are carried at fair value in the condensed consolidated balance sheets. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.12 as of June 30, 2012 and the Company currently does not have the resources to repay the convertible debt.
Revenue Recognition and Deferred Revenue	The Company presents revenue from collaboration and licensing arrangements under FASB ASC 808, Collaboration Arrangements. Our revenue arrangements with multiple elements are evaluated under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13), and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has standalone value to the customer, whether the arrangement includes a general right of return relative to the delivered element and whether delivery or performance of the undelivered element is considered probable and substantially under our control. The consideration we receive under collaboration and licensing arrangements is allocated among the separate units of accounting based on the selling price hierarchy, and the applicable revenue recognition criteria is applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned. Revenues associated with substantive, at-risk milestones pursuant to collaborative and licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in collaboration agreements that are not considered milestones will be recognized as revenue when payments are earned from our collaborators through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured. On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc., to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for [123I]-E-IACFT. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (“FDA”) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence in to July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.
Recent Accounting Pronouncements	In June 2011, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2011-05, “Presentation of Comprehensive Income.” ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. The Company adopted these standards as of January 1, 2012. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and six months ended June 30, 2012.

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Jul. 31, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	ALSERES PHARMACEUTICALS INC /DE
Entity Central Index Key	0000094784
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,635,720

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Jun. 30, 2012	Dec. 31, 2011
Summary of financial asset measured at fair value
Fair value financial assets total	$ 20,389	$ 27,446
Level 2 [Member]
Summary of financial asset measured at fair value
Short-term investments	$ 20,389	$ 27,446

Accounting for Stock-Based Compensation (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2012
Summary of stock options outstanding and exercisable
Number Outstanding	3,011,480
Weighted Average Remaining Contractual Life	2 years 3 months 18 days
Weighted Average Exercise Price	$ 1.51
Range One [Member]
Summary of stock options outstanding and exercisable
Minimum Range of Exercise Price	$ 1.15
Maximum Range of Exercise Price	$ 1.36
Number Outstanding	2,288,000
Weighted Average Remaining Contractual Life	1 year 10 months 24 days
Weighted Average Exercise Price	$ 1.15
Range Two [Member]
Summary of stock options outstanding and exercisable
Minimum Range of Exercise Price	$ 2.00
Maximum Range of Exercise Price	$ 3.00
Number Outstanding	539,980
Weighted Average Remaining Contractual Life	3 years 2 months 12 days
Weighted Average Exercise Price	$ 2.33
Range Three [Member]
Summary of stock options outstanding and exercisable
Minimum Range of Exercise Price	$ 3.10
Maximum Range of Exercise Price	$ 4.65
Number Outstanding	155,000
Weighted Average Remaining Contractual Life	5 years 3 months 18 days
Weighted Average Exercise Price	$ 3.17
Range Four [Member]
Summary of stock options outstanding and exercisable
Minimum Range of Exercise Price	$ 4.99
Maximum Range of Exercise Price	$ 6.96
Number Outstanding	28,500
Weighted Average Remaining Contractual Life	1 year 6 months
Weighted Average Exercise Price	$ 5.47